

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date
2 September 2004 (02.09.2004)

PCT

(10) International Publication Number
WO 2004/074244 A2

(51) International Patent Classification⁷:

C07D

(74) Agents: LEVY, David, J. et al.; GlaxoSmithKline, Five Moore Drive, P.O. Box 13398, Research Triangle Park, NC 27709 (US).

(21) International Application Number:

PCT/US2004/004197

(22) International Filing Date: 11 February 2004 (11.02.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/448,795 20 February 2003 (20.02.2003) US

(71) Applicant (for all designated States except US): **SMITHKLINE BEECHAM CORPORATION** [US/US]; One Franklin Plaza, Philadelphia, PA 19101 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **DAVIS-WARD, Ronda** [US/US]; GlaxoSmithKline, Five Moore Drive, PO Box 13398, Research Triangle Park, NC 27709 (US). **MOOK, Robert, Anthony, Jr.** [US/US]; GlaxoSmithKline, Five Moore Drive, PO Box 13398, Research Triangle Park, NC (US). **NEEB, Michael, J.** [US/US]; GlaxoSmithKline, 709 Swedeland Road, King of Prussia, PA (US). **SALOVICH, James, M.** [US/US]; GlaxoSmithKline, Five Moore Drive, P.O. Box 13398, Research Triangle Park, NC 27709 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

A2

(54) Title: PYRIMIDINE COMPOUNDS



(57) Abstract: The present invention provides compounds of formula (I) : wherein all variables are as defined herein, pharmaceutical compositions containing the same, processes for preparing the same and their use as pharmaceutical agents.

WO 2004/074244

PYRIMIDINE COMPOUNDS

BACKGROUND OF THE INVENTION

5 The present invention relates to novel compounds, pharmaceutical formulations comprising these compounds, and the use of these compounds in therapy. More particularly, the present invention relates to novel compounds and methods for treating conditions mediated by Polo-like Kinase, susceptible neoplasms, and other conditions.

10 Polo-like kinases ("PLK") are evolutionarily conserved serine/threonine kinases that play critical roles in regulating processes in the cell cycle. PLK plays a role in the entry into and the exit from mitosis in diverse organisms from yeast to mammalian cells. PLK includes PLK1, PLK2, and PLK3.

15 Polo-like kinases are known to be essential for mitosis in yeast, Drosophila, and Xenopus. For example, mutants of the homologous PLK genes in these organisms result in disordered mitotic spindles, and in Drosophila mutations can be embryonic lethal. RNA interference experiments on Drosophila *polo* have shown that ablation of *polo* in S2 cells results in G2/M arrest and apoptosis. PLK1 is the human homolog of Drosophila *polo*. It is believed to be involved in the entry into mitosis through the activation of cdk1 by phosphorylating and activating the phosphatase cdc25C, which in turn removes inhibitory phosphates from cdk1. This sets up an activation loop for 20 cdk1 that leads to mitotic entry. PLK1 also phosphorylates cyclin B1, the cyclin partner of cdk1, resulting in nuclear localization. During mitosis, PLK1 has been shown to play roles in centrosome maturation and microtubule dynamics involved in formation of the mitotic spindle. PLK1 is also involved in the exit of cells from mitosis by phosphorylating and activating subunits of the 25 anaphase-promoting complex (cdc16 and cdc27). PLK1 also phosphorylates 30

cohesin proteins that hold sister chromatids together, exposing separase cleavage sites, and allowing separation of sister chromatids during anaphase. PLK1 may also play a role in cytokinesis through phosphorylation of the kinesin-like motor protein MKLP1. Inhibition of PLK1 thus has the potential to 5 interfere with several stages of mitosis. Expression and activity of PLK protein increases during the cell cycle, reaching its peak during mitosis when it is also maximally phosphorylated. PLK1 mRNA is highly expressed in cells with a high mitotic index. PLK2 (serum-inducible kinase, SNK) and PLK3 (Fibroblast Growth Factor-inducible kinase, FNK) were originally identified as immediate- 10 early genes. PLK2 is not very well characterized, but PLK3 appears to be involved in regulation of cell cycle progression through M phase but functions differently from PLK1. Recent published work suggests that PLK3 plays an important role in the regulation of microtubule dynamics and function of the centrosome during mitosis.

15 Overexpression of PLK1 appears to be strongly associated with neoplastic cells (including cancers). A published study has shown high levels of PLK1 RNA expression in >80% of lung and breast tumors, with little to no expression in adjacent normal tissue. Several studies have shown 20 correlations between PLK expression, histological grade, and prognosis in several types of cancer. Significant correlations were found between percentages of PLK-positive cells and histological grade of ovarian and endometrial cancer ($P<0.001$). These studies noted that PLK is strongly expressed in invading endometrial carcinoma cells and that this could reflect 25 the degree of malignancy and proliferation in endometrial carcinoma. Using RT-PCR analysis, PLK overexpression was detected in 97% of esophageal carcinomas and 73% of gastric carcinomas as compared to the corresponding normal tissues. Further, patients with high levels of PLK overexpression in 30 esophageal carcinoma represented a significantly poorer prognosis group than those with low levels of PLK overexpression. In head and neck cancers,


elevated mRNA expression of PLK1 was observed in most tumors; a Kaplan-Meier analysis showed that those patients with moderate levels of PLK1 expression survived longer than those with high levels of PLK1 expression. Analysis of patients with non-small cell lung carcinoma showed similar outcomes related to PLK1 expression.

5 outcomes related to PLK1 expression.

Disruption of mitosis with anti-microtubule drugs has been a successful approach in cancer chemotherapy. The taxanes and vinca alkaloids have been effectively used in the clinic, but they have undesirable side effects. In 10 addition, many tumors appear to have weakened G2/M cell cycle checkpoints; in response to mitotic disruption these tumors attempt to bypass mitosis, leading to mitotic catastrophe and cell death. Several studies suggest that the disruption of mitosis by targeting PLK may be a feasible approach to selective tumor cell destruction. There remains a need in the art for new approaches 15 to the treatment of neoplasms.

BRIEF SUMMARY OF THE INVENTION

According to a first aspect of the invention there is provided a compound of 20 formula (I):



25

wherein:

R¹ is selected from the group consisting of H, halo, alkyl, alkenyl, alkynyl;

R² is selected from the group consisting of halo, alkyl, alkenyl, alkynyl,

cycloalkyl, cycloalkenyl, -(R⁷)_g-C(O)R⁶, -(R⁷)_g-CO₂R⁶, -(R⁷)_g-C(O)N(R⁶)₂,


30 -(R⁷)_g-OR⁶, -O-(R⁷)_g-Ay, -(R⁷)_g-S(O)eR⁶, -(R⁷)_g-N(R⁶)₂,

$-(R^7)_g-N(R^6)C(O)R^6$, $-(R^7)_g-CN$, $-(R^7)_g-SCN$, $-NO_2$, $-N_3$, Ay and 5- to 9-membered heteroaryl containing 1 or 2 heteroatoms selected from N, O and S;

each R^3 is the same or different and is independently H or alkyl;

- 5 Y is selected from the group consisting of $-C(O)R^8$, $-C(S)R^8$, $-S(O)_eR^9$, $-S(O)_eN(R^9)_2$, $-N(R^9)_2$, $-N(R^9)-S(O)_eR^9$, $-N(R^9)-C(O)R^9$, $-N(R^9)-CO_2R^9$, and $-N(R^9)-C(O)N(R^9)_2$, or Y, together with C-2 and C-3 form a fused ring system of formula A:

10



A

wherein

R^8 is selected from the group consisting of alkyl, alkenyl, alkynyl,

15

cycloalkyl, cycloalkenyl, Ay, Het, $-OR^6$, $-O-(R^7)_g-Ay$, $-O-(R^7)_g-Het$, $-N(R^6)_2$, $-N(R^6)-(R^7)_g-Ay$, $-N(R^6)-(R^7)_g-Het$, $-N(R^6)-(R^7)_g-OR^6$, $-N(R^6)-(R^7)_g-C(O)R^6$, $-N(R^6)-(R^7)_g-CO_2R^6$, $-N(R^6)-(R^7)_g-SO_2R^6$, and $-N(R^6)-(R^7)_g-N(R^6)_2$;

each R^9 is the same or different and is independently selected from the

20

group consisting of H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, Ay and Het;

c is 0 or 1;

Z^1 , Z^2 , Z^3 and Z^4 are each independently selected from the group

consisting of C, O, S and N, wherein when c is 0, at least one of

25

Z^1 , Z^2 and Z^3 is C and wherein when c is 1, at least two of Z^1 , Z^2 , Z^3 and Z^4 are C;

each dashed line represents an optional double bond;

d is 0, 1 or 2;

each R¹⁰ is the same or different and is independently selected from the group consisting of halo, alkyl, oxo, hydroxy, mercapto and amino;

a is 0, 1, 2 or 3;

- 5 each R⁴ is the same or different and is independently selected from the group consisting of halo, alkyl, alkenyl, alkynyl, -(R⁷)_g-cycloalkyl, -(R⁷)_g-cycloalkenyl, -(R⁷)_g-Ay, -(R⁷)_g-Het, -(R⁷)_g-C(O)R⁶, -(R⁷)_g-C(O)Ay, -(R⁷)_g-C(O)Het, -(R⁷)_g-CO₂R⁶, -(R⁷)_g-CO₂Ay, -(R⁷)_g-CO₂Het, -(R⁷)_g-C(O)N(R⁶)₂, -(R⁷)_g-OR⁶, -(R⁷)_g-OAy, -(R⁷)_g-OHet, -(R⁷)_g-OC(O)R⁶, -(R⁷)_g-OC(O)Ay, -(R⁷)_g-OC(O)Het, -(R⁷)_g-S(O)_eR⁶, -(R⁷)_g-S(O)_eAy, -(R⁷)_g-S(O)_eHet, -(R⁷)_g-S(O)_eN(R⁶)₂, -(R⁷)_g-S(O)_eN(R⁶)Ay, -(R⁷)_g-S(O)_eN(R⁶)Het, -(R⁷)_g-N(R⁶)C(O)R⁶, -(R⁷)_g-N(R⁶)C(O)Ay, -(R⁷)_g-N(R⁶)C(O)Het, -(R⁷)_g-N(R⁶)C(O)N(R⁶)₂, -(R⁷)_g-N(R⁶)S(O)_eR⁶, -(R⁷)_g-N(R⁶)S(O)_eAy, 15 -(R⁷)_g-N(R⁶)S(O)_eHet, -NO₂, -CN, -SCN and -N₃, or two adjacent R⁴ groups together with the carbon atoms to which they are bonded form a phenyl or a 5- or 6-membered heterocycle or heteroaryl containing 1 or 2 heteroatoms selected from the group consisting of O, N and S;
- 20 each e is the same or different and is independently 0, 1 or 2; b is 0, 1, 2, 3, 4 or 5; each R⁵ is the same or different and is a group of formula (R⁷)_g-R¹¹, or two adjacent R⁵ groups are each the same or different and are independently selected from the group consisting of alkyl, alkenyl, -OR⁶, -S(O)_eR⁶ and -N(R⁶)₂ and, together with the carbon atoms to 25 which they are bonded, they form a C₅₋₆cycloalkyl, C₅₋₆cycloalkenyl or a 5- or 6-membered heterocycle or heteroaryl containing 1 or 2 heteroatoms selected from the group consisting of N, O and S;

each R⁶ is the same or different and is independently selected from the group consisting of H, alkyl, alkenyl, alkynyl, cycloalkyl and cycloalkenyl;

g is 0 or 1;

R⁷ is alkylene or alkenylene;

5 Ay is aryl;

Het is a 5- or 6-membered heterocycle or heteroaryl containing 1, 2 or 3 heteroatoms selected from the group consisting of N, O and S;

R¹¹ is selected from the group consisting of halo, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, Ay, Het, -C(O)R⁶, -C(O)Ay, -C(O)Het, -CO₂R⁶,

10 -CO₂Ay, -CO₂Het, -C(O)-R⁷-OR⁶, -C(O)-R⁷-OAy, -C(O)-R⁷-OHet, -C(O)N(R⁶)₂, -C(O)N(R⁶)Ay, -C(O)N(R⁶)Het, -C(O)N(R⁶)-(R⁷)_g-N(R⁶)₂, -C(O)N(R⁶)-(R⁷)_g-CO₂R⁶, -C(O)N(R⁶)-(R⁷)_g-S(O)_eR⁶, -OR⁶, -OC(O)R⁶, -O-(R⁷)_g-Ay, -OC(O)Ay, -O-(R⁷)_g-Het, -OC(O)Het, -O-R⁷-OR⁶, -O-R⁷-N(R⁶)₂, -S(O)_eR⁶, -S(O)_e-(R⁷)_g-Ay, -S(O)_e-(R⁷)_g-Het,

15 -S(O)_e-(R⁷)_g-N(R⁶)₂, -S(O)_e-(R⁷)_g-N(R⁶)Ay, -S(O)_e-(R⁷)_g-N(R⁶)Het, -S(O)_eN(R⁶)-(R⁷)_g-C(O)R⁶, -S(O)_eN(R⁶)-(R⁷)_g-C(O)Ay, -S(O)_eN(R⁶)-(R⁷)_g-C(O)Het, -N(R⁶)₂, -N(R⁶)-(R⁷)_g-Ay, -N(R⁶)-(R⁷)_g-Het, -N(R⁶)-(R⁷)_g-C(O)R⁶, -N(R⁶)-C(O)-(R⁷)_g-Ay, -N(R⁶)-C(O)-(R⁷)_g-Het, -N(R⁶)-C(O)-(R⁷)_g-N(R⁶)₂, -N(R⁶)-C(O)-(R⁷)_g-N(R⁶)Ay,

20 -N(R⁶)-C(O)-(R⁷)_g-N(R⁶)Het, -N(R⁶)-C(O)-(R⁷)_g-N(R⁶)-(R⁷-O)_h-N(R⁶)-CO₂R⁶, -N(R⁶)-(R⁷)_g-S(O)_eR⁶, -N(R⁶)-(R⁷)_g-S(O)_eAy, -N(R⁶)-(R⁷)_g-S(O)_eHet, -N(R⁶)-R⁷-N(R⁶)₂, -N(R⁶)-R⁷-OR⁶, -CN, -SCN, -NO₂, and -N₃; and

h is 1-20;

25 wherein when R¹ is -CH₃, R² is Br or NO₂, both R³ are H, a is 0 and b is 0 or 1 wherein R⁵ is -CO₂H, then Y is not -CO₂H or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof.

In another aspect of the invention there is provided a pharmaceutical composition comprising a compound of formula (I). In one embodiment, the pharmaceutical composition further comprises a pharmaceutically acceptable carrier, diluent or excipient.

5

In a third aspect of the invention, there is provided a method for treating a condition mediated by PLK in an animal. The method comprises administering to the animal a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof.

10

In a fourth aspect of the invention, there is provided a method for treating a susceptible neoplasm in an animal. The method comprises administering to the animal a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof. The susceptible neoplasm may be selected from the group consisting of breast cancer, colon cancer, lung cancer, prostate cancer, lymphoma, leukemia, endometrial cancer, melanoma, pancreatic cancer, ovarian cancer, squamous carcinoma, carcinoma of the head and neck, and esophageal carcinoma.

20

In a fifth aspect of the invention, there is provided a method for treating a condition characterized by inappropriate cellular proliferation. The method comprises contacting the cell with a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof.

25


In a sixth aspect, the present invention provides a method for inhibiting proliferation of a cell. The method comprises contacting the cell with an amount of a compound of formula (I) or a pharmaceutically acceptable salt,

30


solvate or physiologically functional derivative thereof sufficient to inhibit proliferation of the cell.

In another aspect, the present invention provides a method for inhibiting
5 mitosis in a cell. The method comprises administering to the cell an amount
of a compound of formula (I) or a pharmaceutically acceptable salt, solvate or
physiologically functional derivative thereof sufficient to inhibit mitosis in the
cell.

10 In another aspect, there is provided a process for preparing a compound of
formula (I) comprising reacting a compound of formula (IV):



15 wherein R¹⁵ is selected from the group consisting of halo and -S(O)_eR⁶;
with a compound of formula (V):



20

In another aspect, the present invention provides a radiolabeled compound of
formula (I) or a pharmaceutically acceptable salt, solvate or physiologically
functional derivative thereof. In one embodiment, the present invention
25 provides a tritiated compound of formula (I) or a pharmaceutically acceptable
salt, solvate or physiologically functional derivative thereof. In another
aspect, the present invention provides a biotinylated compound of formula (I)
or a pharmaceutically acceptable salt, solvate or physiologically functional
derivative thereof.

In another aspect, the present invention provides a compound of formula (I) or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof for use in therapy.

- 5 In yet another aspect, the present invention provides a compound of formula (I) or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof for use in the treatment of a condition mediated by PLK in an animal.
 - 10 In yet another aspect, the present invention provides a compound of formula (I) or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof for use in the treatment of a susceptible neoplasm in an animal.
 - 15 In another aspect, the present invention provides a compound of formula (I) or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof for use in the treatment of a condition characterized by inappropriate cellular proliferation.
 - 20 In yet another aspect, the present invention provides a compound of formula (I) or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof for use in inhibiting proliferation of a cell.
- In yet another aspect, the present invention provides a compound of formula (I) or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof for use in inhibiting mitosis in a cell.
- In yet another aspect, the present invention provides the use of a compound of formula (I) or a pharmaceutically acceptable salt, solvate or physiologically

functional derivative thereof for the preparation of a medicament for the treatment of condition mediated by PLK in an animal.

In yet another aspect, the present invention provides the use of a compound
5 of formula (I) or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof for the preparation of a medicament for the treatment of a susceptible neoplasm in an animal.

In yet another aspect, the present invention provides the use of a compound
10 of formula (I) or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof for the preparation of a medicament for the treatment of a condition characterized by inappropriate cellular proliferation in an animal.

15 In yet another aspect, the present invention provides the use of a compound of formula (I) or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof for the preparation of a medicament for inhibiting proliferation of a cell.

20 In yet another aspect, the present invention provides the use of a compound of formula (I) or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof for the preparation of a medicament for inhibiting mitosis in a cell.

25 In yet another aspect, the present invention provides a pharmaceutical composition comprising a compound of formula (I) for use in the treatment of a susceptible neoplasm in an animal.

DETAILED DESCRIPTION OF THE INVENTION

As used herein, "a compound of the invention" or "a compound of formula (I)" means a compound of formula (I) or a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof. Similarly, with respect to isolatable intermediates such as for example compounds of formula (IV) the phrase "a compound of formula (*number*)" means a compound having that formula or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof.

10

As used herein, the terms "alkyl" (and "alkylene") refer to straight or branched hydrocarbon chains containing from 1 to 8 carbon atoms. Examples of "alkyl" as used herein include, but are not limited to, methyl, ethyl, n-propyl, n-butyl, n-pentyl, isobutyl, isopropyl, and tert-butyl. Examples of "alkylene" as used herein include, but are not limited to, methylene, ethylene, propylene, butylene, and isobutylene. "Alkyl" and "alkylene" also include substituted alkyl and substituted alkylene. The alkyl or alkylene groups may be optionally substituted one or more times with halogen or cyano. Thus, the term "alkyl" includes trifluoromethyl and trifluoroethyl, among other halogenated alkyls.

As used herein, the term "alkenyl" refers to straight or branched hydrocarbon chains containing from 2 to 8 carbon atoms (unless a different number of atoms is specified) and at least one and up to three carbon-carbon double bonds. Examples of "alkenyl" as used herein include, but are not limited to ethenyl and propenyl. "Alkenyl" also includes substituted alkenyl. The alkenyl groups may optionally be substituted one or more times with a halogen or cyano.

As used herein, the term "alkynyl" refers to straight or branched hydrocarbon chains containing from 2 to 8 carbon atoms (unless a different number of atoms is specified) and at least one and up to three carbon-carbon triple bonds. Examples of "alkynyl" as used herein include, but are not limited to 5 ethynyl and propynyl. "Alkynyl" also includes substituted alkynyl. The alkynyl groups may optionally be substituted one or more times with a halogen or cyano.

As used herein, the term "cycloalkyl" refers to non-aromatic monocyclic 10 carbocyclic rings having from 3 to 8 carbon atoms (unless a different number of atoms is specified) and no carbon-carbon double bonds. "Cycloalkyl" includes by way of example cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl. "Cycloalkyl" also includes substituted cycloalkyl. The cycloalkyl may optionally be substituted on any available carbon with one 15 or more substituents selected from the group consisting of halo, alkyl (including haloalkyl, e.g., perfluoroalkyl), alkenyl, alkynyl, hydroxyl, oxo, carboxyl, alkyl carboxyl, alkylether, mercapto, sulfonyl, sulfinyl, alkylsulfonyl, sulfonamido, amino, alkylamino, dialkylamino, acetylamino, amino sulfonamide and cyano. Particular cycloalkyl groups include C₃₋₆cycloalkyl and 20 substituted C₃₋₆cycloalkyl.

As used herein, the term "cycloalkenyl" refers to a non-aromatic monocyclic carbocyclic ring having from 3 to 8 carbon atoms (unless a different number of atoms is specified) and up to 3 carbon-carbon double bonds. 25 "Cycloalkenyl" includes by way of example cyclobutenyl, cyclopentenyl and cyclohexenyl. "Cycloalkenyl" also includes substituted cycloalkenyl. The cycloalkenyl may optionally be substituted on any available carbon with one or more substituents selected from the group consisting of halo, alkyl (including haloalkyl, e.g., perfluoroalkyl), alkenyl, alkynyl, hydroxyl, oxo, carboxyl, alkylcarboxyl, alkylether, mercapto, sulfonyl, sulfinyl, alkylsulfonyl, 30

sulfonamido, amino, alkylamino, dialkylamino, acetylamino, amino sulfonamide and cyano.

The terms "halo" and "halogen" refer to fluorine, chlorine, bromine and

5 iodine.

The term "aryl" refers to monocyclic carbocyclic groups and fused bicyclic carbocyclic groups having from 6 to 13 carbon atoms (unless a different number of atoms is specified) and having at least one aromatic ring.

10 Examples of particular aryl groups include but are not limited to phenyl and naphthyl. "Aryl" also includes substituted aryl. The aryl may optionally be substituted on any available carbon with one or more substituents selected from the group consisting of halo, alkyl, alkenyl, alkynyl, hydroxyl, carboxyl, alkylcarboxyl, alkylether, mercapto, sulfonyl, sulfinyl, alkylsulfonyl,
15 sulfonamido, amino, alkylamino, dialkylamino, acetylamino, amino sulfonamido and cyano. Particular aryl groups according to the invention include phenyl and substituted phenyl.

20 The terms "heterocycle" and "heterocyclic" refer to monocyclic saturated or unsaturated non-aromatic groups and fused bicyclic saturated or unsaturated non-aromatic groups, having the specified number of members and containing 1, 2, 3 or 4 heteroatoms selected from N, O and S (unless a different number of heteroatoms is specified). Examples of particular heterocyclic groups include but are not limited to tetrahydrofuran,
25 dihydropyran, tetrahydropyran, pyran, oxetane, thietane, 1,4-dioxane, 1,3-dioxane, 1,3-dioxolane, piperidine, piperazine, tetrahydropyrimidine, pyrrolidine, morpholine, thiomorpholine, thiazolidine, oxazolidine, tetrahydrothiopyran, tetrahydrothiophene, and the like. The heterocycle may optionally be substituted on any available carbon or heteroatom with one or
30 more substituents selected from the group consisting of halo, alkyl, alkenyl,


alkynyl, oxo, hydroxyl, carboxyl, alkylcarboxyl, alkylether, mercapto, sulfonyl, sulfinyl, alkylsulfonyl, sulfonamido, amino, alkylamino, dialkylamino, acetylamino, amino sulfonamide and cyano.

- 5 The term "heteroaryl" refers to aromatic monocyclic groups and fused bicyclic groups wherein at least one ring is aromatic, having the specified number of members and containing 1, 2, 3, or 4 heteroatoms selected from N, O and S (unless a different number of heteroatoms is specified). Examples of particular heteroaryl groups include but are not limited to furan, thiophene,
10 pyrrole, imidazole, pyrazole, triazole, tetrazole, thiazole, oxazole, isoxazole, oxadiazole, thiadiazole, isothiazole, pyridine, pyridazine, pyrazine, pyrimidine, quinoline, isoquinoline, benzofuran, benzothiophene, indole, and indazole. The heteroaryl may optionally be substituted on any available carbon or heteroatom with one or more substituents selected from the group consisting
15 of halo, alkyl, alkenyl, alkynyl, oxo, hydroxyl, carboxyl, alkylcarboxyl, alkylether, mercapto, sulfonyl, sulfinyl, alkylsulfonyl, sulfonamido, amino, alkylamino, dialkylamino, acetylamino, amino sulfonamide and cyano.

- The term "members" (and variants thereof e.g., "membered") in the context
20 of heterocyclic and heteroaryl groups refers to the total atoms, carbon and heteroatoms N, O and/or S, which form the ring. Thus, an example of a 6-membered heterocyclic ring is piperidine and an example of a 6-membered heteroaryl ring is pyridine.
- 25 As used herein, the term "optionally" means that the subsequently described event(s) may or may not occur, and includes both event(s) that occur and events that do not occur.

The present invention provides compounds of formula (I):

5



I

wherein:

R^1 is selected from the group consisting of H, halo, alkyl, alkenyl, alkynyl;

10 R^2 is selected from the group consisting of halo, alkyl, alkenyl, alkynyl,

cycloalkyl, cycloalkenyl, $-(R^7)_g-C(O)R^6$, $-(R^7)_g-CO_2R^6$, $-(R^7)_g-C(O)N(R^6)_2$,
 $-(R^7)_g-OR^6$, $-O-(R^7)_g-Ay$, $-(R^7)_g-S(O)_eR^6$, $-(R^7)_g-N(R^6)_2$,
 $-(R^7)_g-N(R^6)C(O)R^6$, $-(R^7)_g-CN$, $-(R^7)_g-SCN$, $-NO_2$, $-N_3$, Ay and 5- to 9-
membered heteroaryl containing 1 or 2 heteroatoms selected from N,


15 O and S;

each R^3 is the same or different and is independently H or alkyl;

Y is selected from the group consisting of $-C(O)R^8$, $-C(S)R^8$, $-S(O)_eR^9$,

$-S(O)_eN(R^9)_2$, $-N(R^9)_2$, $-N(R^9)-S(O)_eR^9$, $-N(R^9)-C(O)R^9$, $-N(R^9)-CO_2R^9$,
and $-N(R^9)-C(O)N(R^9)_2$,

20 or Y, together with C-2 and C-3 form a fused ring system of formula A:



25

wherein

R^8 is selected from the group consisting of alkyl, alkenyl, alkynyl,

cycloalkyl, cycloalkenyl, Ay, Het, $-OR^6$, $-O-(R^7)_g-Ay$,

$-O-(R^7)_g-Het$, $-N(R^6)_2$, $-N(R^6)-(R^7)_g-Ay$, $-N(R^6)-(R^7)_g-Het$,

$-N(R^6)-(R^7)_g-OR^6$, $-N(R^6)-(R^7)_g-C(O)R^6$, $-N(R^6)-(R^7)_g-CO_2R^6$,

30 $-N(R^6)-(R^7)_g-SO_2R^6$, and $-N(R^6)-(R^7)_g-N(R^6)_2$;

- each R⁹ is the same or different and is independently selected from the group consisting of H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, Ay and Het;
- c is 0 or 1;
- 5 Z¹, Z², Z³ and Z⁴ are each independently selected from the group consisting of C, O, S and N, wherein when c is 0, at least one of Z¹, Z² and Z³ is C and wherein when c is 1, at least two of Z¹, Z², Z³ and Z⁴ are C;
- each dashed line represents an optional double bond;
- 10 d is 0, 1 or 2;
- each R¹⁰ is the same or different and is independently selected from the group consisting of halo, alkyl, oxo, hydroxy, mercapto and amino;
- a is 0, 1, 2 or 3;
- 15 each R⁴ is the same or different and is independently selected from the group consisting of halo, alkyl, alkenyl, alkynyl, -(R⁷)_g-cycloalkyl, -(R⁷)_g-cycloalkenyl, -(R⁷)_g-Ay, -(R⁷)_g-Het, -(R⁷)_g-C(O)R⁶, -(R⁷)_g-C(O)Ay, -(R⁷)_g-C(O)Het, -(R⁷)_g-CO₂R⁶, -(R⁷)_g-CO₂Ay, -(R⁷)_g-CO₂Het, -(R⁷)_g-C(O)N(R⁶)₂, -(R⁷)_g-OR⁶, -(R⁷)_g-OAy, -(R⁷)_g-OHet, -(R⁷)_g-OC(O)R⁶, -(R⁷)_g-OC(O)Ay, -(R⁷)_g-OC(O)Het, -(R⁷)_g-S(O)_eR⁶, -(R⁷)_g-S(O)_eAy, -(R⁷)_g-S(O)_eHet, -(R⁷)_g-S(O)_eN(R⁶)₂, -(R⁷)_g-S(O)_eN(R⁶)Ay, -(R⁷)_g-S(O)_eN(R⁶)Het, -(R⁷)_g-S(O)_eN(R⁶)C(O)R⁶, -(R⁷)_g-S(O)_eN(R⁶)C(O)Ay, -(R⁷)_g-S(O)_eN(R⁶)C(O)Het, -(R⁷)_g-S(O)_eN(R⁶)C(O)N(R⁶)₂, -(R⁷)_g-S(O)_eN(R⁶)S(O)_eR⁶, -(R⁷)_g-S(O)_eN(R⁶)S(O)_eAy, -(R⁷)_g-S(O)_eN(R⁶)S(O)_eHet, -NO₂, -CN, -SCN and -N₃, or
- 20 two adjacent R⁴ groups together with the carbon atoms to which they are bonded form a phenyl or a 5- or 6-membered heterocycle or heteroaryl containing 1 or 2 heteroatoms selected from the group consisting of O, N and S;
- 25
- 30 each e is the same or different and is independently 0, 1 or 2;

b is 0, 1, 2, 3, 4 or 5;

each R⁵ is the same or different and is a group of formula (R⁷)_g-R¹¹, or two

adjacent R⁵ groups are each the same or different and are

independently selected from the group consisting of alkyl, alkenyl,

5 -OR⁶, -S(O)_eR⁶ and -N(R⁶)₂ and, together with the carbon atoms to which they are bonded, they form a C₅₋₆cycloalkyl,

C₅₋₆cycloalkenyl or a 5- or 6-membered heterocycle or heteroaryl

containing 1 or 2 heteroatoms selected from the group consisting of N, O and S;

10 each R⁶ is the same or different and is independently selected from the group consisting of H, alkyl, alkenyl, alkynyl, cycloalkyl and cycloalkenyl;

g is 0 or 1;

R⁷ is alkylene or alkenylene;

Ay is aryl;

15 Het is a 5- or 6-membered heterocycle or heteroaryl containing 1, 2 or 3 heteroatoms selected from the group consisting of N, O and S;

R¹¹ is selected from the group consisting of halo, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, Ay, Het, -C(O)R⁶, -C(O)Ay, -C(O)Het, -CO₂R⁶, -CO₂Ay, -CO₂Het, -C(O)-R⁷-OR⁶, -C(O)-R⁷-OAy, -C(O)-R⁷-OHet,

20 -C(O)N(R⁶)₂, -C(O)N(R⁶)Ay, -C(O)N(R⁶)Het, -C(O)N(R⁶)-(R⁷)_g-N(R⁶)₂, -C(O)N(R⁶)-(R⁷)_g-CO₂R⁶, -C(O)N(R⁶)-(R⁷)_g-S(O)_eR⁶, -OR⁶, -OC(O)R⁶,

-O-(R⁷)_g-Ay, -OC(O)Ay, -O-(R⁷)_g-Het, -OC(O)Het, -O-R⁷-OR⁶,

-O-R⁷-N(R⁶)₂, -S(O)_eR⁶, -S(O)_e-(R⁷)_g-Ay, -S(O)_e-(R⁷)_g-Het,

-S(O)_e-(R⁷)_g-N(R⁶)₂, -S(O)_e-(R⁷)_g-N(R⁶)Ay, -S(O)_e-(R⁷)_g-N(R⁶)Het,

25 -S(O)_eN(R⁶)-(R⁷)_g-C(O)R⁶, -S(O)_eN(R⁶)-(R⁷)_g-C(O)Ay,

-S(O)_eN(R⁶)-(R⁷)_g-C(O)Het, -N(R⁶)₂, -N(R⁶)-(R⁷)_g-Ay, -N(R⁶)-(R⁷)_g-Het,

-N(R⁶)-(R⁷)_g-C(O)R⁶, -N(R⁶)-C(O)-(R⁷)_g-Ay, -N(R⁶)-C(O)-(R⁷)_g-Het,

-N(R⁶)-C(O)-(R⁷)_g-N(R⁶)₂, -N(R⁶)-C(O)-(R⁷)_g-N(R⁶)Ay,

-N(R⁶)-C(O)-(R⁷)_g-N(R⁶)Het,

30 -N(R⁶)-C(O)-(R⁷)_g-N(R⁶)-(R⁷-O)_h-N(R⁶)-CO₂R⁶,

-N(R⁶)-(R⁷)_g-S(O)_eR⁶, -N(R⁶)-(R⁷)_g-S(O)_eAy, -N(R⁶)-(R⁷)_g-S(O)_eHet,
-N(R⁶)-R⁷-N(R⁶)₂, -N(R⁶)-R⁷-OR⁶, -CN, -SCN, -NO₂, and -N₃; and

h is 1-20;

wherein when R¹ is -CH₃, R² is Br or NO₂, both R³ are H, a is 0 and b is 0 or 1

5 wherein R⁵ is -CO₂H, then Y is not -CO₂H

or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof.

In one embodiment, the compounds of formula (I) are defined wherein R¹ is
10 selected from the group consisting of H, halo and alkyl, or any subset thereof.
In one particular embodiment, R¹ is selected from the group consisting of H and alkyl, or any subset thereof. In one embodiment, R¹ is H. Specific examples of groups defining R¹ include but are not limited to H, fluoro, chloro, bromo, methyl, ethyl, propyl and isopropyl. In one particular
15 embodiment, R¹ is selected from the group consisting of H, fluoro, chloro and methyl.

In one embodiment, the compounds of formula (I) are defined wherein R² is selected from the group consisting of halo, alkyl, alkenyl, -(R⁷)_g-C(O)R⁶,
20 -(R⁷)_g-C(O)N(R⁶)₂, -(R⁷)_g-CN and -NO₂, or any subset thereof. In one embodiment, R² is selected from the group consisting of halo, alkyl, alkenyl, -(R⁷)_g-C(O)N(R⁶)₂, -(R⁷)_g-CN and -NO₂, or any subset thereof. In one particular embodiment, R² is -NO₂. Specific examples of groups defining R² include but are not limited to fluoro, chloro, bromo, methyl, ethyl, -C(O)H,
25 -C(O)CH₃, -CH=CH₂, -CH=CHC(O)NH₂, -NO₂ and -CN.

In one embodiment, the compounds of formula (I) are defined wherein each R³ is the same or different and is independently H or methyl. In one embodiment, one R³ is methyl and one R³ is H. In one embodiment, each R³ is H.
30

In one embodiment, the compounds of formula (I) are defined wherein Y is selected from the group consisting of $-C(O)R^8$, $-C(S)R^8$, $-S(O)_eR^9$, $-S(O)_eN(R^9)_2$, $-N(R^9)_2$ and $-N(R^9)-S(O)_eR^9$, or any subset thereof. In one embodiment, Y is selected from the group consisting of $-C(O)R^8$, $-S(O)_eR^9$, $-S(O)_eN(R^9)_2$, $-N(R^9)_2$ and $-N(R^9)-S(O)_eR^9$, or any subset thereof. In one particular embodiment, Y is $-C(O)R^8$.


In one embodiment of the present invention wherein Y is $-C(O)R^8$ or $-C(S)R^8$, R⁸ is selected from the group consisting of R⁸ is selected from the group consisting of alkyl, cycloalkyl, cycloalkenyl, Ay, $-OR^6$, $-O-(R^7)_g-Ay$, $-N(R^6)_2$ and $-N(R^6)-(R^7)_g-Ay$, or any subset thereof. In one embodiment, R⁸ is selected from the group consisting of alkyl, cycloalkyl, Ay, $-OR^6$ and $-N(R^6)_2$, or any subset thereof. In one particular embodiment, R⁸ is selected from the group consisting of alkyl, Ay, $-OR^6$ and $-N(R^6)_2$, or any subset thereof. In one embodiment, Y is $-C(O)R^8$ and R⁸ is $-OR^6$ or $-N(R^6)_2$.

Specific examples of some groups defining R⁸ include but are not limited to methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, ethenyl, propenyl, cyclopentyl, cyclohexyl, phenyl, -OH, -O-methyl, -O-ethyl, -O-propyl, 20 -O-isopropyl, -O-butyl, -O-isobutyl, -O-t-butyl, -O-cyclopentyl, -O-cyclohexyl, -O-phenyl, -O-CH₂-phenyl, -NH₂, -N(H)alkyl, -N(alkyl)₂, -N(H)cycloalkyl, -N(alkyl)cycloalkyl, -N(H)phenyl, -N(alkyl)phenyl, -N(H)CH₂-phenyl, -N(H)CH₂-CO₂H and $-N(H)(CH_2)_2-OCH_3$ and optionally substituted variants thereof consistent with the definitions of terms provided above.

25 In one embodiment of the present invention wherein Y is selected from the group consisting of $-S(O)_eR^9$, $-S(O)_eN(R^9)_2$, $-N(R^9)_2$ and $-N(R^9)-S(O)_eR^9$, each R⁹ is the same or different and is independently selected from H, alkyl, alkenyl, cycloalkyl, Ay and Het, or any subset thereof. In one embodiment, 30 each R⁹ is the same or different and is independently selected from the group

consisting of H, alkyl and cycloalkyl, or any subset thereof. In one particular embodiment, each R⁹ is the same or different and is independently selected from the group consisting of H and alkyl, or any subset thereof. Specific examples of some groups defining R⁹ include but are not limited to H, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, ethenyl, propenyl, cyclopentyl, cyclohexyl and phenyl, and optionally substituted variants thereof consistent with the definitions of terms provided above.

5 In another embodiment, Y together with C-2 and C-3 form a fused ring system of formula A:



wherein

10 c is 0 or 1;

15 Z¹, Z², Z³ and Z⁴ are each independently selected from the group consisting of C, O, S and N, wherein when c is 0, at least one of Z¹, Z² and Z³ is C (carbon) and wherein when c is 1, at least two of Z¹, Z², Z³ and Z⁴ are C (carbon);

20 each dashed line represents an optional double bond;

d is 0, 1 or 2;

each R¹⁰ is the same or different and is independently selected from the group consisting of halo, alkyl, oxo, hydroxy, mercapto and amino.

25

In the embodiment wherein Y together with C-2 and C-3 form a fused ring system of formula A and c is 0, the fused ring system of formula A is a five-membered ring fused at C-2 and C-3. When the fused ring system of formula A is a five-membered ring, typically, at least one of Z¹, Z² and Z³ is carbon; and in one particular embodiment, at least two of Z¹, Z² and Z³ are carbon.



In the embodiment wherein Y together with C-2 and C-3 form a fused ring system of formula A and c is 1, the fused ring system of formula A is a six-membered ring fused at C-2 and C-3. When the fused ring system of formula A is a six-membered ring, typically, at least two of Z¹, Z², Z³ and Z⁴ is carbon.

5



In one particular embodiment wherein Y together with C-2 and C-3 form a fused ring system of formula A, at least one of Z¹, Z², Z³ and Z⁴ is selected from the group consisting of N, O and S. In another particular embodiment, at least two of Z¹, Z², Z³ and Z⁴ is selected from the group consisting of N, O 10 and S.

Specific examples of particular fused ring systems of formula A, defining Y include but are not limited to:


15




20



25




30



and

or any subset thereof, wherein d and R¹⁰ are as defined above and each dashed line represents an optional double bond. The foregoing is intended to encompass both orientations of the moiety, i.e.,

5



Based on the foregoing examples one skilled in the art can readily ascertain other possible fused ring systems of formula A which are contemplated by the present invention.

10

In one embodiment of the present invention, when Y together with C-2 and C-3 form a fused ring system of formula A, d is 0 or 1. In one particular embodiment, d is 0. In one particular embodiment, d is 1.

15


In the embodiment of the present invention wherein Y together with C-2 and C-3 form a fused ring system of formula A and d is 1 or 2, each R¹⁰ is the same or different and is independently selected from halo, alkyl, oxo, hydroxyl, mercapto and amino. In such embodiments, each R¹⁰ may be bound to any available atom Z¹, Z², Z³, or Z⁴ (when c is 1), including any available heteroatom, consistent with the particular choice of substituent R¹⁰. According to one embodiment wherein d is 1 or 2, each R¹⁰ is the same or different and is independently selected from halo, alkyl, oxo and hydroxyl. In one embodiment, each R¹⁰ is the same or different and is halo or alkyl. Specific examples of groups defining R¹⁰ include but are not limited to hydroxyl, oxo, chloro, bromo, methyl, ethyl, propyl and isopropyl.

25

In one embodiment of the present invention, the compounds of formula (I) are defined wherein Y is selected from the group consisting of -C(O)alkyl, -C(O)NH₂, -C(O)N(H)alkyl, -C(O)N(H)cycloalkyl, -C(O)N(alkyl)₂, -C(O)phenyl, -C(O)N(H)phenyl, -CO₂H, -CO₂alkyl, -CO₂cycloalkyl, -CO₂phenyl, -S-alkyl,


30

-NH₂, -N(H)alkyl, -N(alkyl)₂, -N(H)cycloalkyl, -N(H)phenyl, consistent with the definitions of terms provided above; or Y together with C-2 and C-3 form a fused ring system selected from the group consisting of:




or any subset thereof, wherein d and R¹⁰ are as defined above and each dashed line represents an optional double bond.

In one embodiment, wherein Y is a fused ring system of formula A, it is not



In one embodiment wherein Y is a fused ring system of formula A, it is not




In one embodiment, the compounds of formula (I) are defined wherein a is 0 or 1. In one particular embodiment, a is 1. In another particular embodiment, a is 0. In those embodiments wherein Y together with C-2 and C-3 form a fused ring system of formula A, typically a is 0.

In those embodiments of the present invention wherein a is 1 or more, each R⁴ is the same or different and is independently selected from the group

consisting of halo, alkyl, alkenyl, alkynyl, -(R⁷)_g-cycloalkyl, -(R⁷)_g-cycloalkenyl, -(R⁷)_g-Ay, -(R⁷)_g-Het, -(R⁷)_g-C(O)R⁶, -(R⁷)_g-C(O)Ay, -(R⁷)_g-C(O)Het, -(R⁷)_g-CO₂R⁶, -(R⁷)_g-CO₂Ay, -(R⁷)_g-CO₂Het, -(R⁷)_g-C(O)N(R⁶)₂, -(R⁷)_g-OR⁶, -(R⁷)_g-OAy, -(R⁷)_g-OHet, -(R⁷)_g-OC(O)R⁶, -(R⁷)_g-OC(O)Ay, -(R⁷)_g-OC(O)Het, 5 -(R⁷)_g-S(O)_eR⁶, -(R⁷)_g-S(O)_eAy, -(R⁷)_g-S(O)_eHet, -(R⁷)_g-S(O)_eN(R⁶)₂, -(R⁷)_g-S(O)_eN(R⁶)Ay, -(R⁷)_g-S(O)_eN(R⁶)Het, -(R⁷)_g-N(R⁶)₂, -(R⁷)_g-N(R⁶)Ay, -(R⁷)_g-N(R⁶)Het, -(R⁷)_g-N(R⁶)C(O)R⁶, -(R⁷)_g-N(R⁶)C(O)Ay, -(R⁷)_g-N(R⁶)C(O)Het, -(R⁷)_g-N(R⁶)C(O)N(R⁶)₂, -(R⁷)_g-N(R⁶)S(O)_eR⁶, -(R⁷)_g-N(R⁶)S(O)_eAy, -(R⁷)_g-N(R⁶)S(O)_eHet, -NO₂, -CN, -SCN and -N₃, or two adjacent R⁴ groups 10 together with the carbon atoms to which they are bonded form a phenyl or a 5- or 6-membered heterocycle or heteroaryl containing 1 or 2 heteroatoms selected from the group consisting of O, N and S.

In one embodiment, R⁴ is defined wherein R⁷ is C₁₋₃alkyl. In one 15 embodiment, R⁴ is defined wherein g is 0.


By "two adjacent R⁴ groups" is meant two R⁴ groups bonded to adjacent carbon atoms of the phenyl ring. One example of two adjacent R⁴ groups is one R⁴ group bonded to C-3 and one R⁴ group bonded to C-4. In one 20 embodiment, two adjacent R⁴ groups together with the carbon atoms to which they are bonded form a phenyl or a 5 or 6-membered heterocycle containing 1 or 2 heteroatoms. In those embodiments, wherein two adjacent R⁴ groups together with the carbon atoms to which they are bonded form a phenyl or a or a 5- or 6-membered heterocycle or heteroaryl containing 1 or 2 25 heteroatoms selected from the group consisting of O, N and S, each R⁴ is the same or different and is typically selected from the group consisting of alkyl, alkenyl, -(R⁷)_g-OR⁶, -(R⁷)_g-S(O)_eR⁶, and -(R⁷)_g-N(R⁶)₂, where in one embodiment, g is 0. For example, in one embodiment two adjacent R⁴ groups are -OR⁶ and together with the carbon atoms to which they are 30 bonded, they form a heterocyclic group such as:




In another embodiment, two adjacent R⁴ groups are alkenyl and together
5 with the carbon atoms to which they are bonded, they form a phenyl.

In another embodiment two adjacent R⁴ groups are defined as -OR⁶ and
- (R⁷)_g-N(R⁶)₂ respectively, and together with the carbon atoms to which they
are bonded, they form a heterocyclic group such as:

10



In another embodiment two adjacent R⁴ groups are defined as -(R⁷)_g-S(O)_eR⁶
and -(R⁷)_g-N(R⁶)₂ respectively, and together with the carbon atoms to which
15 they are bonded, they form a heterocyclic group such as:



From these examples, additional embodiments can be readily ascertained by
20 those skilled in the art.

In the embodiment wherein two adjacent R⁴ groups bonded at C-3 and C-4 of
the phenyl ring together with the carbon atoms form a phenyl or 5- or 6-
membered heterocycle or heteroaryl ring, then Y, together with C-2 and C-3
25 do not form a fused ring system of formula A.

In one particular embodiment, two adjacent R⁴ groups together with the
carbon atoms to which they are bonded do not form a phenyl or a 5- or 6-
membered heterocycle or heteroaryl containing 1 or 2 heteroatoms selected
30 from the group consisting of O, N and S.

In one embodiment, each R⁴ is the same or different and is independently selected from the group consisting of halo, alkyl, alkenyl, alkynyl, -(R⁷)_g-cycloalkyl, -(R⁷)_g-cycloalkenyl, -(R⁷)_g-Ay, -(R⁷)_g-Het, -(R⁷)_g-C(O)R⁶, -(R⁷)_g-C(O)Ay, -(R⁷)_g-C(O)Het, -(R⁷)_g-CO₂R⁶, -(R⁷)_g-CO₂Ay, -(R⁷)_g-CO₂Het, 5 -(R⁷)_g-C(O)N(R⁶)₂, -(R⁷)_g-OR⁶, -(R⁷)_g-OAy, -(R⁷)_g-OHet, -(R⁷)_g-OC(O)R⁶, -(R⁷)_g-OC(O)Ay, -(R⁷)_g-OC(O)Het, -(R⁷)_g-S(O)_eR⁶, -(R⁷)_g-S(O)_eAy, -(R⁷)_g-S(O)_eN(R⁶)₂, -(R⁷)_g-S(O)_eN(R⁶)Ay, -(R⁷)_g-S(O)_eN(R⁶)Het, -(R⁷)_g-N(R⁶)₂, 10 -(R⁷)_g-N(R⁶)Ay, -(R⁷)_g-N(R⁶)Het, -(R⁷)_g-N(R⁶)C(O)R⁶, -(R⁷)_g-N(R⁶)C(O)N(R⁶)₂, -NO₂, -CN, -SCN and -N₃, or any subset thereof. More particularly, in one 15 embodiment, each R⁴ is the same or different and is independently selected from the group consisting of halo, alkyl, -(R⁷)_g-cycloalkyl, -(R⁷)_g-C(O)R⁶, -(R⁷)_g-CO₂R⁶, -(R⁷)_g-C(O)N(R⁶)₂, -(R⁷)_g-OR⁶, -(R⁷)_g-S(O)_eR⁶, -(R⁷)_g-N(R⁶)₂ and -(R⁷)_g-N(R⁶)C(O)R⁶, or any subset thereof. In one embodiment, each R⁴ is the same or different and is independently selected from the group consisting of halo, alkyl and -(R⁷)_g-OR⁶, or any subset thereof.

Specific examples of particular groups defining R⁴ include but are not limited to fluoro, chloro, bromo, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, hydroxy, -NHC(O)CH₃, -NHSO₂CH₃ and -SO₂NH₂.

- 20 In one embodiment of the present invention, b is 0, 1, 2 or 3. In one embodiment of the invention, b is 1, 2 or 3. In one particular embodiment, b is 2 or 3. In one particular embodiment, b is 3.
- 25 In those embodiments of the present invention wherein b is 1 or more, each R⁵ is the same or different and is a group of formula (R⁷)_g-R¹¹, or two adjacent R⁵ groups are each the same or different and are independently selected from the group consisting of alkyl, alkenyl, -OR⁶, -S(O)_eR⁶ and -N(R⁶)₂ and, together with the carbon atoms to which they are bonded, they 30 form a C₅-₆cycloalkyl, C₅-₆cycloalkenyl or a 5- or 6-membered heterocycle or

heteroaryl containing 1 or 2 heteroatoms selected from the group consisting of N, O and S. Specific examples of embodiments wherein two adjacent R⁵ groups together with the carbon atoms to which they are bonded form a C₅₋₆cycloalkyl, C₅₋₆cycloalkenyl or 5- or 6-membered heterocycle or heteroaryl containing 1 or 2 heteroatoms selected from N, O and S are described above in connection with the description of two adjacent R⁴ groups forming similar rings.

In one particular embodiment two adjacent R⁵ groups together with the carbon atoms to which they are bonded do not form a C₅₋₆cycloalkyl, C₅₋₆cycloalkenyl or 5- or 6-membered heterocycle or heteroaryl containing 1 or 2 heteroatoms selected from N, O and S.

In one embodiment of the present invention, each R⁵ is the same or different and is a group of formula (R⁷)_g-R¹¹, wherein g is 0. In one embodiment, each R⁵ is the same or different and is a group of formula (R⁷)_g-R¹¹, wherein g is 1. In one embodiment, each R⁵ is the same or different and is a group of formula (R⁷)_g-R¹¹, wherein g is 1 and R⁷ is C₁₋₃alkyl.

In one particular embodiment of the present invention, R⁵ is (R⁷)_g-R¹¹ wherien R¹¹ is selected from the group consisting of halo, alkyl, alkenyl, alkynyl, Ay, Het, -C(O)Het, -CO₂R⁶, -CO₂Ay, -CO₂Het, -C(O)N(R⁶)₂, -C(O)N(R⁶)Ay, -C(O)N(R⁶)Het, -C(O)N(R⁶)-(R⁷)_g-N(R⁶)₂, -C(O)N(R⁶)-(R⁷)_g-CO₂R⁶, -C(O)N(R⁶)-(R⁷)_g-S(O)_eR⁶, -OR⁶, -O-(R⁷)_g-Ay, -O-(R⁷)_g-Het, -O-R⁷-OR⁶, -O-R⁷-N(R⁶)₂, -S(O)_eR⁶, -S(O)_e-(R⁷)_g-Het, -S(O)_e-(R⁷)_g-N(R⁶)₂, -S(O)_e-(R⁷)_g-N(R⁶)Het, -S(O)_eN(R⁶)-(R⁷)_g-C(O)Het, -N(R⁶)₂, -N(R⁶)-(R⁷)_g-Ay, -N(R⁶)-(R⁷)_g-Het, -N(R⁶)-(R⁷)_g-C(O)R⁶, -N(R⁶)-C(O)-(R⁷)_g-Het, -N(R⁶)-C(O)-(R⁷)_g-N(R⁶)₂, -N(R⁶)-C(O)-(R⁷)_g-N(R⁶)-(R⁷-O)_h-N(R⁶)-CO₂R⁶, -N(R⁶)-(R⁷)_g-S(O)_eR⁶,

-N(R⁶)-(R⁷)_g-S(O)_eHet, -N(R⁶)-R⁷-N(R⁶)₂, -N(R⁶)-R⁷-OR⁶, -CN and -N₃, or any subset thereof.

More particularly, in one embodiment, R¹¹ is selected from the group consisting of halo, alkyl, Ay, Het, -CO₂R⁶, -C(O)N(R⁶)₂, -OR⁶, -O-(R⁷)_g-Ay, -O-(R⁷)_g-Het, -S(O)_eR⁶, -S(O)_e-(R⁷)_g-N(R⁶)₂, -N(R⁶)₂, -N(R⁶)-(R⁷)_g-Ay, -N(R⁶)-(R⁷)_g-Het, -N(R⁶)-(R⁷)_g-C(O)R⁶, -N(R⁶)-C(O)-(R⁷)_g-N(R⁶)₂, -N(R⁶)-C(O)-(R⁷)_g-N(R⁶)₂-(R⁷-O)_h-N(R⁶)-CO₂R⁶, -N(R⁶)-(R⁷)_g-S(O)_eR⁶, -N(R⁶)-R⁷-N(R⁶)₂, -CN and -N₃, or any subset thereof. In one particular embodiment, R¹¹ is selected from the group consisting of alkyl, Het, -OR⁶, -S(O)_eR⁶, -S(O)_e-(R⁷)_g-N(R⁶)₂, -N(R⁶)₂, -N(R⁶)-(R⁷)_g-C(O)R⁶ and -N(R⁶)-C(O)-(R⁷)_g-N(R⁶)₂.

Specific examples of particular groups defining R¹¹ include but are not limited to -OR⁶, -S(O)₂R⁶, -S(O)₂-N(R⁶)₂, -N(R⁶)-C(O)R⁶, -N(R⁶)-C(O)-N(R⁶)₂, -N(R⁶)-SO₂R⁶ and -N(R⁶)-SO₂Het. More particularly, groups defining R¹¹ include but are not limited to -OR⁶, -S(O)₂R⁶, -S(O)₂-N(R⁶)₂, -N(H)-C(O)R⁶, -N(H)-C(O)-N(R⁶)₂, -N(H)-SO₂R⁶ and -N(H)-SO₂Het. More specifically, in one embodiment each R¹¹ is the same or different and is independently selected from the group consisting of -OH, -OCH₃, -SO₂CH₃, -SO₂CH₂CH₃, -SO₂N(H)CH₃, -SO₂CH₂CH³, -N(H)-C(O)CH₃, -N(H)-C(O)-N(H)(CH₃) and -N(H)SO₂CH₃.

It is to be understood that the present invention includes all combinations and subsets of the particular groups defined hereinabove.

Specific compounds of formula (I) include but are not limited to:

2-({5-nitro-2-[(3,4,5-trimethoxyphenyl)amino]pyrimidin-4-yl}amino)benzoic acid hydrochloride;

- 2-(*{*5-nitro-2-[*(*3,4,5-trimethoxyphenyl)amino]pyrimidin-4-*y**l**}*amino)benzamide hydrochloride;
- N*-(*tert*-butyl)-2-(*{*5-nitro-2-[*(*3,4,5-trimethoxyphenyl)amino]pyrimidin-4-*y**l**}*amino)benzamide hydrochloride;
- 5 *N*-[4-(*{*4-[*(*2-benzoylphenyl)amino]pyrimidin-2-*y**l**}*amino)phenyl]acetamide hydrochloride;
- 8-(*{*5-nitro-2-[*(*3,4,5-trimethoxyphenyl)amino]pyrimidin-4-*y**l**}*amino)-3,4-dihydronephthalen-1(*2H*)-one hydrochloride;
- 10 1-[2-(*{*5-bromo-2-[*(*3,4,5-trimethoxyphenyl)amino]pyrimidin-4-*y**l**}*amino)phenyl]ethanone hydrochloride;
- 2-[*(*2-{*[*4-(acetylamino)phenyl]amino}-5-nitropyrimidin-4-*y**l**}*amino]-*N*-methylbenzamide hydrochloride;
- 15 *N*⁴-(1*H*indol-4-*y**l**)*-5-nitro-*N*²-(3,4,5-trimethoxyphenyl)pyrimidine-2,4-diamine hydrochloride;
- 20 Methyl 2-(*{*5-nitro-2-[*(*3,4,5-trimethoxyphenyl)amino]pyrimidin-4-*y**l**}*amino)benzoate hydrochloride;
- N*⁴-(2,3-dihydro-1,4-benzodioxin-5-*y**l**)*-5-nitro-*N*²-(3,4,5-trimethoxyphenyl)pyrimidine-2,4-diamine hydrochloride;
- Cyclohexyl 2-[*(*2-{*[*4-(acetylamino)phenyl]amino}-5-nitropyrimidin-4-*y**l**}*amino]benzoate hydrochloride;
- 25 5-Hydroxy-2-(*{*5-nitro-2-[*(*3,4,5-trimethoxyphenyl)amino]pyrimidin-4-*y**l**}*amino)benzoic acid hydrochloride;
- 2-[*(*2-{*[*4-(Acetylamino)phenyl]amino}-5-nitropyrimidin-4-*y**l**}*amino]benzoic acid hydrochloride;
- 30 *N*-[4-(*{*4-[*(*2-Acetylphenyl)amino]pyrimidin-2-*y**l**}*amino)phenyl]acetamide hydrochloride;
- N*-[4-(*{*5-Bromo-4-[*(*2-morpholin-4-*y**l*phenyl)amino]pyrimidin-2-*y**l**}*amino)phenyl]acetamide hydrochloride;
- 5-[*(*5-Bromo-4-{*[*2-(methylthio)phenyl]amino}pyrimidin-2-*y**l**}*amino]-1,3-dihydro-2*H*-benzimidazol-2-one hydrochloride;

- 5-Bromo-*N*⁴-(2-morpholin-4-ylphenyl)-*N*²-(3,4,5-trimethoxyphenyl)pyrimidine-2,4-diamine hydrochloride;
- N*[4-(5-Bromo-4-[(3,4,5-trimethoxyphenyl)amino]pyrimidin-2-yl)amino]phenyl]acetamide hydrochloride;
- 5 Dimethyl 2-[(2-{[4-(acetylamino)phenyl]amino}-5-nitropyrimidin-4-yl)amino]terephthalate hydrochloride;
- Benzyl 2-[(2-{[4-(acetylamino)phenyl]amino}-5-nitropyrimidin-4-yl)amino]benzoate hydrochloride;
- Methyl 2-[(2-{[4-(acetylamino)phenyl]amino}-5-nitropyrimidin-4-yl)amino]-6-methylbenzoate hydrochloride;
- 10 Isobutyl 2-[(2-{[4-(acetylamino)phenyl]amino}-5-nitropyrimidin-4-yl)amino]benzoate hydrochloride;
- 2-[(2-{[4-(Acetylamino)phenyl]amino}-5-nitropyrimidin-4-yl)amino]-6-methylbenzoic acid hydrochloride;
- 15 *N*-Cyclohexyl-2-({5-nitro-2-[(3,4,5-trimethoxyphenyl)amino]pyrimidin-4-yl}amino)benzamide hydrochloride;
- 1-[2-({5-Nitro-2-[(3,4,5-trimethoxyphenyl)amino]pyrimidin-4-yl}amino)phenyl]ethanone hydrochloride;
- [5-Chloro-2-({5-nitro-2-[(3,4,5-trimethoxyphenyl)amino]pyrimidin-4-20-yl}amino)phenyl](2-fluorophenyl)methanone hydrochloride;
- 8-({5-Nitro-2-[(3,4,5-trimethoxyphenyl)amino]pyrimidin-4-yl}amino)-2-naphthol hydrochloride;
- N-(*tert*-butyl)-2-({5-methyl ketone-2-[(3,4,5- trimethoxyphenyl)amino]pyrimidin-4-yl} amino) benzamide;
- 25 4-{{2-[(4-Methylbenzoyl)phenyl]amino}-2-[(3,4,5-trimethoxyphenyl)amino]-pyrimidine-5-carbonitrile
- and pharmaceutically acceptable salts, solvates and physiologically functional derivatives thereof.

It will be appreciated by those skilled in the art that the compounds of the present invention may also be utilized in the form of a pharmaceutically acceptable salt or solvate or physiologically functional derivative thereof. The pharmaceutically acceptable salts of the compounds of formula (I) include

- 5 conventional salts formed from pharmaceutically acceptable inorganic or organic acids or bases as well as quaternary ammonium salts. More specific examples of suitable acid salts include hydrochloric, hydrobromic, sulfuric, phosphoric, nitric, perchloric, fumaric, acetic, propionic, succinic, glycolic, formic, lactic, maleic, tartaric, citric, palmoic, malonic, hydroxymaleic,
10 phenylacetic, glutamic, benzoic, salicylic, fumaric, toluenesulfonic, methanesulfonic (mesylate), naphthalene-2-sulfonic, benzenesulfonic hydroxynaphthoic, hydroiodic, malic, steroic, tannic and the like.

Other acids such as oxalic, while not in themselves pharmaceutically acceptable, may be useful in the preparation of salts which are useful as intermediates in obtaining the compounds of the invention or pharmaceutically acceptable salts thereof. More specific examples of suitable basic salts include sodium, lithium, potassium, magnesium, aluminium, calcium, zinc, N,N'-dibenzylethylenediamine, chloroprocaine, choline,
20 diethanolamine, ethylenediamine, N-methylglucamine and procaine salts.

The term "solvate" as used herein refers to a complex of variable stoichiometry formed by a solute (a compound of formula (I)) and a solvent. Solvents, by way of example, include water, methanol, ethanol, or acetic acid.

- 25 The term "physiologically functional derivative" as used herein refers to any pharmaceutically acceptable derivative of a compound of the present invention, for example, an ester or an amide of a compound of formula (I), which upon administration to an animal, particularly a mammal, such as a human, is capable of providing (directly or indirectly) a compound of the present invention or an active metabolite thereof. See, for example, Burger's
30

Medicinal Chemistry And Drug Discovery, 5th Edition, Vol 1: Principles And Practice.

Processes for preparing pharmaceutically acceptable salts, solvates and 5 physiologically functional derivatives of the compounds of formula (I) are conventional in the art. *See, e.g., Burger's Medicinal Chemistry And Drug Discovery 5th Edition, Vol 1: Principles And Practice.*

As will be apparent to those skilled in the art, in the processes described

10 below for the preparation of compounds of formula (I), certain intermediates, may be in the form of pharmaceutically acceptable salts, solvates or physiologically functional derivatives of the compound. Those terms as applied to any intermediate employed in the process of preparing compounds of formula (I) have the same meanings as noted above with respect to 15 compounds of formula (I). Processes for preparing pharmaceutically acceptable salts, solvates and physiologically functional derivatives of such intermediates are known in the art and are analogous to the process for preparing pharmaceutically acceptable salts, solvates and physiologically functional derivatives of the compounds of formula (I).

20 Certain compounds of formula (I) may exist in stereoisomeric forms (e.g. they may contain one or more asymmetric carbon atoms or may exhibit *cis-trans* isomerism). The individual stereoisomers (enantiomers and diastereomers) and mixtures of these are included within the scope of the present invention.

25 The present invention also covers the individual isomers of the compounds represented by formula (I) as mixtures with isomers thereof in which one or more chiral centres are inverted. Certain compounds of formula (I) may be prepared as a mixture of regioisomers. The present invention covers both the mixture of regioisomers as well as the individual compounds. Likewise, it is 30 understood that compounds of formula (I) may exist in tautomeric forms

other than that shown in the formula and these are also included within the scope of the present invention.

The compounds of the present invention are typically inhibitors of PLK. By
5 "PLK inhibitor" is meant a compound which exhibits pIC₅₀ greater than 4 in the PLK Inhibition assay described below in the examples or an IC₅₀ less than 100 μM in the Methylene Blue Growth Inhibition assay described below in the examples; more particularly a PLK inhibitor is a compound which exhibits a pIC₅₀ greater than 5 or an IC₅₀ less than 10 μM using the methods described
10 in the examples below.

The present invention further provides compounds of formula (I) for use in medical therapy in an animal, e.g. a mammal such as a human. In particular, the present invention provides compounds of formula (I) for use in the
15 treatment of a condition mediated by PLK. The present invention also provides compounds of formula (I) for use in the treatment of a susceptible neoplasm. The present invention provides compounds of formula (I) for use in treating a condition characterized by inappropriate cellular proliferation. The present invention also provides compounds of formula (I) for use in
20 inhibiting proliferation of a cell. The present invention also provides compounds of formula (I) for use in inhibiting mitosis in a cell.

The present invention provides methods for the treatment of several conditions or diseases, all of which comprise the step of administering a
25 therapeutically effective amount of a compound of formula (I). As used herein, the term "treatment" refers to alleviating the specified condition, eliminating or reducing the symptoms of the condition, slowing or eliminating the progression of the condition and preventing or delaying the reoccurrence of the condition in a previously afflicted subject.

As used herein, the term "therapeutically effective amount" means an amount of a compound of formula (I) which is sufficient, in the subject to which it is administered, to elicit the biological or medical response of a cell culture, tissue, system, animal (including human) that is being sought, for instance,
5 by a researcher or clinician. For example, a therapeutically effective amount of a compound of formula (I) for the treatment of a condition mediated by PLK is an amount sufficient to treat the PLK mediated condition in the subject. Similarly, a therapeutically effective amount of a compound of formula (I) for the treatment of a susceptible neoplasm is an amount sufficient to treat the
10 susceptible neoplasm in the subject. In one embodiment of the present invention, the therapeutically effective amount of a compound of formula (I) is an amount sufficient to inhibit cell mitosis. In one embodiment of the present invention, a therapeutically effective amount of a compound of formula (I) is an amount sufficient to regulate, modulate, bind or inhibit PLK.
15
The precise therapeutically effective amount of the compounds of formula (I) will depend on a number of factors including, but not limited to, the age and weight of the subject being treated, the precise disorder requiring treatment and its severity, the nature of the formulation, and the route of
20 administration, and will ultimately be at the discretion of the attendant physician or veterinarian. Typically, the compound of formula (I) will be given for treatment in the range of 0.1 to 200 mg/kg body weight of recipient (animal) per day and more usually in the range of 1 to 100 mg/kg body weight per day. Acceptable daily dosages, may be from about 0.1 to about
25 2000 mg/day, and preferably from about 0.1 to about 100 mg/day.

As one aspect, the present invention provides methods of regulating, modulating, binding, or inhibiting PLK for the treatment of conditions mediated by PLK. "Regulating, modulating, binding or inhibiting PLK" refers to regulating, modulating, binding or inhibiting PLK activity, as well as
30

regulating, modulating, binding or inhibiting overexpression of PLK. Such conditions include certain neoplasms (including cancers and tumors) which have been associated with PLK and conditions characterized by inappropriate cellular proliferation.

5

The present invention provides a method for treating a condition mediated by PLK in an animal such as a mammal (e.g., a human), which method comprises administering to the animal a therapeutically effective amount of the compound of formula (I). Conditions which are mediated by PLK are known in the art and include but are not limited to neoplasms and conditions characterized by inappropriate cellular proliferation.

10 The present invention also provides a method for treating a susceptible neoplasm (cancer or tumor) in an animal such as a mammal (e.g., a human),

15 which method comprises administering to the animal a therapeutically effective amount of the compound of formula (I). "Susceptible neoplasm" as used herein refers to neoplasms which are susceptible to treatment with a PLK inhibitor. Neoplasms which have been associated with PLK and are therefore susceptible to treatment with a PLK inhibitor are known in the art, and include both primary and metastatic tumors and cancers. For example, susceptible neoplasms within the scope of the present invention include but are not limited to breast cancer, colon cancer, lung cancer (including small cell lung cancer and non-small cell lung cancer), prostate cancer, lymphoma, leukemia, endometrial cancer, melanoma, ovarian cancer, pancreatic cancer, squamous carcinoma, carcinoma of the head and neck, and esophageal carcinoma. The compounds of formula (I) can be used alone in the treatment of such susceptible neoplasms or can be used to provide additive or synergistic effects with certain existing chemotherapies, and/or be used to restore effectiveness of certain existing chemotherapies and radiation.

20
25
30

The present invention also provides a method for treating a condition characterized by inappropriate cellular proliferation. By "inappropriate cellular proliferation" is meant cellular proliferation resulting from inappropriate cell growth, cellular proliferation resulting from excessive cell division, cellular proliferation resulting from cell division at an accelerated rate, cellular proliferation resulting from inappropriate cell survival, and/or cellular proliferation in a normal cell occurring at a normal rate, which is nevertheless undesired. Conditions characterized by inappropriate cellular proliferation include but are not limited to neoplasms, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders and metabolic diseases. Blood vessel proliferative disorders include arthritis and restenosis. Fibrotic disorders include hepatic cirrhosis and atherosclerosis. Mesangial cell proliferative disorders include glomerulonephritis, malignant nephrosclerosis, thrombotic microangiopathy syndromes, organ transplant rejection and glomerulopathies. Metabolic disorders include psoriasis, chronic wound healing, inflammation and neurodegenerative diseases. Osteoarthritis and other osteoclast proliferation dependent diseases of excess bone resorption are examples of conditions characterized by inappropriate cellular proliferation in which the cellular proliferation occurs in normal cells at a normal rate, but is nevertheless undesired.

The present invention also provides a method for inhibiting proliferation of a cell, which method comprises contacting the cell with an amount of a compound of formula (I) sufficient to inhibit proliferation of the cell. In one particular embodiment, the cell is a neoplastic cell. In one particular embodiment, the cell is an inappropriately proliferative cell. The term "inappropriately proliferative cell" as used herein refers to cells that grow inappropriately (abnormally), cells that divide excessively or at an accelerated rate, cells that inappropriately (abnormally) survive and/or normal cells that proliferate at a normal rate but for which proliferation is undesired.

Neoplastic cells (including cancer cells) are an example of inappropriately proliferative cells but are not the only inappropriately proliferative cells.

PLK is essential for cellular mitosis and accordingly, the compounds of formula (I) are effective for inhibiting mitosis. "Inhibiting mitosis" refers to inhibiting the entry into the M phase of the cell cycle, inhibiting the normal progression of the M phase of the cell cycle once M phase has been entered and inhibiting the normal exit from the M phase of the cell cycle. Thus, the compounds of the present invention may inhibit mitosis by inhibiting the cell's entry into mitosis, by inhibiting the cell's progression through mitosis or by inhibiting the cell's exit from mitosis. As one aspect, the present invention provides a method for inhibiting mitosis in a cell, which method comprises administering to the cell an amount of a compound of formula (I) sufficient to inhibit mitosis. In one particular embodiment, the cell is a neoplastic cell. In one particular embodiment, the cell is an inappropriately proliferative cell.

The present invention also provides the use of a compound of formula (I) for the preparation of a medicament for the treatment of condition mediated by PLK in an animal, such as a mammal (e.g., a human). The present invention further provides the use of a compound of formula (I) for the preparation of a medicament for the treatment of a susceptible neoplasm in an animal. The present invention further provides the use of a compound of formula (I) for the preparation of a medicament for the treatment of a condition characterized by inappropriate cellular proliferation. The present invention further provides the use of a compound of formula (I) for the preparation of a medicament for inhibiting proliferation of a cell. The present invention further provides the use of a compound of formula (I) for the preparation of a medicament for inhibiting mitosis in a cell.

- While it is possible that, for use in therapy, a therapeutically effective amount of a compound of formula (I) may be administered as the raw chemical, it is typically presented as the active ingredient of a pharmaceutical composition or formulation. Accordingly, the invention further provides a pharmaceutical 5 composition comprising a compound of the formula (I). The pharmaceutical composition may further comprise one or more pharmaceutically acceptable carriers, diluents, and/or excipients. The carrier(s), diluent(s) and/or excipient(s) must be acceptable in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient 10 thereof. In accordance with another aspect of the invention there is also provided a process for the preparation of a pharmaceutical formulation including admixing a compound of the formula (I) with one or more pharmaceutically acceptable carriers, diluents and/or excipients.
- 15 Pharmaceutical formulations may be presented in unit dose form containing a predetermined amount of active ingredient per unit dose. Such a unit may contain a therapeutically effective dose of the compound of formula (I) or a fraction of a therapeutically effective dose such that multiple unit dosage forms might be administered at a given time to achieve the desired 20 therapeutically effective dose. Preferred unit dosage formulations are those containing a daily dose or sub-dose, as herein above recited, or an appropriate fraction thereof, of an active ingredient. Furthermore, such pharmaceutical formulations may be prepared by any of the methods well known in the pharmacy art.
- 25 Pharmaceutical formulations may be adapted for administration by any appropriate route, for example by the oral (including buccal or sublingual), rectal, nasal, topical (including buccal, sublingual or transdermal), vaginal or parenteral (including subcutaneous, intramuscular, intravenous or intradermal) route. Such formulations may be prepared by any method 30

known in the art of pharmacy, for example by bringing into association the active ingredient with the carrier(s) or excipient(s).

Pharmaceutical formulations adapted for oral administration may be

5 presented as discrete units such as capsules or tablets; powders or granules; solutions or suspensions in aqueous or non-aqueous liquids; edible foams or whips; or oil-in-water liquid emulsions or water-in-oil liquid emulsions.

For instance, for oral administration in the form of a tablet or capsule, the

10 active drug component can be combined with an oral, non-toxic pharmaceutically acceptable inert carrier such as ethanol, glycerol, water and the like. Powders are prepared by comminuting the compound to a suitable fine size and mixing with a similarly comminuted pharmaceutical carrier such as an edible carbohydrate, as, for example, starch or mannitol. Flavoring, preservative, dispersing and coloring agent can also be present.

Capsules are made by preparing a powder mixture as described above, and

filling formed gelatin sheaths. Glidants and lubricants such as colloidal silica,

talc, magnesium stearate, calcium stearate or solid polyethylene glycol can be

20 added to the powder mixture before the filling operation. A disintegrating or solubilizing agent such as agar-agar, calcium carbonate or sodium carbonate can also be added to improve the availability of the medicament when the capsule is ingested.

25 Moreover, when desired or necessary, suitable binders, lubricants, disintegrating agents and coloring agents can also be incorporated into the mixture. Suitable binders include starch, gelatin, natural sugars such as glucose or beta-lactose, corn sweeteners, natural and synthetic gums such as acacia, tragacanth or sodium alginate, carboxymethylcellulose, polyethylene glycol, waxes and the like. Lubricants used in these dosage forms include

sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride and the like. Disintegrators include, without limitation, starch, methyl cellulose, agar, bentonite, xanthan gum and the like. Tablets are formulated, for example, by preparing a powder mixture,

- 5 granulating or slugging, adding a lubricant and disintegrant and pressing into tablets. A powder mixture is prepared by mixing the compound, suitably comminuted, with a diluent or base as described above, and optionally, with a binder such as carboxymethylcellulose, an aligate, gelatin, or polyvinyl pyrrolidone, a solution retardant such as paraffin, a resorption accelerator
10 such as a quaternary salt and/or an absorption agent such as bentonite, kaolin or dicalcium phosphate. The powder mixture can be granulated by wetting with a binder such as syrup, starch paste, acadia mucilage or solutions of cellulosic or polymeric materials and forcing through a screen. As an alternative to granulating, the powder mixture can be run through the
15 tablet machine and the result is imperfectly formed slugs broken into granules. The granules can be lubricated to prevent sticking to the tablet forming dies by means of the addition of stearic acid, a stearate salt, talc or mineral oil. The lubricated mixture is then compressed into tablets. The compounds of the present invention can also be combined with a free flowing
20 inert carrier and compressed into tablets directly without going through the granulating or slugging steps. A clear or opaque protective coating consisting of a sealing coat of shellac, a coating of sugar or polymeric material and a polish coating of wax can be provided. Dyestuffs can be added to these coatings to distinguish different unit dosages.

25

- Oral fluids such as solution, syrups and elixirs can be prepared in dosage unit form so that a given quantity contains a predetermined amount of active ingredient. Syrups can be prepared by dissolving the compound in a suitably flavored aqueous solution, while elixirs are prepared through the use of a
30 non-toxic alcoholic vehicle. Suspensions can be formulated by dispersing the

compound in a non-toxic vehicle. Solubilizers and emulsifiers such as ethoxylated isostearyl alcohols and polyoxyethylene sorbitol ethers, preservatives, flavor additive such as peppermint oil or natural sweeteners or saccharin or other artificial sweeteners, and the like can also be added.

5

Where appropriate, dosage unit formulations for oral administration can be microencapsulated. The formulation can also be prepared to prolong or sustain the release as for example by coating or embedding particulate material in polymers, wax or the like.

10

The compounds of formula (I) can also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles. Liposomes can be formed from a variety of phospholipids, such as cholesterol, stearylamine or phosphatidylcholines.

15

The compounds of formula (I) may also be delivered by the use of monoclonal antibodies as individual carriers to which the compound molecules are coupled. The compounds may also be coupled with soluble polymers as targetable drug carriers. Such polymers can include peptides, polyvinylpyrrolidone, pyran copolymer, polyhydroxypropylmethacrylamide - phenol, polyhydroxyethylaspartamidephenol, or polyethyleneoxidepolylysine substituted with palmitoyl residues. Furthermore, the compounds may be coupled to a class of biodegradable polymers useful in achieving controlled release of a drug, for example, polylactic acid, polepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrylates and cross-linked or amphipathic block copolymers of hydrogels.

Pharmaceutical formulations adapted for transdermal administration may be presented as discrete patches intended to remain in intimate contact with the epidermis of the recipient for a prolonged period of time. For example, the active ingredient may be delivered from the patch by iontophoresis as

5 generally described in *Pharmaceutical Research*, 3(6):318 (1986).

Pharmaceutical formulations adapted for topical administration may be formulated as ointments, creams, suspensions, lotions, powders, solutions, pastes, gels, sprays, aerosols or oils.

10

For treatments of the eye or other external tissues, for example mouth and skin, the formulations are preferably applied as a topical ointment or cream. When formulated in an ointment, the active ingredient may be employed with either a paraffinic or a water-miscible ointment base. Alternatively, the active

15 ingredient may be formulated in a cream with an oil-in-water cream base or a water-in-oil base.

Pharmaceutical formulations adapted for topical administrations to the eye include eye drops wherein the active ingredient is dissolved or suspended in a

20 suitable carrier, especially an aqueous solvent.

Pharmaceutical formulations adapted for topical administration in the mouth include lozenges, pastilles and mouth washes.

25 Pharmaceutical formulations adapted for rectal administration may be presented as suppositories or as enemas.

Pharmaceutical formulations adapted for nasal administration wherein the carrier is a solid include a coarse powder having a particle size for example in

30 the range 20 to 500 microns which is administered in the manner in which

snuff is taken, i.e. by rapid inhalation through the nasal passage from a container of the powder held close up to the nose. Suitable formulations wherein the carrier is a liquid, for administration as a nasal spray or as nasal drops, include aqueous or oil solutions of the active ingredient.

5

Pharmaceutical formulations adapted for administration by inhalation include fine particle dusts or mists, which may be generated by means of various types of metered, dose pressurised aerosols, nebulizers or insufflators.

- 10 Pharmaceutical formulations adapted for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or spray formulations.

- 15 Pharmaceutical formulations adapted for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents. The formulations may be presented in unit-dose or multi-dose containers, for example sealed ampoules and vials, and may be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example water for injections, immediately prior to use.
- 20 Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets.

25

It should be understood that in addition to the ingredients particularly mentioned above, the formulations may include other agents conventional in the art having regard to the type of formulation in question, for example those suitable for oral administration may include flavouring agents.

30

In the above-described methods of treatment and uses, a compound of formula (I) may be employed alone, in combination with one or more other compounds of formula (I) or in combination with other therapeutic agents. In particular, in methods of treating conditions mediated by PLK and methods of 5 treating susceptible neoplasms, combination with other chemotherapeutic, hormonal and/or antibody agents is envisaged as well as combination with surgical therapy and radiotherapy. The term "chemotherapeutic" as used herein refers to any chemical agent having a therapeutic effect on the subject to which it is administered. "Chemotherapeutic" agents include but are not 10 limited to anti-neoplastic agents, analgesics and anti-emetics. As used herein, "anti-neoplastic agents" include both cytostatic and cytotoxic agents.

Combination therapies according to the present invention thus comprise the administration of at least one compound of formula (I) and the use of at least one other cancer treatment method. In one embodiment, combination 15 therapies according to the present invention comprise the administration of at least one compound of formula (I) and at least one other chemotherapeutic agent. In one particular embodiment, the present invention comprises the administration of at least one compound of formula (I) and at least one anti-neoplastic agent. As an additional aspect, the present invention provides the 20 methods of treatment and uses as described above, which comprise administering a compound of formula (I) together with at least one chemotherapeutic agent. In one particular embodiment, the chemotherapeutic agent is an anti-neoplastic agent. In another embodiment, the present invention provides a pharmaceutical composition as described 25 above further comprising at least one other chemotherapeutic agent, more particularly, the chemotherapeutic agent is an anti-neoplastic agent.

Typically, any chemotherapeutic agent that has activity versus a susceptible neoplasm being treated may be utilized in combination with the compounds of 30 formula (I), provided that the particular agent is clinically compatible with

therapy employing a compound of formula (I). Typical anti-neoplastic agents useful in the present invention include, but are not limited to, anti-microtubule agents such as diterpenoids and vinca alkaloids; platinum coordination complexes; alkylating agents such as nitrogen mustards, 5 oxazaphosphorines, alkylsulfonates, nitrosoureas, and triazenes; antibiotic agents such as anthracyclins, actinomycins and bleomycins; topoisomerase II inhibitors such as epipodophyllotoxins; antimetabolites such as purine and pyrimidine analogues and anti-folate compounds; topoisomerase I inhibitors such as camptothecins; hormones and hormonal analogues; signal 10 transduction pathway inhibitors; non-receptor tyrosine kinase angiogenesis inhibitors; immunotherapeutic agents; proapoptotic agents; and cell cycle signaling inhibitors.

Anti-microtubule or anti-mitotic agents are phase specific agents active 15 against the microtubules of tumor cells during M or the mitosis phase of the cell cycle. Examples of anti-microtubule agents include, but are not limited to, diterpenoids and vinca alkaloids. Examples of diterpenoids include, but are not limited to, paclitaxel and its analog docetaxel. Examples of vinca alkaloids include, but are not limited to, vinblastine, vincristine, and 20 vinorelbine.

Platinum coordination complexes are non-phase specific anti-neoplastic agents, which are interactive with DNA. The platinum complexes enter tumor cells, undergo, aquation and form intra- and interstrand crosslinks with DNA 25 causing adverse biological effects to the tumor. Examples of platinum coordination complexes include, but are not limited to, cisplatin and carboplatin.

Alkylating agents are non-phase anti-neoplastic specific agents and strong 30 electrophiles. Typically, alkylating agents form covalent linkages, by

alkylation, to DNA through nucleophilic moieties of the DNA molecule such as phosphate, amino, and hydroxyl groups. Such alkylation disrupts nucleic acid function leading to cell death. Examples of alkylating agents include, but are not limited to, nitrogen mustards such as cyclophosphamide, melphalan, and chlorambucil; alkyl sulfonates such as busulfan; nitrosoureas such as carmustine; and triazenes such as dacarbazine.

- Antibiotic chemotherapeutic agents are non-phase specific agents, which bind or intercalate with DNA. Typically, such action results in stable DNA complexes or strand breakage, which disrupts ordinary function of the nucleic acids leading to cell death. Examples of antibiotic anti-neoplastic agents include, but are not limited to, actinomycins such as dactinomycin, anthrocyclins such as daunorubicin and doxorubicin; and bleomycins.
- Topoisomerase II inhibitors include, but are not limited to, epipodophyllotoxins.

- Epipodophyllotoxins are phase specific anti-neoplastic agents derived from the mandrake plant. Epipodophyllotoxins typically affect cells in the S and G₂ phases of the cell cycle by forming a ternary complex with topoisomerase II and DNA causing DNA strand breaks. The strand breaks accumulate and cell death follows. Examples of epipodophyllotoxins include, but are not limited to, etoposide and teniposide.
- Antimetabolite neoplastic agents are phase specific anti-neoplastic agents that act at S phase (DNA synthesis) of the cell cycle by inhibiting DNA synthesis or by inhibiting purine or pyrimidine base synthesis and thereby limiting DNA synthesis. Consequently, S phase does not proceed and cell death follows. Examples of antimetabolite anti-neoplastic agents include, but are not limited to, fluorouracil, methotrexate, cytarabine, mercaptoperine and thioguanine.

Camptothecins, including, camptothecin and camptothecin derivatives are available or under development as Topoisomerase I inhibitors.

Camptothecins cytotoxic activity is believed to be related to its Topoisomerase I inhibitory activity. Examples of camptothecins include, but are not limited to
5 irinotecan, topotecan, and the various optical forms of 7-(4-methylpiperazino-methylene)-10,11-ethylenedioxy-20-camptothecin.

Hormones and hormonal analogues are useful compounds for treating cancers in which there is a relationship between the hormone(s) and growth

- 10 and/or lack of growth of the cancer. Examples of hormones and hormonal analogues believed to be useful in the treatment of neoplasms include, but are not limited to, adrenocorti-costeroids such as prednisone and prednisolone which are useful in the treatment of malignant lymphoma and acute leukemia in children; aminoglutethimide and other aromatase inhibitors
15 such as anastrozole, letrozole, vorazole, and exemestane useful in the treatment of adrenocortical carcinoma and hormone dependent breast carcinoma containing estrogen receptors; progestins such as megestrol acetate useful in the treatment of hormone dependent breast cancer and endometrial carcinoma; estrogens, androgens, and anti-androgens such as
20 flutamide, nilutamide, bicalutamide, cyproterone acetate and 5 α -reductases such as finasteride and dutasteride, useful in the treatment of prostatic carcinoma and benign prostatic hypertrophy; anti-estrogens such as tamoxifen, toremifene, raloxifene, droloxifene and iodoxyfene useful in the treatment of hormone dependent breast carcinoma; and gonadotropin-
25 releasing hormone (GnRH) and analogues thereof which stimulate the release of leutinizing hormone (LH) and/or follicle stimulating hormone (FSH) for the treatment prostatic carcinoma, for instance, LHRH agonists and antagonists such as goserelin acetate and luprolide.

Signal transduction pathway inhibitors are those inhibitors which block or inhibit a chemical process which evokes an intracellular change. As used herein this change is cell proliferation or differentiation. Signal transduction inhibitors useful in the present invention include inhibitors of receptor tyrosine

- 5 kinases, non-receptor tyrosine kinases, SH2/SH3 domain blockers, serine/threonine kinases, phosphotidyl inositol-3 kinases, myo-inositol signaling, and Ras oncogenes.

Several protein tyrosine kinases catalyse the phosphorylation of specific
10 tyrosyl residues in various proteins involved in the regulation of cell growth. Such protein tyrosine kinases can be broadly classified as receptor or non-receptor kinases.

Receptor tyrosine kinases are transmembrane proteins having an extracellular
15 ligand binding domain, a transmembrane domain, and a tyrosine kinase domain. Receptor tyrosine kinases are involved in the regulation of cell growth and are sometimes termed growth factor receptors. Inappropriate or uncontrolled activation of many of these kinases, i.e. aberrant kinase growth factor receptor activity, for example by over-expression or mutation, has been
20 shown to result in uncontrolled cell growth. Accordingly, the aberrant activity of such kinases has been linked to malignant tissue growth. Consequently, inhibitors of such kinases could provide cancer treatment methods. Growth factor receptors include, for example, epidermal growth factor receptor (EGFr, ErbB2 and ErbB4,), platelet derived growth factor receptor (PDGFr), vascular
25 endothelial growth factor receptor (VEGFR), tyrosine kinase with immunoglobulin-like and epidermal growth factor homology domains (TIE-2), insulin growth factor-I receptor (IGF-I), macrophage colony stimulating factor (cfms), BTK, ckit, cmet, fibroblast growth factor (FGF) receptors, Trk receptors (TrkA, TrkB, and TrkC), ephrin (eph) receptors, and the RET protooncogene. Several inhibitors of growth factor receptors are under

development and include ligand antagonists, antibodies, tyrosine kinase inhibitors, anti-sense oligonucleotides and aptamers. Growth factor receptors and agents that inhibit growth factor receptor function are described, for instance, in Kath, John C., *Exp. Opin. Ther. Patents* (2000) 10(6):803-818;

- 5 Shawver et al DDT Vol 2, No. 2 February 1997; and Loftis, F. J. et al, "Growth Factor Receptors as Targets", *New Molecular Targets for Cancer Chemotherapy*, Ed. Workman, Paul and Kerr, David, CRC Press 1994, London.

Tyrosine kinases, which are not growth factor receptor kinases are termed

- 10 non-receptor tyrosine kinases. Non-receptor tyrosine kinases useful in the present invention, which are targets or potential targets of anti-neoplastic drugs, include cSrc, Lck, Fyn, Yes, Jak, cAbl, FAK (Focal adhesion kinase), Brutons tyrosine kinase, and Bcr-Abl. Such non-receptor kinases and agents which inhibit non-receptor tyrosine kinase function are described in Sinh, S.
15 and Corey, S.J., (1999) *Journal of Hematotherapy and Stem Cell Research* 8 (5): 465 – 80; and Bolen, J.B., Brugge, J.S., (1997) *Annual Review of Immunology*. 15: 371-404.

SH2/SH3 domain blockers are agents that disrupt SH2 or SH3 domain binding

- 20 in a variety of enzymes or adaptor proteins including, PI3-K p85 subunit, Src family kinases, adaptor molecules (Shc, Crk, Nck, Grb2) and Ras-GAP. SH2/SH3 domains as targets for anti-cancer drugs are discussed in Smithgall, T.E. (1995), *Journal of Pharmacological and Toxicological Methods*. 34(3) 125-32.

- 25 Inhibitors of Serine/Threonine Kinases including MAP kinase cascade blockers which include blockers of Raf kinases (Raf), Mitogen or Extracellular Regulated Kinase (MEKs), and Extracellular Regulated Kinases (ERKs); and Protein Kinase C family member blockers including blockers of subtypes of
30 PKCs (alpha, beta, gamma, epsilon, mu, lambda, iota, zeta), I_kB kinase family

(IKKa, IKK β), PKB family kinases, Akt kinase family members, and TGF beta receptor kinases. Such Serine/Threonine kinases and inhibitors thereof are described in Yamamoto, T., Taya, S., Kaibuchi, K., (1999), Journal of Biochemistry. 126 (5) 799-803; Brodt, P, Samani, A., and Navab, R. (2000),

- 5 Biochemical Pharmacology, 60. 1101-1107; Massague, J., Weis-Garcia, F. (1996) Cancer Surveys. 27:41-64; Philip, P.A., and Harris, A.L. (1995), Cancer Treatment and Research. 78: 3-27, Lackey, K. et al Bioorganic and Medicinal Chemistry Letters, (10), 2000, 223-226; and Martinez-Iacaci, L., et al, Int. J. Cancer (2000), 88(1), 44-52.

10

Inhibitors of Phosphotidyl Inositol-3 Kinase family members including blockers of PI3-kinase, ATM, DNA-PK, and Ku are also useful in combination with the present invention. Such kinases are discussed in Abraham, R.T. (1996), Current Opinion in Immunology. 8 (3) 412-8; Canman, C.E., Lim, D.S. (1998),

- 15 Oncogene 17 (25) 3301-3308; Jackson, S.P. (1997), International Journal of Biochemistry and Cell Biology. 29 (7):935-8; and Zhong, H. et al, Cancer Res, (2000) 60(6), 1541-1545.

Also useful in combination with the present invention are Myo-inositol

- 20 signaling inhibitors such as phospholipase C blockers and Myoinositol analogues. Such signal inhibitors are described in Powis, G., and Kozikowski A., (1994) New Molecular Targets for Cancer Chemotherapy ed., Paul Workman and David Kerr, CRC Press 1994, London.

- 25 Another group of signal transduction pathway inhibitors useful in combination with the present invention are inhibitors of Ras Oncogene. Such inhibitors include inhibitors of farnesyltransferase, geranyl-geranyl transferase, and CAAX proteases as well as anti-sense oligonucleotides, ribozymes and immunotherapy. Such inhibitors have been shown to block Ras activation in
30 cells containing wild type mutant Ras , thereby acting as antiproliferation

agents. Ras oncogene inhibition is discussed in Scharovsky, O.G., Rozados, V.R., Gervasoni, S.I. Matar, P. (2000), Journal of Biomedical Science. 7(4) 292-8; Ashby, M.N. (1998), Current Opinion in Lipidology. 9(2)99-102; and BioChim. Biophys. Acta, (1989) 1423(3):19-30.

5

As mentioned above, antibodies to receptor kinase ligand binding may also serve as signal transduction inhibitors. This group of signal transduction pathway inhibitors includes the use of humanized antibodies to the extracellular ligand binding domain of receptor tyrosine kinases. For example,

- 10 Imclone C225 EGFR specific antibody (see Green, M.C. et al, Monoclonal Antibody Therapy for Solid Tumors, Cancer Treat. Rev., (2000), 26(4), 269-286); Herceptin® ErbB2 antibody (see Tyrosine Kinase Signaling in Breast Cancer:ErbB Family Receptor Tyrosine Kinases, Breast Cancer Res., 2000, 2(3), 176-183); and 2CB VEGFR2 specific antibody (see Brekken, R.A. et al,
- 15 Selective Inhibition of VEGFR2 Activity by a Monoclonal Anti-VEGF Antibody Blocks Tumor Growth in Mice, Cancer Res. (2000) 60, 5117-5124).

Receptor kinase angiogenesis inhibitors may also find use in the present invention. Inhibitors of angiogenesis related VEGFR and TIE2 are discussed 20 above in regard to signal transduction inhibitors (both receptors are receptor tyrosine kinases). Other inhibitors may be used in combination with the compounds of the present invention. For example, anti-VEGF antibodies, which do not recognize VEGFR (the receptor tyrosine kinase), but bind to the ligand; small molecule inhibitors of integrin ($\alpha_v \beta_3$) that will inhibit 25 angiogenesis; endostatin and angiostatin (non-RTK) may also prove useful in combination with PLK inhibitors.

Agents used in immunotherapeutic regimens may also be useful in combination with the compounds of formula (I).

Agents used in proapoptotic regimens (e.g., bcl-2 antisense oligonucleotides) may also be used in the combination of the present invention. Members of the Bcl-2 family of proteins block apoptosis. Upregulation of bcl-2 has therefore been linked to chemoresistance. Studies have shown that the 5 epidermal growth factor (EGF) stimulates anti-apoptotic members of the bcl-2 family (i.e., mcl-1). Therefore, strategies designed to downregulate the expression of bcl-2 in tumors have demonstrated clinical benefit and are now in Phase II/III trials, namely Genta's G3139 bcl-2 antisense oligonucleotide. Such proapoptotic strategies using the antisense oligonucleotide strategy for 10 bcl-2 are discussed in Water JS et al., *J. Clin. Oncol.* **18**:1812-1823 (2000); and Kitada S et al., *Antisense Res. Dev.* **4**:71-79 (1994).

Cell cycle signaling inhibitors inhibit molecules involved in the control of the cell cycle. Cyclin dependent kinases (CDKs) and their interaction cyclins 15 control progression through the eukaryotic cell cycle. The coordinated activation and inactivation of different cyclin/CDK complexes is necessary for normal progression through the cell cycle. Several inhibitors of cell cycle signaling are under development. For instance, examples of cyclin dependent kinases, including CDK2, CDK4, and CDK6 and inhibitors for the same are 20 described in, for instance, Rosania, et al., *Exp. Opin. Ther. Patents* **10(2)**:215-230 (2000).

In one embodiment, the methods of the present invention comprise administering to the animal a compound of formula (I) in combination with a 25 signal transduction pathway inhibitor, particularly gefitinib (IRESSA®).

The methods and uses employing these combinations may comprise the administration of the compound of formula (I) and the other 30 chemotherapeutic/anti-neoplastic agent either sequentially in any order or simultaneously in separate or combined pharmaceutical compositions. When

combined in the same formulation it will be appreciated that the two compounds must be stable and compatible with each other and the other components of the formulation and may be formulated for administration.

When formulated separately they may be provided in any convenient

5 formulation, in such a manner as are known for such compounds in the art.


When a compound of formula (I) is used in combination with a chemotherapeutic agent, the dose of each compound may differ from that when the compound is used alone. Appropriate doses will be readily

10 appreciated by those skilled in the art. The appropriate dose of the compound(s) of formula (I) and the other therapeutically active agent(s) and the relative timings of administration will be selected in order to achieve the desired combined therapeutic effect, and are within the expertise and discretion of the attendant clinician.

15

Compounds of formula (I) may be conveniently prepared by the process outlined in Scheme 1 below.

Scheme 1



20

25

30

wherein:

R^1 is selected from the group consisting of H, halo, alkyl, alkenyl, alkynyl;

R^2 is selected from the group consisting of halo, alkyl, alkenyl, alkynyl,

cycloalkyl, cycloalkenyl, $-(R^7)_g-C(O)R^6$, $-(R^7)_g-CO_2R^6$, $-(R^7)_g-C(O)N(R^6)_2$,

$-(R^7)_g-OR^6$, $-O-(R^7)_g-Ay$, $-(R^7)_g-S(O)_eR^6$, $-(R^7)_g-N(R^6)_2$,

$-(R^7)_g-N(R^6)C(O)R^6$, $-(R^7)_g-CN$, $-(R^7)_g-SCN$, $-NO_2$, $-N_3$, Ay and 5- to 9-

membered heteroaryl containing 1 or 2 heteroatoms selected from N,

O and S;


each R^3 is the same or different and is independently H or alkyl;

10 Y is selected from the group consisting of $-C(O)R^8$, $-C(S)R^8$, $-S(O)_eR^9$,

$-S(O)_eN(R^9)_2$, $-N(R^9)_2$, $-N(R^9)-S(O)_eR^9$, $-N(R^9)-C(O)R^9$, $-N(R^9)-CO_2R^9$,

and $-N(R^9)-C(O)N(R^9)_2$,

or Y , together with C-2 and C-3 form a fused ring system of formula A:



wherein

R^8 is selected from the group consisting of alkyl, alkenyl, alkynyl,

cycloalkyl, cycloalkenyl, Ay, Het, $-OR^6$, $-O-(R^7)_g-Ay$,

$-O-(R^7)_g-Het$, $-N(R^6)_2$, $-N(R^6)-(R^7)_g-Ay$, $-N(R^6)-(R^7)_g-Het$,

$-N(R^6)-(R^7)_g-OR^6$, $-N(R^6)-(R^7)_g-C(O)R^6$, $-N(R^6)-(R^7)_g-CO_2R^6$,

$-N(R^6)-(R^7)_g-SO_2R^6$, and $-N(R^6)-(R^7)_g-N(R^6)_2$;

each R^9 is the same or different and is independently selected from the

group consisting of H, alkyl, alkenyl, alkynyl, cycloalkyl,

cycloalkenyl, Ay and Het;

25 c is 0 or 1;

Z^1 , Z^2 , Z^3 and Z^4 are each independently selected from the group

consisting of C, O, S and N, wherein when c is 0, at least one of

Z^1 , Z^2 and Z^3 is C and wherein when c is 1, at least two of Z^1 ,

Z^2 , Z^3 and Z^4 are C;

each dashed line represents an optional double bond;

d is 0, 1 or 2;

each R¹⁰ is the same or different and is independently selected from
the group consisting of halo, alkyl, oxo, hydroxy, mercapto and
5 amino;

a is 0, 1, 2 or 3;

each R⁴ is the same or different and is independently selected from the group
consisting of halo, alkyl, alkenyl, alkynyl, -(R⁷)_g-cycloalkyl,

-(R⁷)_g-cycloalkenyl, -(R⁷)_g-Ay, -(R⁷)_g-Het, -(R⁷)_g-C(O)R⁶, -(R⁷)_g-C(O)Ay,

10 -(R⁷)_g-C(O)Het, -(R⁷)_g-CO₂R⁶, -(R⁷)_g-CO₂Ay, -(R⁷)_g-CO₂Het,

-(R⁷)_g-C(O)N(R⁶)₂, -(R⁷)_g-OR⁶, -(R⁷)_g-OAy, -(R⁷)_g-OHet, -(R⁷)_g-OC(O)R⁶,

-(R⁷)_g-OC(O)Ay, -(R⁷)_g-OC(O)Het, -(R⁷)_g-S(O)_eR⁶, -(R⁷)_g-S(O)_eAy,

-(R⁷)_g-S(O)_eHet, -(R⁷)_g-S(O)_eN(R⁶)₂, -(R⁷)_g-S(O)_eN(R⁶)Ay,

-(R⁷)_g-S(O)_eN(R⁶)Het, -(R⁷)_g-N(R⁶)₂, -(R⁷)_g-N(R⁶)Ay, -(R⁷)_g-N(R⁶)Het,

15 -(R⁷)_g-N(R⁶)C(O)R⁶, -(R⁷)_g-N(R⁶)C(O)Ay, -(R⁷)_g-N(R⁶)C(O)Het,

-(R⁷)_g-N(R⁶)C(O)N(R⁶)₂, -(R⁷)_g-N(R⁶)S(O)_eR⁶, -(R⁷)_g-N(R⁶)S(O)_eAy,

-(R⁷)_g-N(R⁶)S(O)_eHet, -NO₂, -CN, -SCN and -N₃, or

two adjacent R⁴ groups together with the carbon atoms to which they

are bonded form a phenyl or a 5- or 6-membered heterocycle or

20 heteroaryl containing 1 or 2 heteroatoms selected from the

group consisting of O, N and S;

each e is the same or different and is independently 0, 1 or 2;

b is 0, 1, 2, 3, 4 or 5;

each R⁵ is the same or different and is a group of formula (R⁷)_g-R¹¹, or two

25 adjacent R⁵ groups are each the same or different and are

independently selected from the group consisting of alkyl, alkenyl,

-OR⁶, -S(O)_eR⁶ and -N(R⁶)₂ and, together with the carbon atoms to

which they are bonded, they form a C₅₋₆cycloalkyl, C₅₋₆cycloalkenyl or a

5- or 6-membered heterocycle or heteroaryl containing 1 or 2

30 heteroatoms selected from the group consisting of N, O and S;

each R⁶ is the same or different and is independently selected from the group consisting of H, alkyl, alkenyl, alkynyl, cycloalkyl and cycloalkenyl;

g is 0 or 1;

R⁷ is alkylene or alkenylene;

5 Ay is aryl;

Het is a 5- or 6-membered heterocycle or heteroaryl containing 1, 2 or 3 heteroatoms selected from the group consisting of N, O and S;

R¹¹ is selected from the group consisting of halo, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, Ay, Het, -C(O)R⁶, -C(O)Ay, -C(O)Het, -CO₂R⁶,

10 -CO₂Ay, -CO₂Het, -C(O)-R⁷-OR⁶, -C(O)-R⁷-OAy, -C(O)-R⁷-OHet, -C(O)N(R⁶)₂, -C(O)N(R⁶)Ay, -C(O)N(R⁶)Het, -C(O)N(R⁶)-(R⁷)_g-N(R⁶)₂, -C(O)N(R⁶)-(R⁷)_g-CO₂R⁶, -C(O)N(R⁶)-(R⁷)_g-S(O)_eR⁶, -OR⁶, -OC(O)R⁶, -O-(R⁷)_g-Ay, -OC(O)Ay, -O-(R⁷)_g-Het, -OC(O)Het, -O-R⁷-OR⁶, -O-R⁷-N(R⁶)₂, -S(O)_eR⁶, -S(O)_e-(R⁷)_g-Ay, -S(O)_e-(R⁷)_g-Het,

15 -S(O)_e-(R⁷)_g-N(R⁶)₂, -S(O)_e-(R⁷)_g-N(R⁶)Ay, -S(O)_e-(R⁷)_g-N(R⁶)Het, -S(O)_eN(R⁶)-(R⁷)_g-C(O)R⁶, -S(O)_eN(R⁶)-(R⁷)_g-C(O)Ay, -S(O)_eN(R⁶)-(R⁷)_g-C(O)Het, -N(R⁶)₂, -N(R⁶)-(R⁷)_g-Ay, -N(R⁶)-(R⁷)_g-Het, -N(R⁶)-(R⁷)_g-C(O)R⁶, -N(R⁶)-C(O)-(R⁷)_g-Ay, -N(R⁶)-C(O)-(R⁷)_g-Het, -N(R⁶)-C(O)-(R⁷)_g-N(R⁶)₂, -N(R⁶)-C(O)-(R⁷)_g-N(R⁶)Ay,

20 -N(R⁶)-C(O)-(R⁷)_g-N(R⁶)Het, -N(R⁶)-C(O)-(R⁷)_g-N(R⁶)-(R⁷-O)_h-N(R⁶)-CO₂R⁶, -N(R⁶)-(R⁷)_g-S(O)_eR⁶, -N(R⁶)-(R⁷)_g-S(O)_eAy, -N(R⁶)-(R⁷)_g-S(O)_eHet, -N(R⁶)-R⁷-N(R⁶)₂, -N(R⁶)-R⁷-OR⁶, -CN, -SCN, -NO₂, and -N₃;

h is 1-20; and


25 R¹⁵ is selected from the group consisting of halo and -S(O)_eR⁶.

Generally, compounds of formula (I) can be prepared a process comprising:

a) reacting a compound of formula (II) with a compound of formula (III) to prepare a compound of formula (IV); and

- b) reacting a compound of formula (IV) with a compound of formula (V) to prepare a compound of formula (I).

More specifically, a compound of formula (I) may be prepared by reacting a compound of formula (IV) with a compound of formula (V).




The reaction may be carried out in an inert solvent, in the presence of an acid catalyst. The reaction may be optionally heated to from about 50 to about 150°C. In one embodiment, the reaction is carried out at about 90 °C. In one embodiment, the reaction is carried out using equimolar amounts of the 15 aniline compound of formula (V) and the compound of formula (IV).


However, the reaction may also be performed in the presence of an excess of the compound of formula (V). The acid catalyst is typically present in an amount of 10-30 mol% compared to the compound of formula (IV). An example of a suitable acid catalyst is hydrochloric acid although other acids 20 may be employed as will be appreciated by those skilled in the art. Suitable inert solvents include but are not limited to isopropyl alcohol, ethanol, dioxane, tetrahydrofuran, dichloromethane and N,N-dimethylformamide. The aniline compounds of formula (V) may be obtained from commercial sources or prepared as discreet isolated compounds using methods known to those 25 skilled in the art.

In certain embodiments, it may be advantageous to oxidize the compound of formula (IV) prior to reacting with the compound of formula (V). For example, in the embodiment wherein the compound of formula (IV) is defined 30 wherein R¹⁵ is S-alkyl (i.e., a compound of formula (IV-A) below), the

compound of formula (IV-A) may be oxidized to a compound of formula (IV-B), wherein R¹⁵ is S(O)₂-alkyl.




- Such oxidation may be carried out using conventional techniques and
10 oxidizing agents, such as 3-chloroperoxybenzoic acid, oxone, hydrogen peroxide, potassium permanganate, and the like. The oxidation may be carried out in a suitable solvent, such as dichlormethane, chloroform, carbontetrachloride, aqueous acidic acid, or the like. Based upon this specific example and general principles of organic synthesis, one skilled in the art will
15 appreciate other specific instances wherein the oxidation of a compound of formula (IV) may be desired prior to reacting with the compound of formula (V) and will similarly appreciate appropriate reaction conditions for carry-out such oxidations for other specific compounds.
- 20 A compound of formula (IV) may be prepared by reacting a compound of formula (II) with a compound of formula (III).



- The reaction may be carried out in an inert solvent, in the presence of a base.
The reaction temperature will vary from up to about 100°C, depending upon the particular compounds of formula (II) and (III) employed. In one
30 embodiment, the reaction is carried out at reduced temperature, e.g., about


–78°C. In another embodiment, the reaction is carried out at elevated temperature, e.g., from about 50 to about 80°C. In one embodiment, the reaction is carried out using equimolar amounts of the compound of formula (II) and the compound of formula (III). However, the reaction may also be
5 preformed in the presence of an excess amount of the compound of the formula (II). The base is typically present in a proportion equivalent to, or greater than, that of the compound of formula (II). Examples of suitable bases include but are not limited to diisopropylethylamine, triethylamine, sodium carbonate and sodium bicarbonate. The reaction may be carried out
10 in a suitable solvent. Examples of suitable solvents include but are not limited to ethanol, isopropyl alcohol, dioxane and tetrahydrofuran. The compounds of formula (III) may be obtained from commercial sources or prepared as discreet isolated compounds using methods known to those skilled in the art.

15 The compounds of formula (II) may be obtained from commercial sources or prepared as discreet isolated compounds using conventional organic synthesis techniques. For example, a compound of formula (II-A), wherein R² is -NO₂ or -CO₂H, and R¹⁵ is Cl, may be prepared by chlorinating a compound of formula (X).



25 This chlorination can be carried out by treating the compound of formula (X) with phosphorous oxychloride in the presence of a base. Typical bases include but are not limited to N,N-dimethylaniline and pyridine. The reaction may be heated from 30–115°C. Compounds of formula (X) are commercially available.

If desired, the compound of formula (II-A) may be further converted into another compound of formula (II) before proceeding with the reaction with the compound of formula (III). For example, a compound of formula (II-A) wherein R² is -CO₂H, may be converted to a compound of formula (II-B) wherein R² is -C(O)Cl, which may in turn be converted to a compound of formula (II-C), wherein R² is -CO₂R⁶ as follows.




wherein R¹² is selected from the group consisting of -OR⁶ and -N(R⁶)₂, and all other variables are as defined above.

A compound of formula (II-A) may be converted to a compound of formula (II-B) by a chlorination procedure. Typically the chlorination reaction is carried out by subjecting the compound of formula (II-A) to an appropriate inorganic acid halide reagent in a suitable solvent. Suitable inorganic acid halide reagents include but are not limited to thionyl chloride, and oxalyl choride. Suitable solvents include, for example tetrahydrofuran, benzene, dichloromethane, and the like.

The compound of formula (II-B) may be further converted to a compound of formula (II-C) by reacting with an alcohol of formula HO—R⁶ or an amine of formula HN(R⁶)₂, depending upon whether the ester or amide compound of formula (II-C) is desired. The reaction may be carried out in an inert solvent in the presence of a base and optionally cooled from -78°C to room temperature. Typically, the reaction is performed by reacting equimolar amounts of the compound of formula (II-B) with the alcohol or amine. The reaction is more conveniently carried out by adding a base in a proportion equivalent to or greater than, that of the compound of formula (II-B).


Suitable bases include but are not limited to pyridine, triethylamine, and diisopropylethylamine. Suitable solvents include but are not limited to dichloromethane, benzene, pyridine and tetrahydrofuran. The alcohol and amine compounds may be obtained from commercial sources or prepared as
5 discreet isolated compounds using methods known to those skilled in the art.
(*See e.g.*, Choi, V. *Org. Lett.* **2002** 4,589.)

As another example, a compound of formula (II-D), wherein R² is CN and R¹⁵ is alkyl-S, may be prepared by chlorinating a compound of formula (XI).



15 This chlorination can be carried out by treating the compound of formula (XI) with phosphorous oxychloride. The reaction may be heated from 30-115°C. Compounds of formula (XI) are commercially available or can be prepared using conventional techniques. *See, e.g.*, A. Santilli, *J. Heterocycl. Chem.* **8**:445 (1971).

20 As another example, 2,4,6-trichloropyrimidine may be converted to a compound of formula (II-E) (i.e., a compound of formula (II) wherein R¹ is alkyl, alkenyl or alkynyl, by reacting with a suitable boronic acid.



The reaction may be carried out in an inert solvent, in the presence of a palladium (0) catalyst and a base. The reaction may optionally be heated to a
30 temperature of from about 65 to about 100°C. Preferably the reaction is

performed by reacting equimolar amounts of 2,4,6-trichloropyrimidine and a boronic acid of the foregoing formula. The palladium catalyst is typically present in 3-10 mol% compared to the pyrimidine. Examples of suitable palladium catalysts include but are not limited to tetrakis(tri-


- 5 phenylphosphine)palladium (0), and dichlorobis(triphenylphosphine)palladium (II). Suitable bases include but are not limited to potassium carbonate, sodium hydroxide and cesium carbonate. Suitable solvents include but are not limited to tetrahydrofuran, 1,4-dioxane and 1,2-dimethoxyethane. Boronic acids having the foregoing formula may be obtained from commercial sources
10 or prepared as discreet isolated compounds using methods known to one skilled in the art. *See*, Molander G. *Tetrahedron* **2002**, 58, 1465; Shiota, T. *J. Org. Chem.* **1999**, 64, 453; and Organ, M.G. *Tet. Lett.* **2000**, 41, 6945).

- Compounds of formula (II) wherein R¹ is alkynyl may also be prepared by
15 reacting 2,4,6-trichloropyrimidine with an alkyne. The reaction may be carried out in an inert solvent, in the presence of a palladium (0) catalyst, copper iodide and a base. The reaction may optionally be heated to a temperature of from about 65 to about 100°C. Typically, the reaction is performed by reacting equimolar amounts of trichloropyrimidine and the
20 alkyne. The palladium catalyst is preferably present in 4-10 mol% compared to trichloropyrimidine. Examples of suitable palladium catalysts include but are not limited to tetrakis(triphenylphosphine)palladium (0), and dichlorobis(triphenyl-phosphine)palladium (II). The copper iodide is typically present in 30-40mol% compared to trichloropyrimidine. Suitable bases
25 include diisopropylamine, diethylamine and triethylamine. Suitable solvents include but are not limited to N,N-dimethylformamide, N-methylpyrrolidinone and 1,4-dioxane.

- In addition to processes for preparing a compound of formula (I), the present
30 invention also provides intermediates useful in processes for preparing


compounds of formula (I). Such intermediates are depicted in Scheme 1 above and include, for example, compounds of formula (IV).

As will be apparent to those skilled in the art, a compound of formula (I) may
 5 be converted to another compound of formula (I) using techniques well known in the art. Similarly, an isolatable intermediate used in the process of preparing a compound of formula (I), such as a compound of formula (II), (IV), or (V) may be converted into a different compound having that same formula. For example, a compound of formula (I-A) above may optionally be
 10 converted to a compound of formula (I-B).




wherein all variables are as defined above.

A compound of formula (I-A) may be converted to a compound of formula (I-B) by reacting a compound of formula (I-A) with an alkylborane compound, such as an alkyl borane compound of formula (XII):



The reaction may be carried out in an inert solvent, in the presence of a palladium (0) catalyst and a base. The reaction may optionally be heated to from about 65 to about 100°C. In one embodiment, the reaction is carried out by reacting equimolar amounts of a compound of formula (I-A) and the alkylborane, but the reaction may also be performed in the presence of an excess of alkylborane. The palladium catalyst is typically present in an amount of from about 1 to about 10 mol% compared to the compound of

formula (I-A). Examples of suitable palladium catalysts include but are not limited to tetrakis(triphenylphosphine)palladium (0), dichlorobis(triphenylphosphine)palladium (II), and palladium acetate (II) with 2-(di-*tert*-butylphosphino)biphenyl. The base is typically present in a proportion equivalent to or greater than 200 mol% of the compound of formula (I-A). Suitable bases include but are not limited to potassium phosphate, potassium carbonate, sodium hydroxide and cesium carbonate. Suitable inert solvents include but are not limited to toluene, N,N-dimethylformamide, and tetrahydrofuran. Alkylborane can conveniently be generated *in situ* using methods known to one skilled in the art. *See, De Lera, Angel R. Tetrahedron 2001, 57, 3125.* This same conversion may be employed to convert a compound of formula (IV) wherein R² is Br to a compound of formula (IV) wherein R² is alkyl.



wherein:

R^{16} is alkenyl or alkynyl;


25 R¹⁷ is selected from the group consisting of R² is selected from the
group consisting of alkyl, -C(O)R⁶, -CO₂R⁶, -C(O)N(R⁶)₂, -OR⁶, -S(O)_eR⁶,
-N(R⁶)₂, -N(R⁶)COR⁶, -CN, -SCN, Ay and 5- to 9-membered heteroaryl
containing 1 or 2 heteroatoms selected from N, O and S;
and all other variables are as defined above.

Compounds of formula (I-C) can be prepared by reacting a compound of formula (I-A) with a compound of formula (XIII): $R^{16}-R^{17}$, wherein R^{16} and R^{17} are as defined above.

- 5 The reaction may be carried out in an inert solvent, in the presence of a palladium (0) catalyst and a base. The reaction may optionally be heated to a temperature of from about 65 to about 100°C. In one embodiment, the reaction is carried out by reacting equimolar amounts of a compound of formula (I-A) and the compound of formula (XIII). However, the reaction
- 10 may also be performed in the presence of an excess of compound of the formula (XIII). The palladium catalyst is typically present in 1-20 mol% compared to the compound of formula (I-A). Examples of suitable palladium catalysts include but are not limited to tetrakis(triphenylphosphine)palladium (0), tris(dibenzylideneacetone)dipalladium (0), dichlorobis(triphenyl-
- 15 phosphine)palladium (II), and palladium acetate (II) with triphenylphosphine. In one embodiment, the palladium catalyst is complexed with copper iodide, wherein the copper iodide is present in an amount of 200 mol% compared to the palladium catalyst. The base is typically present in a proportion equivalent to or greater than 400 mol% of the compound of formula (I-A).
- 20 Suitable bases include but are not limited to potassium carbonate, potassium acetate, triethylamine, diethylamine, diisopropylamine, and cesium carbonate. Suitable solvents include but are not limited to dioxane, toluene, N,N-dimethylformamide, and tetrahydrofuran. Compounds of formula (XIII) may be obtained from commercial sources or prepared as discreet isolated
- 25 compounds using methods known to one skilled in the art. *See, S. Rosenblum, Tetrahedron* **56**:5735 (2000).

If desired a compound of formula (I-C) may be hydrogenated to provide an alkylene linker to $-R^{17}$.

In yet another example a compound of formula (I-A) may be converted to a compound of formula (I-D).




wherein R¹⁸ is alkenyl, Ay or 5- to 9-membered heteroaryl containing 1 or 2 heteroatoms selected from N, O and S and all other variables are as defined above.

Compounds of formula (I-D) can be prepared by reacting a compound of formula (I-A) with a compound of formula (XIV). The reaction may be carried out in an inert solvent, in the presence of a palladium (0) catalyst and copper bromide. The reaction may optionally be heated to about 65-100°C. Typically, the reaction is performed by reacting equimolar amounts of a compound of formula (XIV) and the tributyltin compound of formula (XIV), but the reaction may also be performed in the presence of an excess of compound of the formula (XIV). The palladium catalyst is preferably present in 5-20 mol% compared to the compound of formula (I-A). Examples of suitable palladium catalysts include but are not limited to dichlorobis(triphenylphosphine)palladium (II) and palladium acetate (II) with triphenylphosphine, and tris(dibenzylideneacetone)dipalladium (0). The palladium catalyst is typically complexed with copper bromide. The copper bromide is preferably present in 200 mol% compared to the palladium catalyst. Suitable solvents include but are not limited to dioxane, N,N-dimethylformamide, and tetrahydrofuran. The compounds of formula (XIV) may be obtained from commercial sources or prepared as discreet isolated compounds using


methods known to one skilled in the art. (Kukla, M. J. *Bioorg. Med. Chem. Let.* **2001**, 11, 2235; Yamada, K. *J. Med. Chem.* **2001**, 44, 3355).

A compound of formula (I-D) may be further converted to a compound of
5 formula (I-E) by oxidation.



Conventional oxidizing agents and conditions may be employed. Examples of suitable oxidizing agents include but are not limited to mixtures of osmium tetroxide with sodium periodate, osmium tetroxide with N-methylmorpholine N-oxide, ozone with dimethyl sulfide, and potassium permanganate. The oxidation may be carried out in a suitable solvent, such as aqueous tetrahydrofuran, dichloromethane, ether, ethanol or the like. (*See*, Kasibhatla, S. R. *J. Med. Chem.* **2000**, 43, 1508).

In yet another embodiment, a compound of formula (I-A) may be converted
20 to a compound of formula (I-F), which may in turn be oxidized to a compound
of formula (I-G).




10

wherein R³ is other than H and all other variables are as defined above.

Compounds of formula (I-F) can be prepared by reacting a compound of formula (I-A) with a compound of formula (XV). The reaction may be carried out in an inert solvent, such as tetrahydrofuran, with an appropriate metalating agent such as lithium metal. The reaction may optionally be sonicated at room temperature. Typically, the reaction is performed by reacting equimolar amounts of the compound formula (I-A) with the aldehyde of formula (XV), but the reaction may also be performed in the presence of an excess of compound of the formula (XV). Aldehyde compounds of formula (XV) may be obtained from commercial sources or prepared as discreet isolated compounds using methods known to one skilled in the art.

A compound of formula (I-F) may be converted to a compound of formula (I-G) by oxidation using conventional reagents and conditions. Suitable oxidizing agents include but are not limited to pyrimidinium chlorochromate, magnesium dioxide, and 2,3-dichloro-5,6-dicyano-1,4-benzoquinone and the like. Suitable solvents include dichloromethane, benzene, tetrahydrofuran, dioxane and the like.

A compound of formula (I-A) may also be converted to a compound of formula (I-H).



wherein Z¹ is selected from the group consisting of -OR⁶, -OAy, -OR⁷-Ay, -(R⁷)_g-N(R⁶)₂, and -(R⁷)_g-N(R⁶)COR⁶, and

10 all other variables are as defined above.

The reaction may be carried out in an inert solvent, in the presence of a palladium(0) catalyst and a base. The reaction may optionally be heated to a temperature of from about 23 to about 100°C. Typically, the reaction is performed by reacting equimolar amounts of a compound of formula (I-A) and the nucleophile but may also be performed in the presence of an excess of the nucleophile. The palladium catalyst is typically present in an amount of about 1 to about 5 mol% compared to the compound of formula (I-A).


Examples of suitable palladium catalysts include but are not limited to

20 tris(dibenzylideneacetone)dipalladium(0) coupled with Xantphos, palladium acetate (II) coupled with Xantphos, palladium acetate (II) coupled with 2-N,N-dimethylamino-2'-diphenylphosphinobiphenyl, 2-(di-tert-butylphosphino)-biphenyl, 1-(2-Di-tert-butylphosphinophenyl)-2-isopropyl-naphthalene and the like. Suitable bases include but are not limited to cesium carbonate,
25 potassium tert-butoxide, sodium tert-butoxide, potassium carbonate and the like. Suitable solvents for this reaction include but are not limited to toluene, tetrahydrofuran, 1,4-dioxane, and the like. The nucleophiles may be obtained from commercial sources or prepared as discreet isolated compounds using methods known to one skilled in the art. (*See*, Buchwald, S.L. *J. Am. Chem.*

Soc. **2001**, 123, 10770; Buchwald, *Org. Letters.* **2000**, 8, 1101; and Buchwald, *J. Org. Chem.* **1999**, 64, 6019).

As will be apparent to those skilled in the art, a compound of formula (I-H) 5 wherein Z¹ is O-benzyl may be further converted to a compound of formula (I-H) wherein Z¹ is -OH, by hydrogenolysis using conventional techniques. Suitable catalysts for the hydrogenolysis reaction include but are not limited to 5-15% palladium on carbon, palladium on barium sulfate, platinum and nickel. Suitable solvents include but are not limited to ethyl acetate, 10 tetrahydrofuran, ethanol and methanol. (See, Goswami, A. *Tetrahedron Asymmetry* **2001**, 12, 3343).

A compound of formula (I-A) may also be converted to a compound of formula (I-K). 15



wherein all variables are as defined above. 20

Compounds of formula (I-K) can be prepared by reacting a compound of formula (I-A) with a compound of formula (XVI). The reaction may be carried out in an inert solvent, in the presence of a base. The reaction may be optionally heated to a temperature of from about 23 to about 150°C. 25

Typically, the reaction is preformed by reacting equimolar amounts of the thio compound of formula (XVI) with the compound of formula (I-A), but may also be performed in the presence of an excess of compound of the formula (XVI). The base is typically present in an amount of about 10 to about 30 mol% compared to the compound of formula (I-A). Examples of suitable bases 30 include but are not limited to sodium hydride, potassium hydroxide, sodium

methoxide, potassium carbonate and the like. Suitable solvents include but are not limited to dimethylformamide, pyridine, methanol, ethanol, and hexamethylphosphoric acid triamide. Optionally the reaction may be catalyzed with copper oxide (I). Thio compounds of formula (XVI) may be


- 5 obtained from commercial sources or prepared as discreet isolated compounds using methods known to those skilled in the art. (*See, Ng, Dennis, K.P. Tetrahderon.* **2000**, 56, 3881).

Optionally, the thiol compounds of formula (I-K) may be subjected to an

- 10 oxidation procedure to prepare the sulfonyl or sulfinyl compounds of formula (I-K). Typically the oxidation reaction is carried out by subjecting the thiol compound of formula (I-K) to an oxidizing agent in a suitable solvent. Suitable oxidizing agents include but are not limited to 3-chloroperoxybenzoic acid, oxone, hydrogen peroxide, potassium permanganate, and the like.
- 15 Suitable solvents include but are not limited to dichlormethane, chloroform, carbontetrachloride, aqueous acidic acid. (*See, Cushman, M. J. Med. Chem.* **2001**, 44, 3915).

A compound of formula (I-A) may also be converted to a compound of

- 20 formula (I-L) or a compound of formula (I-M) using conventional metallation techniques.



wherein all variables are defined as above with the proviso that when R³ is H, R⁴ and R⁵ are not halo.

- 15 Compounds of formula (I-L) or (I-M) can be prepared by treating a compound of formula (I-A) with a lithium metal followed by either the azide compound or the thiocyanate compound together with N-chlorosuccinimide, respectively. The reaction may be carried out in an inert solvent. Typically, the reaction is cooled to a temperature of between about -78° and about 0°C. The reaction
- 20 is conveniently reacting equimolar amounts of the compound formula (I-A) with the azide or thiocyanate and N-chlorosuccinimide, but the reaction may also be performed in the presence of an excess of the azide or thiocyanate. Suitable lithium metal reagents include but are not limited to, n-butyl-lithium and tert-butyl-lithium. Suitable solvents include but are not limited to
- 25 tetrahydrofuran, ether, pentane and hexane. (See, Creary, X. *J. Org. Chem.* **1999**, 64, 5634 and Takagi, K. *J. Org. Chem.* **1995**, 60, 6552).

Based upon this disclosure and the examples contained herein one skilled in the art can readily convert a compound of formula (I) or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof into

another compound of formula (I), or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof.

The present invention also provides radiolabeled compounds of formula (I) and biotinylated compounds of formula (I) and solid-support-bound versions thereof. Radiolabeled compounds of formula (I) and biotinylated compounds of formula (I) can be prepared using conventional techniques. For example, radiolabeled compounds of formula (I) can be prepared by reacting the compound of formula (I) with tritium gas in the presence of an appropriate catalyst to produce radiolabeled compounds of formula (I).

In one embodiment, the compounds of formula (I) are tritiated.

The radiolabeled compounds of formula (I) and biotinylated compounds of formula (I) are useful in assays for the identification of compounds which inhibit PLK, for the identification of compounds for the treatment of a condition mediated by PLK, for the treatment of susceptible neoplasms, for the treatment of conditions characterized by inappropriate proliferation, for the inhibition of proliferation of a cell and for the inhibition of mitosis in a cell.


Accordingly, the present invention provides an assay method for identifying such compounds, which method comprises the step of specifically binding the radiolabeled compound of formula (I) or the biotinylated compound of formula (I) to the target protein or cellular homogenates. More specifically, suitable assay methods will include competition binding assays. The radiolabeled compounds of formula (I) and biotinylated compounds of formula (I) and solid-support-bound versions thereof, can be employed in assays according to the methods conventional in the art.

The following examples are intended for illustration only and are not intended to limit the scope of the invention in any way, the invention being defined by the claims which follow.

- 5 Reagents are commercially available or are prepared according to procedures in the literature.

Example 1: 2-(*{*5-nitro-2-[*(*3,4,5-trimethoxyphenyl*)*amino]*}*pyrimidin-4-yl*)*amino)benzoic acid hydrochloride


10



- 15 To a mixture of 2-[(2-chloro-5-nitropyrimidin-4-yl)amino]benzoic acid (52 mg, 0.178 mmol) and 3,4,5-trimethoxyaniline (34 mg, 0.185 mmol) in 2-propanol (2 mL) was added 1N HCl in diethyl ether (50uL, 0.05 mmol). The reaction mixture was heated at 90°C for 30 hours. After the reaction was cooled to room temperature the mixture was filtered, and the solid was washed with 2-propanol, hexane, and ethyl acetate. The solid was then dried under vacuum to give 2-(*{*5-nitro-2-[*(*3,4,5-trimethoxyphenyl*)*-amino]*}*pyrimidin-4-yl*)*amino)benzoic acid hydrochloride (53 mg, 63%) as a dirty orange solid. ¹H NMR (DMSO-d₆/D₂O): δ 9.14 (s, 1H), 8.47 (m, 1 H), 8.02 (d, 1 H), 7.46 (m, 1 H), 7.26 (t, 1 H), 6.95 (s, 2 H), 3.69 (s, 3 H), 3.63 (s, 6 H); MS m/z 441 (M+1).
- 20
- 25

Example 2: 2-[(2-chloro-5-nitropyrimidin-4-yl)amino]benzoic acid

5




To a cooled (-78⁰C) solution of 2,4-dichloro-5-nitropyrimidine (0.53 g, 2.75 mmol) in THF (2 mL) was added a solution of anthranilic acid (0.37 g, 2.50 mmol) and N,N-diisopropylethylamine (0.5 mL, 3.0 mmol) in THF (2.0 mL).

- 10 The reaction was stirred for 2.0 hours. The reaction was then poured onto ice and allowed to warm to room temperature then was filtered. The isolated solid was dried under vacuum, then recrystallized from hot ethyl acetate and cold hexane to give 2-[(2-chloro-5-nitropyrimidin-4-yl)amino]benzoic acid (307 mg, 42%) as a yellow solid. ¹H NMR (DMSO-d₆/D₂O): δ 9.20 (s, 1H), 8.36 (d, 1H), 8.07 (d, 1 H), 7.70 (t, 1 H), 7.37 (t, 1 H). MS m/z 294 (M+1).
- 15

Example 3: 2-(5-nitro-2-[(3,4,5-trimethoxyphenyl)amino]pyrimidin-4-yl)amino)benzamide hydrochloride

20

25



- To a mixture of 2-[(2-chloro-5-nitropyrimidin-4-yl)amino]benzamide (52 mg, 0.178 mmol) and 3,4,5-trimethoxyaniline (34 mg, 0.185 mmol) in 2-propanol (2 mL) was added 1N HCl in diethyl ether (50uL, 0.05 mmol). The reaction mixture was heated at 90⁰C for approx. 18 hours. After the reaction was cooled to room temperature cold diethyl ether was added to precipitate out the product. The precipitate was filtered and washed with cold diethyl ether,

then dried under vacuum to give 2-(5-nitro-2-[(3,4,5-trimethoxyphenyl)amino]pyrimidin-4-yl)amino)benzamide hydrochloride (30 mg, 35%) as a dark brown solid. ^1H NMR (DMSO-d₆/D₂O): δ 9.07 (s, 1H), 8.26 (m, 1H), 7.69 (d, 1H), 7.34 (t, 1H), 7.19 (t, 1H), 6.92 (s, 2H), 3.77 (s, 3H), 3.59 (s, 6H). MS *m/z* 440 (M+1).


Example 4: 2-[(2-chloro-5-nitropyrimidin-4-yl)amino]benzamide



10

In a similar manner as described in **Example 2** from 2-aminobenzamide (0.34 g, 2.50 mmol) was obtained 2-[(2-chloro-5-nitropyrimidin-4-yl)amino]benzamide (437 mg, 60%) as a yellow solid. ^1H NMR (DMSO-d₆/D₂O): δ 9.17 (s, 1H), 8.24 (d, 1H), 7.80 (d, 1H), 7.60 (t, 1H), 7.33 (t, 1H). MS *m/z* 293 (M+1).

Example 5: *N*-(*tert*-butyl)-2-(5-nitro-2-[(3,4,5-trimethoxyphenyl)amino]pyrimidin-4-yl)amino)benzamide hydrochloride



20

25


30

In a similar manner as described in **Example 3** from *N*-(*tert*-butyl)-2-[(2-chloro-5-nitropyrimidin-4-yl)amino]benzamide (62 mg, 0.178 mmol) was obtained *N*-(*tert*-butyl)-2-(5-nitro-2-[(3,4,5-trimethoxyphenyl)amino]pyrimidin-4-yl)amino)benzamide hydrochloride (35

mg, 37%) as a tan solid. ^1H NMR (DMSO-d₆/D₂O): δ 9.07 (s, 1H), 8.09 (d, 1H), 7.52 (d, 1 H), 7.33 (t, 1 H), 7.21 (t, 1 H), 6.90 (s, 2 H), 3.64 (s, 3 H), 3.59 (s, 6 H), 1.32 (s, 9 H). MS m/z 496 (M+1).

5 Example 6: N -(*tert*-Butyl)-2-[(2-chloro-5-nitropyrimidin-4-yl)amino]benzamide

10




In a similar manner as described in **Example 2** from 2-amino- N -(*tert*-butyl)benzamide (0.48 g, 2.50 mmol) was obtained: N -(*tert*-butyl)-2-[(2-chloro-5-nitropyrimidin-4-yl)amino]benzamide (630 mg, 72%) as a yellow solid. ^1H NMR (DMSO-d₆/D₂O): δ 9.13 (s, 1H), 8.02 (d, 1 H), 7.60 (d, 1 H), 7.52 (t, 1 H), 7.30 (t, 1 H), 1.33 (s, 9 H). MS m/z 349 (M+1).

20 Example 7: N [(4-[(2-benzoylphenyl)amino]-5-nitropyrimidin-2-yl)amino]phenyl]acetamide hydrochloride

25

30




To a mixture of {2-[(2-chloro-5-nitropyrimidin-4-yl)amino]phenyl}(phenyl)-methanone (63 mg, 0.178 mmol) and N (4-aminophenyl)acetamide (28 mg, 0.185 mmol) in 2-propanol (2 mL) was added 1N HCl in diethyl ether (50uL, 0.05 mmol). The reaction mixture was heated at 90°C for approx. 18 hours. After the reaction was cooled to room temperature cold diethyl ether was added to precipitate out the product. The precipitate was filtered and washed

with cold diethyl ether, then dried under vacuum to give *N*-[4-(*{*4-[*(*2-benzoylphenyl)amino]-5-nitropyrimidin-2-yl*)*amino}phenyl]acetamide hydrochloride (12 mg, 13%) as a tan solid. ^1H NMR (DMSO-d₆/D₂O): δ 8.98 (s, 1H), 8.12 (m, 1H), 7.69-7.43 (m, 12 H), 2.05 (s, 3 H). MS *m/z* 468 (M+1).

5

Example 8: {2-[*(*2-chloro-5-nitropyrimidin-4-yl*)*amino]phenyl*)*(phenyl)methanone


10



20

To a cooled (-78°C) solution of 2,4-dichloro-5-nitropyrimidine (0.53 g, 2.75 mmol) in THF (3 mL) was added a solution of (2-aminophenyl)(phenyl)methanone (0.30 g, 1.55 mmol) and N,N-diisopropylethylamine (0.5 mL, 3.0 mmol) in THF (2.0 mL). The reaction was stirred for 2.0 hours. The reaction was then poured onto ice and allowed to warm to room temperature then was filtered, washing the solid with water. The isolated solid was dried under vacuum to give {2-[*(*2-chloro-5-nitropyrimidin-4-yl*)*amino]phenyl*)*(phenyl)methanone (496 mg, 90%) as a yellow solid. ^1H NMR (DMSO-d₆/D₂O): δ 9.06 (s, 1H), 7.96 (d, 1H), 7.76-7.44 (m, 8 H). MS *m/z* 354 (M+1).

Example 9: 8-({5-nitro-2-[{(3,4,5-trimethoxyphenyl)amino]pyrimidin-4-yl}amino)-3,4-dihydronaphthalen-1(2H)-one hydrochloride




5

10

In a similar manner as described in **Example 3** from 8-[(2-chloro-5-nitropyrimidin-4-yl)amino]-3,4-dihydronaphthalen-1(2H)-one (56 mg, 0.178 mmol) was obtained 8-(5-nitro-2-[(3,4,5-trimethoxyphenyl)amino]pyrimidin-4-yl)amino)-3,4-dihydronaphthalen-1(2H)-one hydrochloride (75 mg, 85%) as a maroon solid. ^1H NMR (DMSO-d₆/D₂O): δ 9.09 (s, 1H), 8.37 (m, 1H), 7.32 (m, 1 H), 7.09 (d, 1 H) 6.91 (s, 2 H), 3.66 (s, 3 H), 3.62 (s, 6 H), 2.94 (t, 2 H), 2.65 (t, 2 H), 1.99 (m, 2 H). MS m/z 465 (M+1).

20 Example 10: 8-[(2-chloro-5-nitropyrimidin-4-yl)amino]-3,4-dihydronaphthalen-1(2H)-one




25

In a similar manner as described in **Example 8** from 8-amino-3,4-dihydronaphthalen-1(2H)-one (0.187 g, 1.16 mmol) was obtained 8-[(2-chloro-5-nitropyrimidin-4-yl)amino]-3,4-dihydronaphthalen-1(2H)-one (313 mg, 85%) as a light tan solid. ^1H NMR (DMSO-d₆/D₂O): δ 9.21 (s, 1H), 8.32 (d, 1H), 7.62 (t, 1 H), 7.24 (d, 1 H) 3.02 (t, 2 H), 2.72 (t, 2 H), 2.06 (m, 2 H). MS m/z 318 (M+1).

Example 11: 1-[2-(5-bromo-2-[(3,4,5-trimethoxyphenyl)amino]pyrimidin-4-yl}amino)phenyl]ethanone hydrochloride


5



In a similar manner as described in **Example 1** from 1-{2-[(5-bromo-2-chloropyrimidin-4-yl)amino]phenyl}ethanone (58 mg, 0.178 mmol) was obtained 1-[2-(5-bromo-2-[(3,4,5-trimethoxyphenyl)amino]pyrimidin-4-yl}amino)phenyl]ethanone hydrochloride (68 mg, 75%) as an off white solid. ^1H NMR (DMSO-d₆/D₂O): δ 8.75 (d, 1H), 8.30 (s, 1H), 8.06 (d, 1H), 7.50 (t, 1H), 7.20 (t, 1H), 6.92 (s, 2H), 3.67 (s, 6H), 3.65 (s, 3H), 2.65 (s, 3H). MS *m/z* 473 (M+1).

Example 12: 1-{2-[(5-bromo-2-chloropyrimidin-4-yl)amino]phenyl}ethanone

20




A mixture of 5-bromo-2,4-dichloropyrimidine (1.25 g, 5.5 mmol) and 1-(2-aminophenyl)ethanone (675 mg, 5.0 mmol) with sodium bicarbonate (1.26 g, 15.0 mmol) in 4:1 EtOH/THF (7.5 mL) was stirred at 80°C for 14 hours. The reaction was cooled to room temperature and the resulting mixture was filtered, washing the solid with cold EtOH. The collected solid was stirred in hot water, filtered, and the resulting solid washed with cold EtOH. The solid was then dried under vacuum to give 1-{2-[(5-bromo-2-chloropyrimidin-4-yl)amino]phenyl}ethanone (761 mg, 47%) as a yellow solid. ^1H NMR (DMSO-

d₆): δ 11.91 (s, 1H), 8.60-8.64 (m, 2H), 8.15 (d, 1 H), 7.74 (t, 1 H), 7.31 (t, 1 H), 2.72 (s, 3 H). MS m/z 326 (M+1).

Example 13: 2-[(2-{[4-(acetylamino)phenyl]amino}-5-nitropyrimidin-4-

5 yl)amino]-N-methylbenzamide hydrochloride

10



To a mixture of 2-[(2-chloro-5-nitropyrimidin-4-yl)amino]-N-methylbenzamide (54 mg, 0.178 mmol) and N-(4-aminophenyl)acetamide (28 mg, 0.185 mmol) in 2-propanol (2 mL) was added 1N HCl in diethyl ether (50uL, 0.05 mmol).

15 The reaction mixture was heated at 90°C for 30 hours. After the reaction was cooled to room temperature the mixture was filtered, and the solid was washed with 2-propanol, hexane, and ethyl acetate. The solid was then dried under vacuum to give 2-[(2-{[4-(acetylamino)phenyl]amino}-5-nitropyrimidin-4-yl)amino]-N-methylbenzamide hydrochloride (58 mg, 71%) as a yellow tan solid. ¹H NMR (DMSO-d₆/D₂O): δ 9.05 (s, 1H), 8.20 (m, 1H), 7.59 (d, 1 H), 7.40-7.50 (m, 5 H), 7.24 (t, 1 H), 2.76 (s, 3 H), 2.02 (s, 3H). MS m/z 421 (M+1).

20


Example 14: 2-[(2-chloro-5-nitropyrimidin-4-yl)amino]-N-methylbenzamide

25




In a similar manner as described in **Example 2** from 2-amino-*N*-methylbenzamide (0.37 g, 2.50 mmol) was obtained 2-[(2-chloro-5-nitropyrimidin-4-yl)amino]-*N*-methylbenzamide (685 mg, 89%) as a yellow solid. ¹H NMR (DMSO-d₆/D₂O): δ 9.13 (s, 1 H), 8.12 (d, 1 H), 7.66 (d, 1 H), 7.55 (t, 1 H), 7.30 (t, 1 H), 2.77 (s, 3 H). MS m/z 307 (M+1).

Example 15: *N*¹-(1*H*indol-4-yl)-5-nitro-*N*²-(3,4,5-trimethoxyphenyl)pyrimidine-2,4-diamine hydrochloride



10 In a similar manner as described in **Example 1** from *N*-(2-chloro-5-nitropyrimidin-4-yl)-1*H*indol-4-amine (51 mg, 0.178 mmol) was obtained *N*¹-(1*H*indol-4-yl)-5-nitro-*N*²-(3,4,5-trimethoxyphenyl)pyrimidine-2,4-diamine hydrochloride (72 mg, 86%) as a brown solid. ¹H NMR (DMSO-d₆/D₂O): δ 9.10 (s, 1 H), 7.67 (m, 1 H), 7.28-7.34 (m, 2 H), 7.03 (t, 1 H), 6.90 (s, 3 H), 3.62 (s, 3 H), 3.49 (s, 6 H). MS m/z 436 (M+1).

Example 16: *N*-(2-chloro-5-nitropyrimidin-4-yl)-1*H*indol-4-amine




25 In a similar manner as described in Example 2 from 1*H*indol-4-amine (0.33 g, 2.50 mmol) was obtained *N*-(2-chloro-5-nitropyrimidin-4-yl)-1*H*indol-4-amine (556 mg, 77%) as a maroon solid. ¹H NMR (DMSO-d₆): δ 11.17 (s, 1 H),

10.45 (s, 1 H), 9.14 (s, 1 H), 7.37-7.42 (m, 3 H), 7.16 (t, 1 H), 6.40 (s, 1 H).
 MS *m/z* 289 (M+1).

5 **Example 17: Methyl 2-({5-nitro-2-[(3,4,5-trimethoxyphenyl)amino]pyrimidin-4-yl}amino)benzoate hydrochloride**


10



In a similar manner as described in **Example 1** from methyl 2-[(2-chloro-5-nitropyrimidin-4-yl)amino]benzoate (55 mg, 0.178 mmol) was obtained methyl 2-(5-nitro-2-[(3,4,5-trimethoxyphenyl)amino]pyrimidin-4-yl)amino)benzoate hydrochloride (60 mg, 69%) as a tan solid. ¹H NMR (DMSO-d₆/D₂O): δ 9.10 (s, 1 H), 8.37 (m, 1 H), 7.96 (d, 1 H), 7.46 (t, 1 H), 7.26 (t, 1 H), 6.90 (s, 2 H), 3.87 (s, 3 H), 3.65 (s, 3 H), 3.58 (s, 6 H)3+. MS *m/z* 455 (M+1).

20 **Example 18: Methyl 2-[(2-chloro-5-nitropyrimidin-4-yl)amino]benzoate**

25




30 In a similar manner as described in Example 2 from methyl 2-aminobenzoate (0.37 g, 2.50 mmol) was obtained Methyl 2-[(2-chloro-5-nitropyrimidin-4-yl)amino]benzoate (486 mg, 63%) as a yellow solid. ¹H NMR (DMSO-d₆): δ 9.17 (s, 1 H), 8.19 (d, 1 H), 8.00 (d, 1 H), 7.69 (t, 1 H), 7.37 (t, 1 H), 3.87 (s, 3 H). MS *m/z* 308 (M+1).

Example 19: N^4 -(2,3-dihydro-1,4-benzodioxin-5-yl)-5-nitro- N^2 -(3,4,5-trimethoxyphenyl)pyrimidine-2,4-diamine hydrochloride

5

ClH




In a similar manner as described in **Example 3** from 2-chloro- N -(2,3-dihydro-1,4-benzodioxin-5-yl)-5-nitropyrimidin-4-amine (55 mg, 0.178 mmol) was obtained N^4 -(2,3-dihydro-1,4-benzodioxin-5-yl)-5-nitro- N^2 -(3,4,5-trimethoxyphenyl)pyrimidine-2,4-diamine hydrochloride (60 mg, 69%) as a tan solid. 1 H NMR (DMSO-d₆/D₂O): δ 9.07 (s, 1 H), 7.80 (m, 1 H), 6.92 (s, 2 H), 6.67-6.71 (m, 2 H), 4.31-4.33 (m, 2 H), 4.22-4.26 (m, 2 H), 3.75 (s, 3 H), 3.64 (s, 6 H). MS *m/z* 455 (M+1).

15

Example 20: 2-chloro- N -(2,3-dihydro-1,4-benzodioxin-5-yl)-5-nitropyrimidin-4-amine

20




25

In a similar manner as described in Example 8 from 2,3-dihydro-1,4-benzodioxin-5-amine (187 mg, 1.87 mmol) was obtained 2-chloro- N -(2,3-dihydro-1,4-benzodioxin-5-yl)-5-nitropyrimidin-4-amine (209 mg, 68%) as a yellow solid. 1 H NMR (DMSO-d₆): δ 9.13 (s, 1 H), 7.57 (d, 1 H), 6.77-6.92 (m, 2 H), 4.26-4.38 (m, 4 H). MS *m/z* 308 (M+1).

Example 21: Cyclohexyl 2-[(2-{[4-(acetylamino)phenyl]amino}-5-nitropyrimidin-4-yl)amino]benzoate hydrochloride


5



In a similar manner as described in **Example 1** from cyclohexyl 2-[(2-chloro-5-nitropyrimidin-4-yl)amino]benzoate (67 mg, 0.178 mmol) and *N*-(4-aminophenyl)acetamide (28 mg, 0.185 mmol) was obtained cyclohexyl 2-[(2-{[4-(acetylamino)phenyl]amino}-5-nitropyrimidin-4-yl)amino]benzoate hydrochloride (13 mg, 14%) as a yellow solid. ^1H NMR (DMSO-d₆/D₂O): δ 9.07 (s, 1H), 8.20 (m, 1 H), 7.98 (d, 1 H), 7.57 (t, 1 H), 7.30-7.46 (m, 5 H), 4.92 (m, 1 H), 2.01 (s, 3 H), 1.20-1.80 (m, 10 H). MS *m/z* 490 (M+1).

Example 22: 5-Hydroxy-2-({5-nitro-2-[(3,4,5-trimethoxyphenyl)amino]pyrimidin-4-yl}amino)benzoic acid hydrochloride

20




25

In a similar manner as described in Example 1 from 2-[(2-chloro-5-nitropyrimidin-4-yl)amino]-5-hydroxybenzoic acid (55 mg, 0.178 mmol) was obtained 5-hydroxy-2-({5-nitro-2-[(3,4,5-trimethoxyphenyl)amino]pyrimidin-4-yl}amino)benzoic acid hydrochloride (21 mg, 24%) as a tan solid. ^1H NMR

(DMSO-d₆/D₂O): δ 9.05 (s, 1H), 8.08 (m, 1H), 7.34 (d, 1 H), 6.85-6.91 (m, 3 H), 3.65 (s, 3 H), 3.59 (s, 6 H). MS *m/z* 457(M+1).

5 **Example 23: 2-[(2-{[4-(Acetylamino)phenyl]amino}-5-nitropyrimidin-4-yl)amino]benzoic acid hydrochloride**


10



In a similar manner as described in **Example 1** from 2-[(2-chloro-5-nitropyrimidin-4-yl)amino]benzoic acid (52 mg, 0.178 mmol) and *N*-(4-aminophenyl)acetamide (28 mg, 0.185 mmol) was obtained 2-[(2-{[4-acetylaminophenyl]amino}-5-nitropyrimidin-4-yl)amino]benzoic acid hydrochloride (7 mg, 8%) as a tan solid. ¹H NMR (DMSO-d₆/D₂O): δ 9.08 (s, 1H), 8.39 (m, 1H), 7.83 (d, 1 H), 7.42-7.55 (m, 5 H), 7.27 (t, 1 H), 2.02 (s, 3 H). MS *m/z* 408(M+1).

20 **Example 24: *N*[4-({4-[(2-Acetylphenyl)amino]-5-bromopyrimidin-2-yl}amino)phenyl]acetamide hydrochloride**

25




In a similar manner as described in **Example 1** from 1-{2-[(5-bromo-2-chloropyrimidin-4-yl)amino]phenyl}ethanone (58 mg, 0.178 mmol) and *N*-(4-

aminophenyl)acetamide (28 mg, 0.185 mmol) was obtained *N*-[4-(*{*4-[*(*2-acetylphenyl*)*amino]*}*5-bromopyrimidin-2-yl*)*amino]phenyl]acetamide hydrochloride (72 mg, 85%) as a light tan solid. ^1H NMR (DMSO-d₆/D₂O): δ 8.72 (d, 1H), 8.27 (s, 1H), 8.06 (dd, 1 H), 7.53 (m, 1 H), 7.46 (s, 4 H), 7.20 (m, 1 H), 2.65 (s, 3 H), 2.02 (s, 3 H). MS *m/z* 440 (M+1).

Example 25: *N*-[4-(*{*5-Bromo-4-[*(*2-morpholin-4-ylphenyl*)*amino]*}*pyrimidin-2-yl*)*amino]phenyl]acetamide hydrochloride


ClH



- 15 In a similar manner as described in **Example 1** from 5-bromo-2-chloro-*N*-(2-morpholin-4-ylphenyl)pyrimidin-4-amine (66 mg, 0.178 mmol) and *N*-(4-aminophenyl)acetamide (28 mg, 0.185 mmol) was obtained *N*-[4-(*{*5-bromo-4-[*(*2-morpholin-4-ylphenyl*)*amino]*}*pyrimidin-2-yl*)*amino]phenyl]acetamide hydrochloride (80 mg, 87%) as a blue grey solid. ^1H NMR (DMSO-d₆/D₂O): δ 8.25 (s, 1H), 7.40-7.51 (m, 5H), 7.29 (m, 1 H), 7.1 (m, 2 H), 3.78 (t, 4 H), 2.82 (t, 4 H), 2.03 (s, 3 H). MS *m/z* 483 (M+1).

Example 26: 5-[(5-Bromo-4-*{*[2-(methylthio)phenyl]amino}*}*pyrimidin-2-yl)amino]-1,3-dihydro-2*H*-benzimidazol-2-one hydrochloride

25 ClH




30

In a similar manner as described in **Example 1** from 5-bromo-2-chloro-*N*-(2-(methylthio)phenyl)pyrimidin-4-amine (59 mg, 0.178 mmol) and 5-amino-1,3-dihydro-2*H*-benzimidazol-2-one (28 mg, 0.185 mmol) was obtained 5-[(5-bromo-4-{[2-(methylthio)phenyl]amino}pyrimidin-2-yl)amino]-1,3-dihydro-
5 2*H*-benzimidazol-2-one hydrochloride (7 mg, 8%) as an off-white solid. ¹H NMR (DMSO-d₆/D₂O): δ 8.20 (s, 1H), 7.82 (m, 1H), 7.47 (m, 1 H), 7.23 (m, 1 H), 6.92-7.05 (m, 3 H), 6.74 (d, 1 H), 2.40 (s, 3 H). MS *m/z* 443 (M+1).

Example 27: 5-Bromo-*N*⁴-(2-morpholin-4-ylphenyl)-*N*²-(3,4,5-trimethoxyphenyl)-pyrimidine-2,4-diamine hydrochloride


15



In a similar manner as described in **Example 1** from 5-bromo-2-chloro-*N*-(2-morpholin-4-ylphenyl)pyrimidin-4-amine (66 mg, 0.178 mmol) was obtained 5-bromo-*N*⁴-(2-morpholin-4-ylphenyl)-*N*²-(3,4,5-trimethoxyphenyl)pyrimidine-
20 2,4-diamine hydrochloride (88 mg, 90%) as a dark grey solid. ¹H NMR (DMSO-d₆/D₂O): δ 8.40-8.44 (m, 1H), 8.26 (s, 1H), 7.28-7.72 (m, 1 H), 7.10 (m, 2 H), 6.94 (s, 2 H), 3.80 (m, 4 H), 3.69 (s, 6 H), 3.66 (s, 3 H), 2.85 (m, 4 H). MS *m/z* 516 (M+1).

Example 28: N-[4-(5-Bromo-4-[(3,4,5-trimethoxyphenyl)amino]pyrimidin-2-yl]amino]phenyl]acetamide hydrochloride


5



To a mixture of 5-bromo-2-chloro-N-(3,4,5-trimethoxyphenyl)pyrimidin-4-amine (67 mg, 0.178 mmol) and N-(4-aminophenyl)acetamide (28 mg, 0.185 mmol) in 2-propanol (2 mL) was added 1N HCl in diethyl ether (50uL, 0.05 mmol). The reaction mixture was heated at 90°C for approx. 36 hours. After the reaction was cooled to room temperature the mixture was taken up in 1:1 acetonitrile/H₂O (60 mL) and lyophilized to give N-[4-(5-bromo-4-[(3,4,5-trimethoxyphenyl)amino]pyrimidin-2-yl)amino]phenyl]acetamide hydrochloride (67 mg, 72%) as a grey solid. ¹H NMR (DMSO-d₆/D₂O): δ 8.21 (s, 1H), 7.25-7.67 (m, 4H), 6.87 (s, 2 H), 3.70 (s, 3 H), 3.69 (s, 6 H), 2.00 (s, 3H). MS m/z 488 (M+1).

20 Example 29: Dimethyl 2-[(2-{[4-(acetylamino)phenyl]amino}-5-nitropyrimidin-4-yl)amino]terephthalate hydrochloride

25




In a similar manner as described in **Example 1** from dimethyl 2-[(2-chloro-5-nitropyrimidin-4-yl)amino]terephthalate (65 mg, 0.178 mmol) and N-(4-aminophenyl)acetamide (28 mg, 0.185 mmol) was obtained dimethyl 2-[(2-

{[4-(acetylamino)phenyl]amino}-5-nitropyrimidin-4-yl)amino]terephthalate hydrochloride (72 mg, 78%) as an off yellow solid. ^1H NMR (DMSO-d₆/D₂O): δ 9.12 (s, 1 H), 8.67 (s, 1 H), 8.10 (d, 1 H), 7.88 (dd, 1 H), 7.44 (d, 2 H), 7.33 (d, 2 H), 3.90 (s, 3 H), 3.81 (s, 3 H), 2.03 (s, 3 H). MS *m/z* 480 (M+1).

5

Example 30: Benzyl 2-[(2-{[4-(acetylamino)phenyl]amino}-5-nitropyrimidin-4-yl)amino]benzoate hydrochloride

10




- 15 In a similar manner as described in **Example 1** from benzyl 2-[(2-chloro-5-nitropyrimidin-4-yl)amino]benzoate (68 mg, 0.178 mmol) and *N*-(4-aminophenyl)acetamide (28 mg, 0.185 mmol) was obtained benzyl 2-[(2-{[4-(acetylamino)phenyl]amino}-5-nitropyrimidin-4-yl)amino]benzoate hydrochloride
20 (73 mg, 77%) as a yellow solid. ^1H NMR (DMSO-d₆/D₂O): δ 9.03 (s, 1 H), 8.22 (m, 1 H), 8.01 (d, 1 H), 7.58 (t, 1 H), 7.29-7.45 (m, 10 H), 5.31 (s, 2 H), 2.01 (s, 3 H). MS *m/z* 498 (M+1).

Example 31: Methyl 2-[(2-{[4-(acetylamino)phenyl]amino}-5-nitropyrimidin-4-yl)amino]-6-methylbenzoate hydrochloride

CIH


5



- 10 In a similar manner as described in **Example 1** from methyl 2-[(2-chloro-5-nitropyrimidin-4-yl)amino]-6-methylbenzoate (57 mg, 0.178 mmol) and *N*-(4-aminophenyl)acetamide (28 mg, 0.185 mmol) was obtained methyl 2-[(2-{[4-(acetylamino)phenyl]amino}-5-nitropyrimidin-4-yl)amino]-6-methylbenzoate hydrochloride (47 mg, 56%) as a yellow solid. ^1H NMR (DMSO-d₆/D₂O): δ
- 15 9.03 (s, 1 H), 7.73 (m, 1 H), 7.33-7.45 (m, 5 H), 7.22 (d, 1 H), 3.80 (s, 3 H), 2.35 (s, 3 H), 2.00 (s, 3 H). MS *m/z* 436 (M+1).

Example 32: Isobutyl 2-[(2-{[4-(acetylamino)phenyl]amino}-5-nitropyrimidin-4-yl)amino]benzoate hydrochloride

20




25

- In a similar manner as described in **Example 1** from isobutyl 2-[(2-chloro-5-nitropyrimidin-4-yl)amino]benzoate (62 mg, 0.178 mmol) and *N*-(4-aminophenyl)acetamide (28 mg, 0.185 mmol) was obtained isobutyl 2-[(2-{[4-(acetylamino)phenyl]amino}-5-nitropyrimidin-4-yl)amino]benzoate hydrochloride (17 mg, 19%) as an off yellow solid. ^1H NMR (DMSO-d₆/D₂O):

§ 9.06 (s, 1 H), 8.24 (m, 1 H), 7.99 (dd, 1 H), 7.57 (t, 1 H), 7.28-7.46 (m, 5 H), 4.05 (d, 2 H), 2.01 (s, 3 H), 0.91 (d, 6 H). MS *m/z* 464 (M+1).

Example 33: 2-[(2-{[4-(Acetylamino)phenyl]amino}-5-nitropyrimidin-4-yl)amino]-6-methylbenzoic acid hydrochloride




10

In a similar manner as described in **Example 1** from 2-[(2-chloro-5-nitropyrimidin-4-yl)amino]-6-methylbenzoic acid (54 mg, 0.178 mmol) and *N*-(4-aminophenyl)acetamide (28 mg, 0.185 mmol) was obtained 2-[(2-{[4-(acetylamino)phenyl]amino}-5-nitropyrimidin-4-yl)amino]-6-methylbenzoic acid hydrochloride (25 mg, 30%) as an off yellow solid. ¹H NMR (DMSO-d₆/D₂O): § 9.04 (s, 1 H), 7.74 (m, 1 H), 7.34-7.47 (m, 5 H), 7.19 (d, 1 H), 2.39 (s, 3 H), 2.01 (s, 3 H). MS *m/z* 422 (M+1).

15

Example 34: *N*-Cyclohexyl-2-({5-nitro-2-[(3,4,5-trimethoxyphenyl)amino]pyrimidin-4-yl}amino)benzamide hydrochloride



25


In a similar manner as described in **Example 1** from 2-[(2-chloro-5-nitropyrimidin-4-yl)amino]-*N*-cyclohexylbenzamide (66 mg, 0.178 mmol) was obtained *N*-cyclohexyl-2-({5-nitro-2-[(3,4,5-trimethoxyphenyl)amino]pyrimidin-4-yl}amino)benzamide hydrochloride (32

mg, 32%) as an off yellow solid. ^1H NMR (DMSO-d₆/D₂O): δ 9.07 (s, 1 H), 8.15 (m, 2 H), 7.58 (d, 1 H), 7.34 (m, 1 H), 7.21 (t, 1 H), 6.91 (s, 2 H), 3.75 (m, 1 H), 3.64 (s, 3 H), 3.59 (s, 6H), 1.05-1.84 (m, 10 H). MS *m/z* 522 (M+1).

5

Example 35: 1-[2-(5-Nitro-2-[(3,4,5-trimethoxyphenyl)amino]pyrimidin-4-yl)amino]phenyl]ethanone hydrochloride

ClH




10

In a similar manner as described in **Example 3** from 1-{2-[(2-chloro-5-nitropyrimidin-4-yl)amino]phenyl}ethanone (52 mg, 0.178 mmol) was obtained 1-[2-(5-nitro-2-[(3,4,5-trimethoxyphenyl)amino]pyrimidin-4-yl)amino]phenyl]ethanone (63 mg, 74%) as a tan solid. ^1H NMR (DMSO-d₆/D₂O): δ 9.09 (s, 1 H), 8.37 (m, 1 H), 8.00 (d, 1 H), 7.44 (t, 1 H), 7.28 (t, 1 H), 6.91 (s, 2 H), 3.65 (s, 3 H), 3.60 (s, 6H), 2.59 (s, 3 H). MS *m/z* 439 (M+1).

Example 36: [5-Chloro-2-(5-nitro-2-[(3,4,5-trimethoxyphenyl)amino]pyrimidin-4-yl)amino]phenyl](2-fluorophenyl)methanone hydrochloride


ClH



25

In a similar manner as described in **Example 1** from {5-chloro-2-[{(2-chloro-5-nitropyrimidin-4-yl)amino]phenyl}(2-fluorophenyl)methanone (72 mg, 0.178 mmol) was obtained [5-chloro-2-(5-nitro-2-[(3,4,5-trimethoxyphenyl)amino]pyrimidin-4-yl)amino]phenyl](2-fluorophenyl)methanone hydrochloride (25 mg, 23%) as brown solid. ¹H NMR (DMSO-d₆/D₂O): δ 9.00 (s, 1 H), 8.10 (m, 1 H), 7.20-7.65 (m, 6 H), 6.91 (s, 2 H), 3.69 (s, 3 H), 3.62 (s, 6H). MS m/z 553 (M+1).

Example 37: 8-(5-Nitro-2-[(3,4,5-trimethoxyphenyl)amino]pyrimidin-4-yl)amino)-2-naphthol hydrochloride




15

In a similar manner as described in **Example 3** from 8-[(2-chloro-5-nitropyrimidin-4-yl)amino]-2-naphthol (56 mg, 0.178 mmol) was obtained 8-(5-nitro-2-[(3,4,5-trimethoxyphenyl)amino]pyrimidin-4-yl)amino)-2-naphthol hydrochloride (32 mg, 36%) as a brown solid. ¹H NMR (DMSO-d₆/D₂O): δ 9.11 (s, 1 H), 7.66-7.86 (m, 3 H), 7.26 (t, 1 H), 7.09-7.18 (m, 2 H), 6.77 (s, 2 H), 3.55 (s, 3 H), 3.32 (s, 6H). MS m/z 463 (M+1).

Example 38: N-(*tert*-butyl)-2-(*{*5-methyl ketone-2-[*(*3,4,5-trimethoxyphenyl)amino]*}* pyrimidin-4-yl*{* amino*}*) benzamide


5



To a heated (100 °C) mixture of N-(*tert*-butyl)-2-(*{*5-Bromo-2-[*(*3,4,5-trimethoxyphenyl)amino]*}* pyrimidin-4-yl*{* amino*}*) benzamide (102mg, 0.192 mmol), tributyl (1-ethoxyvinyl)tin (85 mg. 0.235 mmol) in dimethylformamide (3 ml) was added tetrakis(triphenylphosphine) palladium (0) (15 mg, 0.013 mmol). The reaction was heated for 18 h. The reaction was poured into a vigorously stirring mixture of 5M potassium fluoride solution:ethyl acetate /1:1 and stirred for 0.5h. The biphasic mixture was flushed through a Celite pad and the pad washed with hot ethyl acetate. The combined organic phase was washed with water, saturated sodium chloride and filtered through Whatman PS 1 paper. The organic phase was concentrated *in vacuo* to a crude solid. The solid was triturated in diethyl ether and further purified by chromatography to yield N-(*tert*-butyl)-2-(*{*5-methyl ketone-2-[*(*3,4,5-trimethoxyphenyl)amino]*}* pyrimidin-4-yl*{* amino*}*) benzamide (10 mg, 11%) as a cream solid. ¹H NMR (DMSO-d₆): δ 11.52 (br s, 1H), 9.69 (br s, 1H), 8.84 (s, 1H), 7.99 (br s, 1H), 7.86 (s, 1H), 7.62 – 7.52 (m, 2H), 7.38 (d, 1H, J=7.5 Hz), 7.13 (t, 1H, J=7.4 Hz), 6.95 (br s, 1H), 3.58 (s, 3H), 3.53 (br s, 6H), 2.49 (s, 3H), 1.28 (s, 9H); ES-MS *m/z* 494 (M+H).

Example 39: 4-{[2-(4-Methylbenzoyl)phenyl]amino}-2-[(3,4,5-trimethoxyphenyl)amino]pyrimidine-5-carbonitrile

5



To a mixture of 4-{[2-(4-methylbenzoyl)phenyl]amino}-2-(methylsulfonyl)pyrimidine-5-carbonitrile (54 mg, 0.138 mmol) and 3,4,5-trimethoxyaniline (26 mg, 0.142 mmol) in absolute ethanol (3 ml) was added 1N HCl in diethyl ether (3 drops). The reaction was facilitated using microwave irradiation. The reaction was heated at 180°C for 600 sec. using Personal Chemistry SmithSynthesizer. On cooling a crude yellow solid was collected by filtration. Pure sample was obtained after chromatography to give 4-{[2-(4-methylbenzoyl)phenyl]amino}-2-[(3,4,5-trimethoxyphenyl)amino]pyrimidine-5-carbonitrile (25 mg, %) as a canary yellow solid. ¹H NMR (DMSO-d₆): δ 10.0 (s, 1H), 9.39 (br s, 1H), 8.39 (s, 1H), 8.04 (d, 1H, J=8.4 Hz), 7.58 – 7.48 (m, 4H), 7.28 (t, 1H, J=7.6 Hz), 7.22 (d, 2H, J=7.9 Hz), 6.91 (s, 1H), 3.65 (s, 3H), 3.61 (s, 6H), 2.35 (s, 3H); ES-MS m/z 496 (M+H).

20 Example 40: Biological Examples

I. Assay for inhibition of PLK1

A. Preparation of 6x N-terminal His-tagged PLK kinase domain

6x N-terminal His-tagged PLK kinase domain (amino acids 21-346 preceded by MKKGHHHHHD) was prepared from baculovirus infected T. ni cells under polyhedrin promoter control. All procedures were performed at 4°C. Cells were lysed in 25 mM HEPES, 200 mM NaCl, 25 mM imidazole; pH 8.0. The homogenate was centrifuged at 14K rpm in a SLA-1500 rotor for 40 min and the supernatant filtered through a 1.2 micron filter. The supernatant was loaded onto a Nickel chelating Sepharose (Amersham Pharmacia) column and

washed with 25 mM HEPES, 500 mM NaCl, 25 mM imidazole; pH 8.0. The column was then washed with a 16.6%B step where buffer B is 25 mM HEPES, 500 mM NaCl, 300 mM imidazole; pH 8.0. Protein was eluted using a 10-column volume linear gradient from 16.6%B to 100%B. Fractions 5 containing PLK were determined by SDS-PAGE. PLK was concentrated using a 10 kDa molecular weight cutoff membrane and then loaded onto a Superdex 75 gel filtration (Amersham Pharmacia) column equilibrated in 25 mM HEPES, 1 mM DTT, 500 mM NaCl; pH 8.0. Fractions containing PLK were determined by SDS-PAGE. PLK was pooled, aliquoted and stored at -80°C. 10 Samples were quality controlled using mass spectrometry.

B. Enzyme activity +/- inhibitors was determined as follows: Compounds were added to the plate (1µl in 100% DMSO). DMSO (2% final) and EDTA (55.5mM final) were used as controls. Reaction Mix A is prepared 15 as follows at 4°C:

Reaction Mix A (substrate Mix):
25mM HEPES, pH 7.2
15mM MgCl₂
2µM ATP
20 0.1µCi/well ³³P-γ ATP (10Ci/mMol)
2µM substrate peptide (Biotin-Ahx-SFNDTLDFD)

Reaction Mix B is prepared as follows at 4°C:

Reaction Mix B (Enzyme Mix)
25 25mM HEPES, pH 7.2
15mM MgCl₂
0.15mg/ml BSA
2mM DTT
2-10 nM PLK1 kinase domain

Reaction Mix A (20 μ l) is added per well. Reaction Mix B (20 μ l) is added per well. Incubate 1.5hrs. at RT. The enzymatic reaction is stopped with 175 μ l of SPA/EDTA bead mix (29mM EDTA, 2.5 mg/ml Streptavidin-coated SPA in Standard Dulbecco's PBS (without Mg²⁺ and Ca²⁺), 60 μ M ATP). Plates are
5 sealed spun (after a 1 hr incubation at RT) at 1,000 x g for 7 min or settled overnight, then plates counted in Packard TopCount for 30 seconds/well.

C. Results

The data obtained is reported in **Table 1** below. In Table 1, + =
10 pIC50 <5; ++ = pIC50 5-7; +++ = pIC50 >7.

II. Methylene Blue Growth Inhibition Assay

Normal Human foreskin fibroblasts (HFF) and human colon (HCT116, RKO), lung (H460), prostate (PC3), and breast tumor (MCF7) cell lines were cultured
15 in high glucose DMEM (Life Technologies) containing 10% fetal bovine serum (FBS) at 37°C in a humidified 10% CO₂, 90% air incubator. Cells were harvested using trypsin/EDTA, counted using a haemocytometer, and plated in 100 μ l of the appropriate media, at the following densities, in a 96-well tissue culture plate (Falcon 3075): HFF 5,000 cells/well, HCT116 3,000
20 cells/well, RKO 2,500 cells/well, H460 2,000 cells/well, PC3 8,000 cells/well, MCF7 4,000 cells/well. The next day, compounds were diluted in DMEM containing 100 μ g/ml gentamicin, at twice the final required concentration, from 10 mM stock solutions in DMSO. 100 μ l/well of these dilutions were added to the 100 μ l of media currently on the cell plates. Medium containing
25 0.6% DMSO was added to control wells. Compounds diluted in DMEM were added to all cell lines. The final concentration of DMSO in all wells was 0.3%. Cells were incubated at 37°C, 10% CO₂ for 3 days. Medium was removed by aspiration. Cell biomass was estimated by staining cells with 90 μ l per well methylene blue (Sigma M9140, 0.5% in 50:50 ethanol:water), and incubation
30 at room temperature for at least 30 minutes. Stain was removed, and the

plates rinsed under a gentle stream of water, and air-dried. To release stain from the cells 100 μ l of solubilization solution was added (1% N-lauroyl sarcosine, Sodium salt, Sigma L5125, in PBS), and plates were shaken gently for about 30 minutes. Optical density at 620 nM was measured on a

5 microplate reader. Percent inhibition of cell growth was calculated relative to vehicle treated control wells. Concentration of compound that inhibits 50% of cell growth (IC_{50}) was interpolated using nonlinear regression (Levenberg-Marquardt) and the equation, $y = V_{max} * (1 - (x/(K+x))) + Y_2$, where "K" was equal to the IC_{50} . The data obtained reported in **Table 1** below. In **Table 1**,

10 + = 10 - >30 μ M; ++ = 1 -10 μ M: +++ = <1 μ M.

Table 1

Example	Ave pIC50 PLK Enzyme Inhibition	MeB Cell Line	IC50 (μ M)
1	+++	--	--
3	+++	H460	+++
		HCT116	+++
		HFF	++
		MCF7	+++
		PC3	++
		RKO	+++
5	+++	H460	++
		HCT116	++
		HFF	++
		MCF7	++
		PC3	++
		RKO	++
7	+++	H460	++
		HCT116	++
		HFF	+

Example	Ave pIC50 PLK Enzyme Inhibition	MeB Cell Line	IC50 (μ M)
		MCF7	++
		PC3	++
		RKO	++
9	+++	H460	++
		HCT116	++
		HFF	+
		MCF7	++
		PC3	++
		RKO	++
11	+++	--	--
13	+++	--	--
15	+++	H460	++
		HCT116	++
		HFF	++
		MCF7	++
		PC3	++
		RKO	+++
17	+++	--	--
19	+++	H460	++
		HCT116	+
		HFF	+
		MCF7	++
		PC3	+
		RKO	++
21	+++	--	--
22	+++	H460	+
		HCT116	+
		HFF	+


Example	Ave pIC50 PLK Enzyme Inhibition	MeB Cell Line	IC50 (μ M)
		MCF7	+
		PC3	+
		RKO	+
23	+++	--	--
24	+++	--	--
25	+++	--	--
27	++	--	--
28	+	--	--
29	++	--	--
30	++	--	--
31	+++	--	--
32	+++	--	--
33	+++	--	--
34	+++	H460	++
		HCT116	++
		HFF	++
		MCF7	++
		PC3	+
		RKO	++
35	+++	--	--
36	+++	H460	++
		HCT116	++
		HFF	+
		MCF7	++
		PC3	+
		RKO	++
37	+++	--	--
38	+++	--	--

Example	Ave pIC50 PLK Enzyme Inhibition	MeB Cell Line	IC50 (μ M)
39	+++	H460	++
		HCT116	++
		HFF	+
		MCF7	++
		PC3	++
		RKO	++

CLAIMS

1. A compound of formula (I):


5



wherein:

- 10 R¹ is selected from the group consisting of H, halo, alkyl, alkenyl, alkynyl;
- R² is selected from the group consisting of halo, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, -(R⁷)_g-C(O)R⁶, -(R⁷)_g-CO₂R⁶, -(R⁷)_g-C(O)N(R⁶)₂, -(R⁷)_g-OR⁶, -O-(R⁷)_g-Ay, -(R⁷)_g-S(O)_eR⁶, -(R⁷)_g-N(R⁶)₂, -(R⁷)_g-N(R⁶)C(O)R⁶, -(R⁷)_g-CN, -(R⁷)_g-SCN, -NO₂, -N₃, Ay and 5- to 9- membered heteroaryl containing 1 or 2 heteroatoms selected from N, O and S;
- 15 each R³ is the same or different and is independently H or alkyl;
- Y is selected from the group consisting of -C(O)R⁸, -C(S)R⁸, -S(O)_eR⁹, -S(O)_eN(R⁹)₂, -N(R⁹)₂, -N(R⁹)-S(O)_eR⁹, -N(R⁹)-C(O)R⁹, -N(R⁹)-CO₂R⁹, and -N(R⁹)-C(O)N(R⁹)₂,
- 20 or Y, together with C-2 and C-3 form a fused ring system of formula A:

20



25

wherein

- R⁸ is selected from the group consisting of alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, Ay, Het, -OR⁶, -O-(R⁷)_g-Ay, -O-(R⁷)_g-Het, -N(R⁶)₂, -N(R⁶)-(R⁷)_g-Ay, -N(R⁶)-(R⁷)_g-Het, -N(R⁶)-(R⁷)_g-OR⁶, -N(R⁶)-(R⁷)_g-C(O)R⁶, -N(R⁶)-(R⁷)_g-CO₂R⁶,

30

-N(R⁶)-(R⁷)_g-SO₂R⁶, and -N(R⁶)-(R⁷)_g-N(R⁶)₂;

each R⁹ is the same or different and is independently selected from the group consisting of H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, Ay and Het;

5 c is 0 or 1;

Z¹, Z², Z³ and Z⁴ are each independently selected from the group consisting of C, O, S and N, wherein when c is 0, at least one of Z¹, Z² and Z³ is C and wherein when c is 1, at least two of Z¹, Z², Z³ and Z⁴ are C;

10 each dashed line represents an optional double bond;

d is 0, 1 or 2;

each R¹⁰ is the same or different and is independently selected from the group consisting of halo, alkyl, oxo, hydroxy, mercapto and amino;

15 a is 0, 1, 2 or 3;

each R⁴ is the same or different and is independently selected from the group consisting of halo, alkyl, alkenyl, alkynyl, -(R⁷)_g-cycloalkyl, -(R⁷)_g-cycloalkenyl, -(R⁷)_g-Ay, -(R⁷)_g-Het, -(R⁷)_g-C(O)R⁶, -(R⁷)_g-C(O)Ay, -(R⁷)_g-C(O)Het, -(R⁷)_g-CO₂R⁶, -(R⁷)_g-CO₂Ay, -(R⁷)_g-CO₂Het, -(R⁷)_g-C(O)N(R⁶)₂, -(R⁷)_g-OR⁶, -(R⁷)_g-OAy, -(R⁷)_g-OHet, -(R⁷)_g-OC(O)R⁶, -(R⁷)_g-OC(O)Ay, -(R⁷)_g-OC(O)Het, -(R⁷)_g-S(O)_eR⁶, -(R⁷)_g-S(O)_eAy, -(R⁷)_g-S(O)_eHet, -(R⁷)_g-S(O)_eN(R⁶)₂, -(R⁷)_g-S(O)_eN(R⁶)Ay, -(R⁷)_g-S(O)_eN(R⁶)Het, -(R⁷)_g-N(R⁶)C(O)R⁶, -(R⁷)_g-N(R⁶)C(O)Ay, -(R⁷)_g-N(R⁶)C(O)Het, -(R⁷)_g-N(R⁶)C(O)N(R⁶)₂, -(R⁷)_g-N(R⁶)S(O)_eR⁶, -(R⁷)_g-N(R⁶)S(O)_eAy, -(R⁷)_g-N(R⁶)S(O)_eHet, -NO₂, -CN, -SCN and -N₃, or

25 two adjacent R⁴ groups together with the carbon atoms to which they are bonded form a phenyl or a 5- or 6-membered heterocycle or heteroaryl containing 1 or 2 heteroatoms selected from the group consisting of O, N and S;

30

- each e is the same or different and is independently 0, 1 or 2;
- b is 0, 1, 2, 3, 4 or 5;
- each R⁵ is the same or different and is a group of formula (R⁷)_g-R¹¹, or two adjacent R⁵ groups are each the same or different and are
- 5 independently selected from the group consisting of alkyl, alkenyl, -OR⁶, -S(O)_eR⁶ and -N(R⁶)₂ and, together with the carbon atoms to which they are bonded, they form a C₅₋₆cycloalkyl, C₅₋₆cycloalkenyl or a 5- or 6-membered heterocycle or heteroaryl containing 1 or 2 heteroatoms selected from the group consisting of N, O and S;
- 10 each R⁶ is the same or different and is independently selected from the group consisting of H, alkyl, alkenyl, alkynyl, cycloalkyl and cycloalkenyl;
- g is 0 or 1;
- R⁷ is alkylene or alkenylene;
- Ay is aryl;
- 15 Het is a 5- or 6-membered heterocycle or heteroaryl containing 1, 2 or 3 heteroatoms selected from the group consisting of N, O and S;
- R¹¹ is selected from the group consisting of halo, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, Ay, Het, -C(O)R⁶, -C(O)Ay, -C(O)Het, -CO₂R⁶, -CO₂Ay, -CO₂Het, -C(O)-R⁷-OR⁶, -C(O)-R⁷-OAy, -C(O)-R⁷-OHet,
- 20 -C(O)N(R⁶)₂, -C(O)N(R⁶)Ay, -C(O)N(R⁶)Het, -C(O)N(R⁶)-(R⁷)_g-N(R⁶)₂, -C(O)N(R⁶)-(R⁷)_g-CO₂R⁶, -C(O)N(R⁶)-(R⁷)_g-S(O)_eR⁶, -OR⁶, -OC(O)R⁶, -O-(R⁷)_g-Ay, -OC(O)Ay, -O-(R⁷)_g-Het, -OC(O)Het, -O-R⁷-OR⁶,
- 25 -O-R⁷-N(R⁶)₂, -S(O)_eR⁶, -S(O)_e-(R⁷)_g-Ay, -S(O)_e-(R⁷)_g-Het, -S(O)_e-(R⁷)_g-N(R⁶)₂, -S(O)_e-(R⁷)_g-N(R⁶)Ay, -S(O)_e-(R⁷)_g-N(R⁶)Het, -S(O)_eN(R⁶)-(R⁷)_g-C(O)R⁶, -S(O)_eN(R⁶)-(R⁷)_g-C(O)Ay,
- S(O)_eN(R⁶)-(R⁷)_g-C(O)Het, -N(R⁶)₂, -N(R⁶)-(R⁷)_g-Ay, -N(R⁶)-(R⁷)_g-Het, -N(R⁶)-(R⁷)_g-C(O)R⁶, -N(R⁶)-C(O)-(R⁷)_g-Ay, -N(R⁶)-C(O)-(R⁷)_g-Het,
- 30 -N(R⁶)-C(O)-(R⁷)_g-N(R⁶)₂, -N(R⁶)-C(O)-(R⁷)_g-N(R⁶)Ay, -N(R⁶)-C(O)-(R⁷)_g-N(R⁶)Het, -N(R⁶)-C(O)-(R⁷)_g-N(R⁶)-(R⁷-O)_h-N(R⁶)-CO₂R⁶, -N(R⁶)-(R⁷)_g-S(O)_eR⁶,

-N(R⁶)-(R⁷)_g-S(O)_eAy, -N(R⁶)-(R⁷)_g-S(O)_eHet, -N(R⁶)-R⁷-N(R⁶)₂,
-N(R⁶)-R⁷-OR⁶, -CN, -SCN, -NO₂, and -N₃; and

h is 1-20;

wherein when R¹ is -CH₃, R² is Br or NO₂, both R³ are H, a is 0 and b is 0 or 1

5 wherein R⁵ is -CO₂H, then Y is not -CO₂H

or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof.

2. The compound according to claim 1, wherein R¹ is selected from the
10 group consisting of H, halo and alkyl.

3. The compound according to claim 1, wherein R¹ is H.

4. The compound according to claim 1-3, wherein R² is selected from the
15 group consisting of halo, alkyl, alkenyl, -(R⁷)_g-C(O)R⁶, -(R⁷)_g-C(O)N(R⁶)₂,
-(R⁷)_g-CN and -NO₂.

5. The compound according to claim 1-3, wherein R² is -NO₂.

20 6. The compound according to claim 1-5, wherein each R³ is the same or different and is independently H or methyl.

7. The compound according to claim 1-5, wherein each R³ is H.

25 8. The compound according to any of claims 1-7, wherein Y is selected from the group consisting of -C(O)R⁸, -C(S)R⁸, -S(O)_eR⁹, -S(O)_eN(R⁹)₂, -N(R⁹)₂ and -N(R⁹)-S(O)_eR⁹.

30 9. The compound according to any of claims 1-7, wherein Y is selected from the group consisting of -C(O)R⁸, -S(O)_eR⁹, -S(O)_eN(R⁹)₂, -N(R⁹)₂ and

-N(R⁹)-S(O)_eR⁹.

10. The compound according to any of claims 1-7, wherein Y is -C(O)R⁸.

5 11. The compound according to any of claims 1-7, wherein Y together with
C-2 and C-3 form a fused ring system of formula A.

10 12. The compound according to any of claims 1-7, wherein Y together with
C-2 and C-3 form a fused ring system of formula A and at least one of Z¹, Z²,
Z³ and Z⁴ is selected from the group consisting of N, O and S.

13. The compound according to any of claims 1-7, wherein Y together with
C-2 and C-3 form a fused ring system of formula A and d is 0 or 1.

15 14. The compound according to any of claims 1-7, wherein Y together with
C-2 and C-3 form a fused ring system of formula A, d is 1 or 2 and each R¹⁰ is
the same or different and is independently selected from halo and alkyl.

15. The compound according to any of claims 1-14, wherein a is 0 or 1.

20

16. The compound according to any of claims 1-15, wherein each R⁴ is the
same or different and is independently selected from the group consisting of
halo, alkyl, alkenyl, alkynyl, -(R⁷)_g-cycloalkyl, -(R⁷)_g-cycloalkenyl, -(R⁷)_g-Ay,
-(R⁷)_g-Het, -(R⁷)_g-C(O)R⁶, -(R⁷)_g-C(O)Ay, -(R⁷)_g-C(O)Het, -(R⁷)_g-CO₂R⁶,
-(R⁷)_g-CO₂Ay, -(R⁷)_g-CO₂Het, -(R⁷)_g-C(O)N(R⁶)₂, -(R⁷)_g-OR⁶, -(R⁷)_g-OAy,
-(R⁷)_g-OHet, -(R⁷)_g-OC(O)R⁶, -(R⁷)_g-OC(O)Ay, -(R⁷)_g-OC(O)Het, -(R⁷)_g-S(O)_eR⁶,
-(R⁷)_g-S(O)_eAy, -(R⁷)_g-S(O)_eN(R⁶)₂, -(R⁷)_g-S(O)_eN(R⁶)Ay, -(R⁷)_g-S(O)_eN(R⁶)Het,
-(R⁷)_g-N(R⁶)₂, -(R⁷)_g-N(R⁶)Ay, -(R⁷)_g-N(R⁶)Het, -(R⁷)_g-N(R⁶)C(O)R⁶,
-(R⁷)_g-N(R⁶)C(O)N(R⁶)₂, -NO₂, -CN, -SCN and -N₃.

30

17. The compound according to any of claims 1-15, wherein each R⁴ is the same or different and is independently selected from the group consisting of halo, alkyl, -(R⁷)_g-cycloalkyl, -(R⁷)_g-C(O)R⁶, -(R⁷)_g-CO₂R⁶, -(R⁷)_g-C(O)N(R⁶)₂, -(R⁷)_g-OR⁶, -(R⁷)_g-S(O)_eR⁶, -(R⁷)_g-N(R⁶)₂ and -(R⁷)_g-N(R⁶)C(O)R⁶.

5

18. The compound according to any of claims 1-17, wherein b is 0, 1, 2 or 3.

19. The compound according to any of claims 1-18, wherein R¹¹ is selected from the group consisting of halo, alkyl, alkenyl, alkynyl, Ay, Het, -C(O)Het, -CO₂R⁶, -CO₂Ay, -CO₂Het, -C(O)N(R⁶)₂, -C(O)N(R⁶)Ay, -C(O)N(R⁶)Het, -C(O)N(R⁶)-(R⁷)_g-N(R⁶)₂, -C(O)N(R⁶)-(R⁷)_g-CO₂R⁶, -C(O)N(R⁶)-(R⁷)_g-S(O)_eR⁶, -OR⁶, -O-(R⁷)_g-Ay, -O-(R⁷)_g-Het, -O-R⁷-OR⁶, -O-R⁷-N(R⁶)₂, -S(O)_eR⁶, -S(O)_e-(R⁷)_g-Het, -S(O)_e-(R⁷)_g-N(R⁶)₂, -S(O)_e-(R⁷)_g-N(R⁶)Het, -S(O)_eN(R⁶)-(R⁷)_g-C(O)Het, -N(R⁶)₂, -N(R⁶)-(R⁷)_g-Ay, -N(R⁶)-(R⁷)_g-Het, -N(R⁶)-(R⁷)_g-C(O)R⁶, -N(R⁶)-C(O)-(R⁷)_g-Het, -N(R⁶)-C(O)-(R⁷)_g-N(R⁶)₂, -N(R⁶)-C(O)-(R⁷)_g-N(R⁶)Het, -N(R⁶)-C(O)-(R⁷)_g-N(R⁶)-(R⁷-O)_h-N(R⁶)-CO₂R⁶, -N(R⁶)-(R⁷)_g-S(O)_eR⁶, -N(R⁶)-(R⁷)_g-S(O)_eHet, -N(R⁶)-R⁷-N(R⁶)₂, -N(R⁶)-R⁷-OR⁶, -CN and -N₃.

20

20. The compound according to any of claims 1-19, wherein each R¹¹ is the same or different and is independently selected from the group consisting of alkyl, Het, -OR⁶, -S(O)_eR⁶, -S(O)_e-(R⁷)_g-N(R⁶)₂, -N(R⁶)₂, -N(R⁶)-(R⁷)_g-C(O)R⁶ and -N(R⁶)-C(O)-(R⁷)_g-N(R⁶)₂.

25

21. A compound selected from the group consisting of:

2-({5-nitro-2-[(3,4,5-trimethoxyphenyl)amino]pyrimidin-4-yl}amino)benzoic acid hydrochloride;

2-({5-nitro-2-[(3,4,5-trimethoxyphenyl)amino]pyrimidin-4-

30 yl}amino)benzamide hydrochloride;

- N*-(*tert*-butyl)-2-({5-nitro-2-[(3,4,5-trimethoxyphenyl)amino]pyrimidin-4-yl}amino)benzamide hydrochloride;
- N*-[4-({4-[(2-benzoylphenyl)amino]-5-nitropyrimidin-2-yl}amino)phenyl]acetamide hydrochloride;
- 5 8-({5-nitro-2-[(3,4,5-trimethoxyphenyl)amino]pyrimidin-4-yl}amino)-3,4-dihydronaphthalen-1(2*H*)-one hydrochloride;
- 1-[2-({5-bromo-2-[(3,4,5-trimethoxyphenyl)amino]pyrimidin-4-yl}amino)phenyl]ethanone hydrochloride;
- 10 2-[(2-{[4-(acetylamino)phenyl]amino}-5-nitropyrimidin-4-yl)amino]-*N*-methylbenzamide hydrochloride;
- N*⁴-(1*H*-indol-4-yl)-5-nitro-*N*²-(3,4,5-trimethoxyphenyl)pyrimidine-2,4-diamine hydrochloride;
- Methyl 2-({5-nitro-2-[(3,4,5-trimethoxyphenyl)amino]pyrimidin-4-yl}amino)benzoate hydrochloride;
- 15 *N*⁴-(2,3-dihydro-1,4-benzodioxin-5-yl)-5-nitro-*N*²-(3,4,5-trimethoxyphenyl)pyrimidine-2,4-diamine hydrochloride;
- Cyclohexyl 2-[(2-{[4-(acetylamino)phenyl]amino}-5-nitropyrimidin-4-yl)amino]benzoate hydrochloride;
- 20 5-Hydroxy-2-({5-nitro-2-[(3,4,5-trimethoxyphenyl)amino]pyrimidin-4-yl}amino)benzoic acid hydrochloride;
- 2-[(2-{[4-(Acetylamino)phenyl]amino}-5-nitropyrimidin-4-yl)amino]benzoic acid hydrochloride;
- 25 *N*-[4-({4-[(2-Acetylphenyl)amino]-5-bromopyrimidin-2-yl}amino)phenyl]acetamide hydrochloride;
- N*-[4-({5-Bromo-4-[(2-morpholin-4-ylphenyl)amino]pyrimidin-2-yl}amino)phenyl]acetamide hydrochloride;
- 5-[(5-Bromo-4-{[2-(methylthio)phenyl]amino}pyrimidin-2-yl)amino]-1,3-dihydro-2*H*-benzimidazol-2-one hydrochloride;
- 30 5-Bromo-*N*⁴-(2-morpholin-4-ylphenyl)-*N*²-(3,4,5-trimethoxyphenyl)pyrimidine-2,4-diamine hydrochloride;

- N*-[4-(5-Bromo-4-[(3,4,5-trimethoxyphenyl)amino]pyrimidin-2-yl)amino]phenyl]acetamide hydrochloride;
- Dimethyl 2-[(2-{[4-(acetylamino)phenyl]amino}-5-nitropyrimidin-4-yl)amino]terephthalate hydrochloride;
- 5 Benzyl 2-[(2-{[4-(acetylamino)phenyl]amino}-5-nitropyrimidin-4-yl)amino]benzoate hydrochloride;
- Methyl 2-[(2-{[4-(acetylamino)phenyl]amino}-5-nitropyrimidin-4-yl)amino]-6-
- 10 methylbenzoate hydrochloride;
- Isobutyl 2-[(2-{[4-(acetylamino)phenyl]amino}-5-nitropyrimidin-4-yl)amino]benzoate hydrochloride;
- 15 2-[(2-{[4-(Acetylamino)phenyl]amino}-5-nitropyrimidin-4-yl)amino]-6-
- methylbenzoic acid hydrochloride;
- N*-Cyclohexyl-2-({5-nitro-2-[(3,4,5-trimethoxyphenyl)amino]pyrimidin-4-yl}amino)benzamide hydrochloride;
- 20 1-[2-({5-Nitro-2-[(3,4,5-trimethoxyphenyl)amino]pyrimidin-4-yl}amino)phenyl]ethanone hydrochloride;
- [5-Chloro-2-({5-nitro-2-[(3,4,5-trimethoxyphenyl)amino]pyrimidin-4-yl}amino)phenyl](2-fluorophenyl)methanone hydrochloride;
- 25 8-({5-Nitro-2-[(3,4,5-trimethoxyphenyl)amino]pyrimidin-4-yl}amino)-2-
- naphthol hydrochloride;
- N-(*tert*-butyl)-2-({5-methyl ketone-2-[(3,4,5- trimethoxyphenyl)amino]pyrimidin-4-yl} amino) benzamide;
- 4-{[2-(4-Methylbenzoyl)phenyl]amino}-2-[(3,4,5-trimethoxyphenyl)amino]-
- pyrimidine-5-carbonitrile; and
- 25 pharmaceutically acceptable salts, solvates and physiologically functional derivatives thereof.

22. A pharmaceutical composition comprising a compound according to any of claims 1-21.

23. The pharmaceutical composition according to claim 22 further comprising a pharmaceutically acceptable carrier, diluent or excipient.

24. The pharmaceutical composition according to any of claims 22-23
5 further comprising a chemotherapeutic agent.

25. A method for treating a condition mediated by PLK in an animal, said method comprising administering to the animal a therapeutically effective amount of a compound according to any of claims 1-21.


10 26. A method for treating a susceptible neoplasm in an animal, said method comprising administering to the animal a therapeutically effective amount of a compound according to any of claims 1-21.
15 27. The method according to claim 26, wherein said susceptible neoplasm is selected from the group consisting of breast cancer, colon cancer, lung cancer, prostate cancer, lymphoma, leukemia, endometrial cancer, melanoma, ovarian cancer, pancreatic cancer, squamous carcinoma, carcinoma of the head and neck, and esophageal carcinoma.

20 28. A method for treating a condition characterized by inappropriate cellular proliferation in an animal, said method comprising administering to the animal a therapeutically effective amount of a compound according to any of claims 1-21.


25 29. A method for inhibiting proliferation of a cell, said method comprising contacting the cell with an amount of a compound according to any of claims 1-21 sufficient to inhibit proliferation of the cell.

30. A method for inhibiting mitosis in a cell, said method comprising administering to the cell an amount of a compound according to any of claims 1-21 sufficient to inhibit mitosis in the cell.

5 31. A process for preparing a compound according to any of claims 1-21, said process comprising reacting a compound of formula (IV):



wherein R¹⁵ is selected from the group consisting of halo and -S(O)_eR⁶.
with a compound of formula (V):



32. The process according to claim 31, said process further comprising the step of converting a compound of formula (I) to a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof.

20

33. The process according to any of claims 31-32 further comprising the step of converting a compound of formula (I) or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof to another compound of formula (I) or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof.

25

34. A compound according to any of Claims 1-21 for use in therapy.

35. A compound according to any of Claims 1-21 for use in the treatment
30 of a condition mediated by PLK in an animal.

36. A compound according to any of claims 1-21 for use in the treatment of a susceptible neoplasm in an animal.

37. A compound according to any of claims 1-21 for use in the treatment
5 of a condition characterized by inappropriate cellular proliferation in an animal.

38. A compound according to any of claims 1-21 for use in inhibiting proliferation of a cell.

10

39. A compound according to any of claims 1-21 for use in inhibiting mitosis in a cell.

40. The use of a compound according to any of claims 1-21 for the preparation of a medicament for the treatment of condition mediated by PLK
15 in an animal.

41. The use of a compound according to any of claims 1-21 for the preparation of a medicament for the treatment of a susceptible neoplasm in an animal.

20

42. The use of a compound according to any of claims 1-21 for the preparation of a medicament for the treatment of a condition characterized by inappropriate cellular proliferation.

25 43. A pharmaceutical composition comprising a compound according to any of claims 1-21 for use in the treatment of a susceptible neoplasm in an animal.

SEQUENCE LISTING

<110> SmithKline Beecham Corporation

<120> PYRIMIDINE COMPOUNDS

<130> PR60085

<140> to be assigned

<141>

<150> 60/448,795

<151> 2003-02-20

<160> 2

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 11

<212> PRT

<213> baculovirus infected T.ni cells

<400> 1

Met Lys Lys Gly His His His His His Asp
1 5 10

<210> 2

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> optimized PLK peptide substrate

<400> 2

Ser Phe Asn Asp Thr Leu Asp Phe Asp
1 5

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date
2 September 2004 (02.09.2004)

PCT

(10) International Publication Number
WO 2004/074244 A3

(51) International Patent Classification⁷: **C07D 403/12**, 239/48, 405/12, A61K 31/505, 31/506, A61P 35/00

(74) Agents: LEVY, David, J. et al.; GlaxoSmithKline, Five Moore Drive, P.O. Box 13398, Research Triangle Park, NC 27709 (US).

(21) International Application Number:
PCT/US2004/004197

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(22) International Filing Date: 11 February 2004 (11.02.2004)

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/448,795 20 February 2003 (20.02.2003) US

(71) Applicant (for all designated States except US): **SMITHKLINE BEECHAM CORPORATION** [US/US]; One Franklin Plaza, Philadelphia, PA 19101 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **DAVIS-WARD, Ronda** [US/US]; GlaxoSmithKline, Five Moore Drive, PO Box 13398, Research Triangle Park, NC 27709 (US). **MOOK, Robert, Anthony, Jr.** [US/US]; GlaxoSmithKline, Five Moore Drive, PO Box 13398, Research Triangle Park, NC (US). **NEEB, Michael, J.** [US/US]; GlaxoSmithKline, 709 Swedeland Road, King of Prussia, PA (US). **SALOVICH, James, M.** [US/US]; GlaxoSmithKline, Five Moore Drive, P.O. Box 13398, Research Triangle Park, NC 27709 (US).


Published:

— with international search report

(88) Date of publication of the international search report: 11 November 2004

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: PYRIMIDINE COMPOUNDS



(57) Abstract: The present invention provides compounds of formula (I) : wherein all variables are as defined herein, pharmaceutical compositions containing the same, processes for preparing the same and their use as pharmaceutical agents.

INTERNATIONAL SEARCH REPORT

ational Application No
PCT/US2004/004197

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7	C07D403/12	C07D239/48	C07D405/12	A61K31/505	A61K31/506
	A61P35/00				

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data, BEILSTEIN Data, WPI Data, PAJ

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	KARP, V. K. ET AL: "Synthesis and antiinflammatory properties of o-carboxyphenylaminopyrimidines" KHIMIKO-FARMATSEVTICHESKII ZHURNAL , 17(11), 1304-7 CODEN: KHFZAN; ISSN: 0023-1134, 1983, XP009031557 see compound IB -----	1-43
P, X	WO 03/078404 A (NOVARTIS AG) 25 September 2003 (2003-09-25) see examples 117-121, 124-126, 233, formulae X12 and X13, Tables 12 and 14 and general formula ----- -/-	1-4, 6-9, 15-20, 22, 23, 26-34, 36-39, 41-43

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

° Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the International search

2 June 2004

Date of mailing of the International search report

17/08/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Scruton-Evans, I

INTERNATIONAL SEARCH REPORT

national Application No
PCT/US2004/004197

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	WO 03/030909 A (BOYER STEPHEN ; CHEN JIANQING (US); CLARK ROGER B (US); FAN JIANMEI (U) 17 April 2003 (2003-04-17) see formula I, I-1, page 6, I-4, page 8, examples 181,257,258 and claims -----	1-43
Y	WO 00/39101 A (BREULT GLORIA ANNE ; PEASE JANET ELIZABETH (GB); ASTRAZENECA UK LTD () 6 July 2000 (2000-07-06) see general formula, definitions of substituents on Q1 and formula Ia and pages 1-2 -----	1-43
Y	WO 97/19065 A (CELLTECH THERAPEUTICS LTD ; DAVIS PETER DAVID (GB); MOFFAT DAVID FESTU) 29 May 1997 (1997-05-29) see general formula, definitions of X,R7 and R12 and examples 89->. -----	1-43
A	WO 00/27825 A (AKEN KOEN JEANNE ALFONS VAN ; KOYMANS LUCIEN MARIA HENRICUS (BE); HEER) 18 May 2000 (2000-05-18) see general formula and Table 2 -----	1-43
P,Y	WO 03/032997 A (STEEGMAIER MARTIN ; KRIST BERND (AT); SPEVAK WALTER (AT); SCHOOP ANDRE) 24 April 2003 (2003-04-24) see general formula and page 2 -----	1-43
Y	WO 01/64655 A (BREULT GLORIA ANNE ; PEASE ELIZABETH JANET (GB); ASTRAZENECA UK LTD () 7 September 2001 (2001-09-07) see general formula, definitions of substituents on Q1 and of Y and Z, and examples 83-85 -----	1-43
Y	WO 01/64654 A (BREULT GLORIA ANNE ; PEASE ELIZABETH JANET (GB); ASTRAZENECA UK LTD () 7 September 2001 (2001-09-07) see general formula and examples 24,27,28 -----	1-43
Y	WO 01/64656 A (PEARSON STUART ERIC ; PEASE ELIZABETH JANET (GB); ASTRAZENECA UK LTD () 7 September 2001 (2001-09-07) see general formula, pages 9/10 and claim 4 -----	1-43
P,X	WO 03/063794 A (RIGEL PHARMACEUTICALS INC ; ROSSI ALEXANDER B (US); SYLVAIN CATHERINE) 7 August 2003 (2003-08-07) see general formula defintions and examples 7.3.43 and 7.3.189 -----	1-4, 6-13,15, 16, 18-20, 22,23, 31-34

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US2004/004197

Patent document cited in search report		Publication date		Patent family member(s)		Publication date
WO 03078404	A	25-09-2003	WO	03078404 A1		25-09-2003
WO 03030909	A	17-04-2003	WO	03030909 A1		17-04-2003
WO 0039101	A	06-07-2000	AU	763091 B2		10-07-2003
			AU	1874300 A		31-07-2000
			BR	9916590 A		23-10-2001
			CA	2352896 A1		06-07-2000
			CN	1335838 T		13-02-2002
			EP	1140860 A1		10-10-2001
			WO	0039101 A1		06-07-2000
			JP	2002533446 T		08-10-2002
			NO	20013038 A		22-08-2001
			NZ	512118 A		29-08-2003
			US	6593326 B1		15-07-2003
			ZA	200104413 A		29-08-2002
WO 9719065	A	29-05-1997	AU	7631496 A		11-06-1997
			DE	69627179 D1		08-05-2003
			DE	69627179 T2		29-01-2004
			EP	0862560 A1		09-09-1998
			ES	2195020 T3		01-12-2003
			WO	9719065 A1		29-05-1997
			US	6235746 B1		22-05-2001
			US	5958935 A		28-09-1999
WO 0027825	A	18-05-2000	AT	233740 T		15-03-2003
			AU	762523 B2		26-06-2003
			AU	6200899 A		29-05-2000
			BG	105418 A		30-11-2001
			BR	9915552 A		14-08-2001
			CA	2350801 A1		18-05-2000
			CN	1322198 T		14-11-2001
			CZ	20011533 A3		17-10-2001
			DE	69905683 D1		10-04-2003
			DE	69905683 T2		18-03-2004
			DK	1002795 T3		30-06-2003
			EA	4049 B1		25-12-2003
			EE	200100252 A		15-10-2002
			WO	0027825 A1		18-05-2000
			EP	1270560 A1		02-01-2003
			EP	1002795 A1		24-05-2000
			ES	2193664 T3		01-11-2003
			HK	1025330 A1		13-06-2003
			HR	20010161 A1		28-02-2002
			HU	0104177 A2		28-03-2002
			ID	28376 A		17-05-2001
			JP	2002529456 T		10-09-2002
			NO	20011696 A		04-04-2001
			NZ	511116 A		29-08-2003
			PL	347586 A1		08-04-2002
			PT	1002795 T		31-07-2003
			SI	1002795 T1		31-10-2003
			SK	6032001 A3		07-01-2002
			TR	200101306 T2		22-10-2001
			US	2003114472 A1		19-06-2003
			US	2004039005 A1		26-02-2004
			ZA	200103769 A		12-08-2002

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US2004/004197

Patent document cited in search report		Publication date		Patent family member(s)		Publication date
WO 03032997	A	24-04-2003	WO US	03032997 A1 2003171359 A1		24-04-2003 11-09-2003
WO 0164655	A	07-09-2001	AU AU BR CA CN EP WO JP NO US	771144 B2 3397601 A 0108834 A 2398685 A1 1406230 T 1268444 A1 0164655 A1 2003525278 T 20024153 A 2003149266 A1		11-03-2004 12-09-2001 10-12-2002 07-09-2001 26-03-2003 02-01-2003 07-09-2001 26-08-2003 29-10-2002 07-08-2003
WO 0164654	A	07-09-2001	AU AU BR CA CN EP WO JP NO US	765151 B2 3395301 A 0108841 A 2399196 A1 1406231 T 1272477 A1 0164654 A1 2003525277 T 20024154 A 2003149064 A1		11-09-2003 12-09-2001 06-05-2003 07-09-2001 26-03-2003 08-01-2003 07-09-2001 26-08-2003 28-10-2002 07-08-2003
WO 0164656	A	07-09-2001	AU BR CA CN EP WO JP NO	3397901 A 0108879 A 2398887 A1 1416423 T 1278735 A1 0164656 A1 2003525279 T 20024126 A		12-09-2001 29-04-2003 07-09-2001 07-05-2003 29-01-2003 07-09-2001 26-08-2003 29-08-2002
WO 03063794	A	07-08-2003	WO US WO WO WO US US US US WO	03063794 A2 2004029902 A1 03063333 A1 03061449 A1 03063390 A2 03063391 A2 2003137264 A1 2003137263 A1 2003142982 A1 2003170033 A1 2004014382 A1		07-08-2003 12-02-2004 31-07-2003 31-07-2003 31-07-2003 24-07-2003 24-07-2003 31-07-2003 11-09-2003 19-02-2004